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Abstract 
 
 
Chapter 1 provides an introduction to stroke including its current prevalence both 
nationally and globally, aetiology, global importance and social & financial burden. We 
also describe here current acute stroke management practices, the role of clinical trials 
in the development of therapies, the richness of data within clinical trials and changes 
in regulatory thinking regarding data access. We provide recommendations for the use 
of trial data for novel exploratory investigations of clinical trial design and 
epidemiological studies.  
In Chapter 2 we describe the establishment of the Virtual International Stroke Trials 
Archive (VISTA) to address the need for reliable data on which to plan future clinical 
trials. This chapter details the methodology and logistics of establishing the resource, 
including details of regulatory policy for data collection and use, establishment of a 
Steering Committee and development of a constitution to safeguard data access and 
use.  
As of June 2008, VISTA contains 28 acute stroke clinical trials and one acute stroke 
registry. We collated data on over 27,500 patients with either ischaemic or 
haemorrhagic stroke. Patient age ranges from 18 to 103 years and outcome measures 
include Barthel Index, Scandinavian Stroke Scale, National Institutes of Health Stroke 
Scale, Orgogozo Scale, and modified Rankin Scale. Medical history and onset to 
treatment times are readily available and computed tomography (CT) lesion data are 
available for selected trials. We discuss the establishment and potential uses of this 
resource in the context of existing stroke resources. 
Chapter 3 demonstrates how we utilised VISTA to investigate natural history patterns in 
acute stroke. There are prominent differences in stroke incidence and outcome across 
different geographical locations; these are not confined to the Eastern- Western axis. 
We aimed to examine whether there were any differences in index stroke severity, 
stroke risk factors, and stroke outcome between geographical locations, after adjusting 
for case-mix.  
We found that patients who were enrolled in the USA and Canada had the worst index 
strokes, whilst patients enrolled in Austria and Switzerland had the mildest index 
stroke, and better functional (p=0.023) and neurological outcome (p=0.034) at 90 days. 
90 –day survival was greater in patients who were enrolled in Spain and Portugal 
(p<0.0001).  
Chapter 4 demonstrates the use of VISTA to inform stroke clinical trial design by 
examining the impact of early follow up on adverse event and functional outcome 
profiles. We aimed to assess the contribution of adverse complications unrelated to 
stroke, to 30 and 90- day functional outcome. If fewer ‘stroke-unrelated’ adverse 
events were seen at later time points, and if the absence of these events appeared to 
influence functional outcome, then further investigation into shortening the follow up 
period of clinical trials with a view to minimizing complications may be warranted.   
We identified idiopathic post-stroke complications (deemed to be ‘stroke- unrelated’) 
but their absence did not beneficially alter outcome at either 30 days (p<0.0001, 
adjusted OR for good outcome =0.47, 95% CI [0.26, 0.67]), or 90 days (p=0.002, adjusted 
OR for good outcome =0.38, 95% CI [0.14, 0.61]). We concluded that shortening the 
follow up period with the aim of minimizing ‘stroke-unrelated’ complications did not 
benefit functional outcome, however further investigation is required. 
Chapter 5 illustrates the use of VISTA to investigate the natural history of complications 
after intracerebral haemorrhage (ICH). Treatments available for ICH remain limited. 
The use of haemostatic agents to promote local coagulation has had no significant 
benefit on outcome. However promising results from a subgroup analysis of patients 
from the FAST trial has raised the possibility of treatment with recombinant factor VIIa 
(rFVIIa) in patients with ICH. We sought to document the natural history of 
complications after ICH in order to inform safety in future trials of haemostatic agents 
for ICH.  
We found that the risk of thromboembolic complications after ICH was low (4 events 
affecting 2% of patients). The absence of these thromboembolic complications did not 
significantly affect the attainment of good functional outcome (p>0.05). The occurrence 
of haemorrhagic expansion was common, affecting 14% of patients, and significantly 
influenced attainment of good functional outcome at 90 days (p= p<0.0001, adjusted 
odds ratio for good functional outcome=21.9, 95% confidence interval [5.5, 88.3]). 
Although infection occurred in 11% of patients, this did not significantly influence 
attainment of good functional outcome at 90 days (p=0.8). The complications 
encountered in this investigation and their time to onset will serve to inform 
prophylaxis in future ICH clinical trials.   
Chapter 6 describes the processes involved in drug development from phase I, first- in –
man studies to phase III efficacy trials and identifies a key area in the drug development 
process where use of VISTA as a historical comparator resource could be of benefit: 
phase II studies. We detail here the types of conventional comparator groups available 
for use in a phase II investigation, advantages and disadvantages of using each of these 
comparator groups, the potential for use of historical comparators in some scenarios 
where use of conventional comparator groups is infeasible, and possible solutions to 
address the limitations associated with use of historical comparators.   
Chapter 7 illustrates the use of VISTA as a resource for historical comparators in the 
context of an acute stroke device trial conducted by a small company with limited 
resources. BrainsGate, the manufacturers of the NeuroPath™ Device for treatment of 
ischaemic stroke, sought to collaborate with the VISTA group to examine initial efficacy 
of their device against outcomes derived from VISTA historical comparators. We discuss 
the example of this device in early phase testing, where VISTA was primed for use as a 
resource for historical comparators. We also describe the limitations associated with the 
use of historical comparators, how these limitations could be overcome in practice 
through use of matched patients, implementation of strict eligibility criteria and use of 
similar follow up periods and stroke scales, as well as the measures taken to ensure the 
validity of results. 
Chapter 8 describes a collaboration with the DESTINY trial group to investigate stroke 
outcomes after malignant middle cerebral artery occlusion (mMCAO). The DESTINY trial 
examined the impact of decompressive hemicraniectomy on outcome after mMCAO, 
compared with randomised controls. We compared the outcomes of operated patients 
from the DESTINY trial with historical comparators from VISTA to determine whether 
the findings could be replicated and if historical comparators could be used as an 
alternative in a situation where a randomised controlled trial (RCT) is infeasible or 
unethical.  
We found that fewer patients in the VISTA comparator group achieved a good functional 
outcome by mRS at final follow up (19%), when compared with the DESTINY surgical 
group (47%, Chi- Square test p=0.04). This difference persisted after adjusting for 
baseline NIHSS (logistic regression p=0.04). Analysis of Barthel Index at final follow up 
revealed no significant difference between the two groups and we also found no 
difference in 6 month survival rates between the surgical and VISTA comparator groups 
(Cox Proportional Hazards model p>0.05). We concluded that for effective replication of 
results, the database from which historical comparators are to be drawn should cover a 
similar or broader spectrum of patient prognostic factors.  
Chapter 9 discusses the implications of the investigations described in this thesis, 
outlines the scope for expanding the resource and proposes areas for future research.   
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Abbreviation Expanded Definition 
ACEI ACE Inhibitors 
Ang II Angiotensin II 
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ARB Angiotensin Receptor Blockers 
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MONICA Monitoring Trends and Determinants in Cardiovascular Disease 
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mRS Modified Rankin Scale  
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1 Introduction 
1.1 Stroke 
1.1.1 Definition  
The World Health Organisation (WHO) defines stroke as “rapidly developing clinical signs 
of focal (or global) disturbance of cerebral function with symptoms lasting 24 hours or 
longer or leading to death with no apparent cause other than of vascular origin” (1). 
This definition includes ischaemic stroke, subarachnoid and intracerebral haemorrhage 
(ICH), but excludes transient ischaemic attack (TIA), subdural or extradural 
haemorrhage, and ischaemic or haemorrhagic stroke that occurs as a secondary 
consequence of infection or malignancy (2). Stroke manifests in a reduction of cerebral 
blood flow, and a subsequent decrease in oxygen and nutrient levels in the brain. 
Cerebral grey matter has one of the highest rates of oxygen consumption, making the 
brain extremely sensitive to hypoxia. Irreversible cell death takes place within minutes 
of sustained hypoxia (3) and a stroke can cause temporary or permanent loss of normal 
body function.  
1.1.2 Pathology 
Stroke can be classified into three distinct groups: intracerebral haemorrhage, cerebral 
infarction, and subarachnoid haemorrhage (SAH) (4). Within ischaemic stroke, the 
location and extent of the infarct can be described as belonging to one of five 
categories according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) 
classification, and 4 categories using the Oxfordshire Community Stroke Project (OCSP) 
classification scheme. 
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Causative events for stroke identified using the TOAST classification scheme include 
large-artery atherosclerosis, cardioembolism, small-vessel occlusion, stroke of other 
determined aetiology and stroke of undetermined aetiology (5). Large vessel 
atherosclerosis and small vessel disease account for 40% of ischaemic strokes, while 30% 
are a consequence of cardioembolism (6;7). Diagnoses are based on clinical features, 
brain imaging and laboratory tests. The OCSP classification method identifies Lacunar 
Circulatory Syndrome (LACS), where the infarct mainly affects the pons or basal ganglia, 
Total Anterior Circulatory Syndrome (TACS), where the infarct affects both deep and 
superficial territories of the middle cerebral artery (MCA), Partial Anterior Circulatory 
Syndrome (PACS), which involves occlusion of the upper or lower division of the MCA in 
addition to individual branch occlusions (8), or Posterior Circulatory Syndrome (POCS), 
classified as any infarct that is clinically linked to the brainstem, cerebellum, and 
occipital lobe (9). Schemes for stroke classification are widely implemented and 
description of the location and extent of ischaemic stroke may help to determine the 
best course of treatment. 
Intracerebral haemorrhage occurs mainly as a result of acute bleeding into the brain by 
ruptured arteries. Other causes include arteriovenous malformations (AVM) cavernous 
angioma or ruptured aneurysms (10). ICH, a particularly lethal form of stroke (11) is 
associated with poor disability outcomes (12). It is occurs more frequently in men and in 
African or Asian populations (13;14).   
Subarachnoid haemorrhage (SAH) is the extravasation of blood into the subarachnoid 
space surrounding the brain. In 80% of cases it is caused by a ruptured cerebral 
aneurysm (15). Non aneurysmal SAH accounts for about 20% of cases and carries a 
better prognosis than aneurysmal SAH (16).   
1.1.3 Epidemiology 
Stroke is the leading cause of disability worldwide (2;17;18) and between 10 and 12% of 
deaths in industrialised countries are stroke-related (2). At one year follow up 30% of 
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stroke patients will have died, and of the remaining 70%, up to 40% will be dependent 
on family or carers for acts of daily living (19). 
Ischaemic stroke is more prevalent in developed countries, with incidence ranging 
between 67 and 80%. Only 6-19% are haemorrhagic in nature (20-22). This is in stark 
contrast with incidence in Asian populations where up to 35% of all strokes are 
haemorrhagic (12;23-26). SAH has an aggregate worldwide incidence of about 10.5 cases 
per 100,000 people (27).  
Some stroke epidemiology characteristics can reflect poverty or social status. An 
increased prevalence of intracerebral haemorrhage, a higher stroke case fatality rate, 
and a younger stroke onset age are indicative of lower social status (28). 
Industrialisation was hypothesised to be a mechanism for the transition from poverty 
related stroke subtype presentation to increased prevalence of ischaemic stroke and 
lower case fatality (29;30). This was illustrated in the SINO MONICA study where marked 
changes in the prevalence of stroke subtypes between 1984 and 2004 were observed in 
China (28). In that investigation the risk of ischaemic stroke increased annually by an 
average of 8.7%, and the risk of ICH decreased by an average of 1.7%.  
Stroke risk shifts over time from causes related to nutritional deficiencies and 
infections, to chronic non-communicable diseases such as cardiovascular disease and 
diabetes (31). Regions that undergo this transition first experience an increased disease 
burden associated with hypertension, (for example, haemorrhagic stroke). The latter 
stages of this transition are characterised by an increased risk of heart disease and 
ischaemic stroke. Zhang et al. (2003) postulated that China and other Asian populations 
were mid-stage in this transition (24). This could explain the increased prevalence of 
intracerebral haemorrhage observed in the Asian populations compared with those from 
Europe and North America.      
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1.1.3.1 Stroke Prevalence and Mortality in the United Kingdom 
Annually in the UK, between 101,000 and 130,000 people experience a stroke, with the 
majority occurring in people aged over 65 years (32-34). Of these, a significant 
proportion is comprised of first- ever strokes. Within the UK, the crude annual 
prevalence for first -ever stroke is about 2 per 1000 people (23;32;35). 1 in 4 men and 1 
in 5 women aged 45 can expect to experience a stroke by the time they are 85 years old 
(2;36). It is estimated that this incidence will increase as a result of the ageing 
population.  
Stroke related mortality increases with patient age: mortality rates range from 7 per 
100,000 patients aged between 35 and 44 years, to 1400 per 100,000 patients aged over 
75 years (37). The Oxfordshire Community Stroke Project (OCSP) reported a 30 -day 
mortality rate of 19% and a 1 -year case fatality rate of 31% in their series. Stroke 
related mortality is currently in decline, (38) however in recent years the rate of this 
decline has decreased in many regions (38;39).  
Within Scotland in 2004, the crude stroke rate per 100,000 people was 271 (40), a 
decline from 317.9 per 100,000 people in 1997. Since 1995 the mortality rates from 
coronary heart disease (CHD) and stroke have fallen by more than a third (41) (Figure 1-
1). The crude stroke mortality rate in 1997 was 136.9 per 100,000 people, and had 
declined to 107.1 per 100,000 people by 2006 (40)  
1.1.3.2 Global Stroke Prevalence and Mortality  
Stroke was reported to affect 5.8 million Americans in 2005, killing 150,100 in 2004 
(42). Stroke incidence in Asia is generally higher than in the USA and Europe (43-45). In 
Europe alone it is estimated that over 1 million acute ischaemic strokes occur per year 
(46;47). Within Europe the lowest stroke prevalence can be observed in Scandinavia, 
(303 per 100,000 men in Sweden) while Eastern Europe has the highest prevalence (660 
per 100,000 men in Russia) (48). Cardiovascular disease accounts for 32% of all deaths in 
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European countries (49) and remains a major cause of morbidity. Stroke mortality is also 
five times higher in Eastern Europe compared with Western Europe (48;50-52) (Figure 1-
2, 1-3). The World Health Organisation (WHO) estimated a stroke mortality rate of 280 
per 100,000 people in Russia and 156 per 100,000 people in the Ukraine in 2002. The 
latter observation was on par with the stroke mortality rate reported in China and 
Malawi in 2002 (53) (Figure 1-4). 
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Figure 1-1 Mortality rates for cerebrovascular disease per 100 000 patients aged <75 years. 
ASR= Age Standardised Results. Adapted from the Scottish Executive CHD and Stroke 
Strategy 2004, http://www.scotland.gov.uk/Resource/Doc/30859/0012660.pdf 
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Figure 1-2 Estimate of the healthy years of life lost to stroke in Europe (2002) Adapted from 
Mackay & Mensah (2004) 
5Uhttp://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdfH (54).  
 
 
Figure 1-3 Number of deaths from stroke in Europe (2002) Adapted from Mackay & Mensah 
(2004) 5Uhttp://www.who.int/cardiovascular_diseases/en/cvd_atlas_16_death_from_stroke.pdfH  
(51). 
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Figure 1-4 Age standardised mortality rate for selected countries worldwide. 
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1.2 Global Importance of Stroke 
Stroke is a leading cause of death and disability in the developed world (55), and affects 
one in five people during their lifetime (56). Stroke accounts for around 5% of all 
monetary expenditure on health and has an increasing global profile (57).  
The World Health Organisation (WHO) initiated the Monitoring of Trends and 
Determinants in Cardiovascular Disease (MONICA) project (58). The aim was to 
document the incidence of heart attack and stroke in diverse populations in order to 
analyse trends in morbidity, mortality and cardiovascular risk factors. The investigators 
found that there was an overall decrease in the incidence and fatality of stroke over the 
past 2 decades in the majority of populations studied (58).   
1.2.1 Financial Burden of Stroke 
The financial burden of stoke impacts both patients and society as a whole in terms of 
premature death, long term disability, restricted social functioning, cost of treatment 
and loss of productivity (59). In the USA alone, the direct and indirect cost of stroke was 
estimated at $58bn in 2006 (60). The estimated cost of stroke to the NHS and social 
services in the UK is £2.3bn per annum, more than double the cost of coronary heart 
disease management (61).  
The huge economic and social burden of stroke is attributed to its high prevalence, 
hospitalisation rates, morbidity and mortality, and its association with long -term 
disability in survivors (62;63). In Scotland, England, Wales and the Netherlands, 3-4% of 
the direct costs of healthcare are attributed to stroke (64-66). The cost of management 
after stroke often stems from patient requirements of intensive inpatient treatment. 
Subsequent complications can also lead to extensive outpatient care. The direct costs of 
stroke are attributed to medical management, while its indirect costs take the form of 
loss of income and productivity. As a result, the estimated cost of stroke management is 
between $30 and $40 billion per annum, and after the age of 55 the risk of stroke is 
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almost doubled with each successive decade, (67) further contributing to the financial 
burden of stroke as the population ages (68;69).    
Previous studies of the cost of first ischaemic stroke estimated a long -term cost of 
$159,000 for a stroke resulting in major impairment, and $58,600 for a stroke resulting 
in minor impairment (70). The majority of this cost was due to the length of 
hospitalisation. Kolominsky-Rabas et al. (2006) utilised data from the Erlangen Stroke 
Registry to investigate the direct cost of ischaemic stroke. They estimated the overall 
cost of stroke at 1 year to be €18,517 and of this, 37% was attributed to stroke 
rehabilitation (71).  
Caro et al. (1999) estimated the short-term cost of stroke to be £8326, with the length 
of hospitalisation contributing to the majority of this cost (70). Their long -term cost 
model estimated expenditure at £75,985 for a patient with a major stroke, and £27,995 
for a minor stroke (70). Furthermore Taylor et al. (1996) developed a model for the 
lifetime cost of stroke. They estimated the per -person expenditure on first -ever 
ischaemic stroke to be $90,981, and $123,565 for patients with ICH (72). In the two 
years after index stroke, acute care costs accounted for 45% of the aggregate lifetime 
cost of stroke, closely followed by the cost of long term ambulatory care (35%), and 
nursing home costs (17.5%) (72).  
It is unlikely that there will be a decrease in hospital admissions for stroke due to the 
nature of the aging population. This observation, combined with the fact that there is 
an overall decline in the incidence of stroke- fatality, means that there is an increase in 
the prevalence of stroke survivors (73). Projections for the period between 2006-2025 
estimate new cases of ischaemic stroke at 1.5 and 1.9 million cases in men and women 
respectively, highlighting the increasing profile of stroke in the future (71).   
The development of novel therapeutic interventions, primary and secondary prevention 
strategies are of vital importance, as these could lead to a reduction in both the 
financial and social costs of stroke.   
Myzoon Ali,   Chapter 1, 26 
 
1.3 Development of Stroke Interventions 
Development of therapeutic interventions for stroke progresses through 5 conventional 
stages. Following positive results of a pre-clinical study, drug development progresses to 
assessment of an intervention in a phase I trial. This phase examines the maximally 
tolerated dose of a particular drug in healthy subjects, while early phase II studies may 
elucidate the dose range for therapeutic effect (74). Late phase II studies are designed 
to analyse the biological activity of a drug, but may not specifically determine the 
efficacy (75). Phase III clinical trials are designed to examine efficacy of the drug. Phase 
IV studies may take place after an intervention has been approved for marketing, and 
are aimed at investigating efficacy in a previously unspecified patient population (76). 
Numerous clinical trials have taken place in an attempt to translate the success of 
animal studies into the development of viable stroke clinical therapies. 
1.4 Current Therapies for Acute Stroke 
1.4.1 Medical Management  
1.4.1.1 Acute Ischaemic Stroke 
Currently the European Stroke Organisation (ESO) recommends management of vital 
physiological functions such as blood pressure, oxygen saturation, blood glucose and 
temperature in patients with acute ischaemic stroke (77). Airway protection, 
electrocardiogram (ECG) monitoring and fluid replacement are also part of standard 
stroke care. Neurological status should be monitored using validated assessment scales 
such as the National Institutes of Health Stroke Scale (NIHSS) (78).  
1.4.1.2 Acute Intracerebral Haemorrhage (ICH) 
For patients with ICH the management of blood pressure, prophylaxis for fever and 
seizures, monitoring of intracranial pressure, and nutritional supplementation are 
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implemented in the acute care setting (79;80). Beyond the maintenance of the internal 
milieu, there are few therapeutic options for patients with ICH.  
1.5 Successful Development of Interventions for Acute 
Ischaemic Stroke 
1.5.1 Thrombolysis with Recombinant Tissue Plasminogen 
Activator (rt-PA)   
One of the few breakthroughs in acute ischaemic stroke clinical care has been the 
investigation of thrombolytics. These agents aim to dissolve the blood clots that cause 
blockage of arteries. In 1994 The National Institute of Neurological Disorders and Stroke 
(NINDS) recombinant tissue plasminogen activator (rt-PA) investigators examined the 
use of thrombolytics for acute ischaemic stroke. They found that administration of 0.9 
mg/Kg body weight of rt-PA within 3 hours of index ischaemic stroke did not confer a 
benefit on 24 hour outcome measures, but a significantly better functional outcome was 
seen at 90 days (81). Currently this is one of the only interventions that have been 
approved for marketing. Fagan et al. (1998) reported that acute and long-term stroke 
care costs totalled $76,581 for patients who were treated with rt-PA, compared with 
$82,155 for patients who received placebo (82). This difference of over $5500 illustrates 
the positive effect of rt-PA administration on reducing the financial burden of stroke. 
The cost of rt-PA administration could be offset by the reduction in cost of 
hospitalisation, rehabilitation and institutionalisation. However many patients do not 
reach hospital soon enough for thrombolysis to be safely administered (41). The time 
window, risk of haemorrhage and necessity for neuroimaging is only realistically met in 
less than 5% of ischaemic stroke patients, and this further narrows the field of patients 
who are eligible to receive this treatment (83;84). 
The European Cooperative Acute Stroke Studies (ECASS I and ECASS II) in 1994 and 1998 
respectively, utilised a later therapeutic time window for rt-PA administration (up to 6 
hours). The investigators found that administration within 6 hours of onset did not 
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confer any beneficial outcome (85;86). Hacke et al. (2004) conducted a pooled analysis 
of rt-PA trials and reported a potential therapeutic benefit for rt-PA administration up 
to 4.5 hours after index stroke (87). Two recent trials (ECASS III (88) and IST-3) 
investigated the potential for broadening the treatment window for rt-PA administration 
beyond 3 hours. 
1.5.2 The MERCI Retriever Device  
Blood clots within large arteries are relatively resistant to intravenous treatment with 
thrombolytics such as rt-PA (89). Mechanical removal of a thrombus using the 
Mechanical Embolus Removal in Cerebral Ischemia (MERCI) Retriever Device was 
investigated by Gobin et al. (2004) (90) in a phase I trial. The device is introduced 
through the femoral artery and once proximal to the site of the thrombus, ensnares it 
with a coil. The thrombus can then be removed and cerebral perfusion restored. These 
investigators reported recanalisation in 43% of patients using the MERCI Retriever Device 
alone, and in 64% using combination therapy with rt-PA. Wade et al. (2008) (89) 
examined a newer generation of the MERCI Retriever Device and reported a successful 
recanalisation rate of 57% with the device alone, and 70% when used in combination 
with intra-arterial thrombolysis. Brekenfeld et al. (2008) investigated the efficacy and 
complications associated with the use of the MERCI Retriever Device compared with the 
Catch Device, a similar technology for mechanical thrombectomy (91). The Catch device 
utilises a basket- like extension to ensnare the thrombus as opposed to the coils used in 
the MERCI Device. Analyses were carried out in an established animal model. Successful 
recanalisation was achieved in the majority of cases for both devices (90% for the MERCI 
Device and 70% for the Catch device) however the design of the MERCI device appeared 
to be more efficient for clot retrieval and was associated with fewer instances of clot 
fragmentation. These investigations have demonstrated the safety and preliminary 
efficacy of the MERCI Retriever Device for use up to 8 hours after index stroke. 
However, despite these promising results, the issue of clinical benefit has yet to be 
formally tested in a randomised controlled trial, and as a result this intervention is not 
as widely available.    
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However a longer therapeutic window for intervention means that more patients may be 
eligible to receive this therapy. An analysis by Nguyen-Huynh et al. (2008) revealed that 
mechanical clot removal using the MERCI Device was cost effective when compared with 
best medical care (92).    
1.5.3 Decompressive Surgery for Malignant Middle Cerebral 
Artery Occlusion 
Between 1 and 10% of patients with ischaemic stroke develop severe, life threatening 
cerebral oedema due to massive middle cerebral artery occlusion (93;94). If untreated 
mortality rates can reach up to 80% (95). The DESTINY (96) and DECIMAL (97) trials 
investigated decompressive surgery for malignant middle cerebral artery occlusion 
(mMCAO). The trialists found that decompressive surgery significantly improved survival 
in treated patients compared with those who had undergone best medical management. 
The unequivocal results of these trials illustrated the life- saving potential of 
decompressive hemicraniectomy in patients with mMCAO. 
To date these are the only 3 interventions for the treatment of acute ischaemic stroke 
that have influenced clinical practice. Numerous clinical trials of putative 
neuroprotectants and thrombolytics have been conducted, but there has been little 
success. In contrast with the progress made in the development of therapies for 
ischaemic stroke, little progress has been made for the treatment of ICH.   
1.6 Disappointing Results from Acute Stroke Clinical 
Trials 
1.6.1 Ischaemic Stroke Trials 
1.6.1.1 Thrombolysis Trials 
Other trials have investigated the administration of thrombolytics with mixed results. 
These include the Multicentre Acute Stroke Trial-Italy (MAST-I) (98), Multicentre Acute 
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Stroke Trial-Europe (MAST-E) (99) and Australian Streptokinase Trial (ASK) (100). Results 
have either been negative or equivocal. The thrombolytic agent desmoteplase was 
investigated in patients who were selected on the basis of perfusion / diffusion 
mismatch. The presence of a larger area of hypoperfusion on the perfusion weighted 
magnetic resonance imaging (PWI) when compared with the infarct size detected on the 
diffusion weighted magnetic resonance imaging (DWI) identifies the penumbral region, 
which is potentially salvageable (101). Initial small scale trials of desmoteplase in 
patients with this mismatch revealed a beneficial effect on clinical outcome compared 
with administration of a placebo (102;103). However these observations were not 
replicated in the phase III Desmoteplase in Acute Ischaemic Stroke (DIAS II) trial (104).    
1.6.1.2 Neuroprotectant Trials 
There are many physiological pathways in the brain that are altered during injury and 
these form targets for putative neuroprotectants. These pathways are often interlinked, 
with differing mechanisms of action in the core of the infarct compared with the 
penumbra (105-107). Therapies that target neuroprotective pathways include 
magnesium sulphate (108) and lubeluzole (109). These drugs have had limited efficacy 
in the treatment of acute ischaemic stroke. This may be indicative of the multifaceted 
mechanisms and pathways in effect after ischaemic stroke, and could signal the need to 
develop synergistic therapies which target multiple mechanisms in adjunct.  
Until recently NXY-059 (110), a free radical scavenger that had success in animal models 
of ischaemic stroke, was thought to be a promising candidate for acute stroke therapy. 
Administration was initially found to reduce the extent of infarct evolution and 
neuroprotective benefits were observed (111;112). This lead to an investigation of NXY-
059 in a phase III clinical trial. Despite initial encouragement, administration did not 
confer any significant benefit over placebo (110).  
Administration of 500mg citicoline in patients with acute ischaemic stroke was 
investigated by Clark et al. (1999) (113). Despite previously successful animal studies in 
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which administration of citicoline was found to evoke neurological recovery and 
neuronal survival (114;115), and promising early clinical trials where neurological 
function at 90 days was improved with citicoline administration (116), the larger scale 
randomised controlled trial (RCT) by Clark et al. (1999) did not find a significant benefit 
for citicoline administration over placebo (113).  
The benzothiazole lubeluzole, demonstrated neuroprotective activity in some models of 
ischaemic stroke (117), leading to further study in the LUB-INT-9 (118) and LUB-INT-13 
(109) trials. In the earlier trial conducted in North America (118), administration of 
lubeluzole within 6 hours of onset resulted in significantly better neurological and 
functional outcome at 3 months, with no significant impact on mortality. In contrast, 
the larger European lubeluzole trial (109) did not confirm a beneficial treatment effect 
of administration on either functional outcome or mortality at 3 months.   
1.6.1.3 Calcium Channel Blockers 
Nimodipine was proposed to limit cerebral vasospasm in some models of subarachnoid 
haemorrhage (119). It was hypothesised to prevent calcium overload in ischaemic 
neurons and was investigated as a potential therapy for ischaemic stroke in the 
Intravenous Nimodipine West European Stroke Trial (INWEST) (120). Administration of 
nimodipine did not confer a beneficial functional or neurological outcome when 
compared with placebo treated patients, and indeed, appeared to have an unfavourable 
haemodynamic effect on the ischaemic area in the early period after administration.   
The TRUST trial also examined the effects of oral nimodipine administration on 6 month 
outcomes in patients with acute ischaemic stroke (121). Assessment using the 
Nottingham Acts of Daily Living scale and neurological outcomes at 3 weeks indicated an 
unfavourable outcome in patients who were randomised to the nimodipine group.   
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1.6.2 Intracerebral Haemorrhage (ICH) Trials  
1.6.2.1 Surgical Evacuation of the Haematoma 
The Surgical Trial in Intracerebral Haemorrhage (STICH) investigated the benefit of 
early surgical evacuation of the haematoma compared with best medical care for the 
treatment of ICH. The investigators found no beneficial effect of surgery on functional 
outcome at 6 months (122). However evacuation of the haematoma may still be a viable 
therapeutic option for ICH and recruitment for the STICH II trial commenced in late 
2006.   
1.6.2.2 Recombinant Factor VIIa for ICH 
Recombinant Factor VIIa (rFVIIa) administration was, until recently, thought to be a 
promising intervention for patients with ICH. A successful phase IIb trial of rFVIIa 
demonstrated a beneficial effect of administration on haemorrhage volume, rate of 
haemorrhage growth and 90 day outcomes (11). However the beneficial functional 
outcome was not replicated in the subsequent FAST trial of rFVIIa for ICH (123).  
The paucity of clinical trials that have influenced clinical practice has highlighted a 
need to develop methods through which the chances of eliciting a positive trial result 
are maximised. Adequate planning and selection of patient subgroups that may benefit 
from certain types of interventions is critical to achieve this.  
1.7 Future Steps 
Given the prevalence of stroke and the limited effective therapies available, ventures 
that aim to further the development of clinical trials in stroke are vital. The Stroke 
Academic Industry Roundtable group (STAIR) (124;125) was set up to identify factors 
that may impede the translation of laboratory research into positive clinical 
developments. STAIR have provided guidelines for the design and interpretation of 
animal studies in stroke that may aid the selection of drugs that are to make the 
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transition from animal studies to clinical trials. They have also provided guidelines for 
the conduction of phase II and III trials and recommendations for novel clinical outcome 
measures (126-129). Implementation of these recommendations enhances clinical trial 
design and can contribute to positive clinical trial outcomes. The STAIR group identified 
the use of electronic databases as a promising tool for the design, implementation and 
performance of acute stroke therapy clinical trials (130).   
The Stroke Programme Review Group was also established to identify and prioritise 
stroke research needs. They identified the need for collaboration amongst investigators, 
with an emphasis on improving access to shared databases, investigator networks and 
human tissue and genetic repositories (131). Taking these recommendations into 
account, we sought to develop a means through which clinical trial data could be 
collated and accessed for novel analyses with the aim of improving clinical trial design.  
1.7.1  Richness of Data within Clinical Trials  
There have been more than 50 clinical trials aimed at improving neuroprotection after 
stroke (132), but with few exceptions, the majority have failed. Despite this, patient 
data that were collected during the course of these trials can still have a valuable 
function. For example, in the successful phase IIb trial of rFVIIa for ICH, 399 patients 
were randomised to either the treatment or control groups. In the failed phase III trial 
of rFVIIa, over 800 patients were randomised. Similar protocols were applied for data 
collection in these two trials, with the exception of some patient medical history 
variables. These two trials contain rich data including patient demography, brain 
imaging, laboratory measures, stroke scale measures at multiple time points, adverse 
event rates, timing of these events in relation to the start of treatment, baseline 
prognostic factors and outcomes at 90 days. Disregarding the treatment groups, these 
datasets are rich in ICH patient natural history data and can be used for many different 
analyses. For example, an investigation of the natural history of recovery from ICH, or 
the development of regression models to chart recovery trends after ICH could be 
performed.  
Myzoon Ali,   Chapter 1, 34 
 
The datasets from many studies reside in industry and academic archives long after 
publication but the importance of the information contained within is often 
underestimated. These data can be put to better use through contribution to 
epidemiological studies, which are essential to the development and planning of future 
clinical trials (133). The waste of such data is even more apparent when it is considered 
that some of these trials may not have been published or only an abstract has been 
submitted. The sheer volume, the protocols implemented and the depth of patient 
variables recorded make these data valuable. Investigators adhere to stringent 
guidelines for data collection, contributing to a cohesive and uniform patient dataset on 
which further analyses may be performed.   
1.7.2 Ethics, Changes in Regulatory Thinking and Data Access  
Collaboration is vital to improve health care services. With the availability of the 
internet it is now easier than ever to share data. The advancement of technology was 
identified as one of the main factors for the reorganisation of scientific research around 
the availability and free transfer of large volumes of data (134). The changes in 
computer and network technologies over the past 10 years have given rise to an 
increased potential for the acquisition, reuse and management of a large volume of 
data. There has also been an increase in the prevalence and power of online research 
and training tools. These tools can aid the translation from basic research findings to 
clinical practice. The main driving forces behind the increase in online research are an 
enhanced ability to gather and transport data quickly and easily, and the benefit of 
fewer demands on physical storage space.  
The Registry of the Canadian Stroke Network (135) is an example of a successful 
initiative for sharing patient data for the express purpose of improving stroke care. This 
network takes advantage of section 39(1) (c) of the Personal Health Information 
Protection Act, 2004 (PHIPA) whereby the Canadian Stroke Network is able to gather 
data without requiring explicit consent of the patient or next of kin. Anonymity is 
maintained through the presentation of analyses in grouped form only; the identity of 
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any individual patient is never revealed. These new projects have paved the way for 
access to data that would ordinarily have been inaccessible.   
Mandl & Kohane (2008) described a further evolution of patient data storage and access 
(136). Personally Controlled Health Records (PCHR) are medical records that are stored 
online and can be accessed by patients anywhere in the world. Email alerts can be sent 
to patients who are eligible for entry into new research trials by virtue of their current 
medical diagnosis, demographic and prognostic variables; this could revolutionise 
clinical trial recruitment. In addition, patients could make available selected prognostic 
and demographic information to investigators for use in novel analyses. Collation of 
data in this manner would result in a more concurrent natural history population than 
seen in many electronic databases. However, development and use of such a resource 
would require declarations of research intent on the part of the PCHR service providers 
and stringent regulations to govern data access (136). We sought to capitalise on these 
technological advances to develop the Virtual International Stroke Trials Archive 
(VISTA): a large collaborative project that aims to contribute to mutually beneficial 
ventures to aid progress in stroke clinical trials. This project aims to bring together 
large datasets from previously conducted clinical trials that would ordinarily have been 
left dormant. 
1.7.3 Aims of the VISTA Project   
Yusuf & Bosch (2006) commented that success in clinical trials can only be achieved 
through collaboration (137). Through VISTA we sought to collate clinical trial data and 
provide a method for accessing these data for use in novel analyses to inform clinical 
trial design.  
Stroke databases and registries already exist and can be used for similar purposes. 
These include the German Stroke Databank (GSDB) where prospective patient data are 
collected from participating institutions over a certain time period. These data can then 
be used to answer specific questions about the natural history of patient populations. 
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No exclusion criteria are employed to narrow the range of patient data collected and 
these databases are representative of the general population of stroke patients who are 
admitted to a stroke unit within a given time period. VISTA differs from this model in 
that the patient data that are collected correspond to a subset of stroke patients who 
are eligible for entry into clinical trials. Novel analyses using these patients are 
therefore applicable to clinical trial populations. Collation of this specific subset of data 
within VISTA has an advantage over general collation in a stroke registry. Novel analyses 
that aim to inform clinical trial design will have to implement exclusion criteria to 
generate a patient population similar to that seen in an acute stroke trial. However 
VISTA already contains this trial population and therefore fewer patient data are 
deemed unsuitable, increasing the sample size and power of analyses.    
 There are many considerations such as intellectual property and confidentiality which 
need to be taken into account when data are collated in this manner. Security, validity 
and reliability of data are paramount; the management of VISTA requires astute 
planning with the categorisation of all the types of data entered into the database. The 
conditions under which the data were collected also have to be recorded and a method 
by which the data can be accessed has to be implemented. The VISTA project aims to 
provide these data to investigators in a structured way, therefore an application process 
needs to be established, and an assessment on the ethical and scientific merits of its 
use must be undertaken.  
There is huge potential for the use of such a database, especially with the depth of 
monitoring and volume of patient data available. Collation of trial data from many 
different types of trials involving different interventions and stroke subpopulations 
enhances our ability to provide data on many different topics relating to stroke. The 
following chapters detail the development of this database, implementation of a 
management system for the categorisation of the variables contained within, 
establishment of a system for the assessment of new project proposals that are 
submitted to the VISTA group, and lastly the use of the database for novel exploratory 
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analyses including stroke epidemiology, aspects of clinical trial design and the potential 
for use of historical comparators to inform clinical trials. 
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2 The Virtual International Stroke Trials Archive 
(VISTA): Establishment of a Clinical Trial 
Resource. 
2.1 Introduction 
Our objective was to establish a comprehensive resource comprising patient data from 
acute stroke clinical trials, on which novel analyses to inform clinical trial design could 
be performed. This chapter describes the reasoning, aims and benefits of establishing 
the Virtual International Stroke Trials Archive (VISTA). This chapter details the eligibility 
criteria for trial recruitment into the resource, methods of documentation, data entry 
and manipulation, issues such as confidentiality and a summary of the contents of 
VISTA. Areas of research where VISTA may be beneficial are also briefly summarised.    
2.1.1 The Need for VISTA 
Development of drugs for clinical use in acute stroke has remained slow since the 
licensing of rt-PA (81). Drugs such as prourokinase (138) and ancrod (139), that seemed 
promising have yet to be approved for marketing. Similarly, translating the success of 
acute stroke interventions in animal models or phase II trials into efficacy in phase III 
trials has been troublesome (140). With the exception of rt-PA, use of the MERCI 
Retriever Device (90;141) and the recently established benefit of decompressive surgery 
for patients with malignant middle cerebral artery occlusion (142), there has been little 
impact on clinical practice. The failure to confirm efficacy in many recent large, 
multinational trials of novel acute stroke interventions (110;123;143), has reinforced 
the need for reliable data on which to plan future trials. 
Many studies worldwide have investigated the risk factors, (34) aetiology, geographic 
prevalence (144-149), ethnic disparity (1;150-152) and potential benefits of treatment 
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regimens for stroke. The datasets from such studies reside in industry and academic 
archives long after the studies were published but the importance of the information 
contained within is often underestimated.  
By collating these data sets, a large and rich pool of information can be utilised for 
novel analyses of the natural history of homogeneous subgroups of stroke patients. This 
wealth of information could inform the design of future randomised controlled trials 
(RCT). It could also allow testing of specific hypotheses. The Virtual International Stroke 
Trials Archive (VISTA) was set up in the spirit of contributing to mutually beneficial 
ventures to aid progress and breakthroughs in stroke clinical trials.  
Studies using registries and databases have contributed to health care policies which 
have lowered the mortality rate associated with common conditions (153). The recent 
Stroke Therapy Academic Industry Roundtable (STAIR) meeting highlighted the potential 
for use of electronic databases to aid collaborative research. Proposed uses included 
trial simulations or elucidation of sample size requirements (130). VISTA was developed 
with the aim of aiding clinical trial design and subsequently increasing the chances of 
attaining a favourable outcome after a novel stroke intervention.   
2.1.2 Aims of VISTA 
Through the collation and categorisation of numerous trials, the VISTA collaboration 
seeks to bring together under one umbrella, large datasets which would otherwise have 
been left dormant within university and industry archives. The VISTA database does not 
sanction reanalysis of any trial data which will test treatment effects; rather it provides 
an unrivalled opportunity to access a large volume of patient data on which to carry out 
novel exploratory analyses which would ultimately aid clinical trial design and 
development. This represents a major international resource.  
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2.2 Guidelines to Govern VISTA 
Previous reluctance to amass data in this way related to issues such as patient 
confidentiality, commercial sensitivity, reliability of data, authorship or intellectual 
property of a particular study and its scientific merit. Similarly, investigators were 
apprehensive due to the loss of control over the potential use or misuse of such data. 
We addressed these issues through stringent guidelines detailing the handling of 
confidential patient information, ethics, representation and publication. The data also 
require secure storage and restriction of access to authorised individuals. Regulations to 
govern eligibility criteria, promotion, data protection and storage, compatibility and 
data documentation are detailed in the VISTA constitution (Appendix Chapter 10.1).   
2.2.1 Membership  
VISTA is a collaborative venture involving clinical scientists from numerous international 
groups with experience in designing and conducting clinical trials in acute stroke. Table 
2-1 details the Steering Committee members and collaborators who have been integral 
to the initial development, promotion and use of VISTA. With the addition of new trials 
and use of VISTA for novel analyses, this list is constantly evolving. 
VISTA does not favour a particular organization, sponsor or individual group. 
Membership is therefore open to all trials and registries that meet the eligibility criteria 
(Table 2-2), and the results of analyses carried out using this resource should be used 
for the benefit of the wider population in academia, clinics and industry. Membership is 
granted to trials and organisations rather than to individuals and each organization is 
represented on the Steering Committee by a named individual, usually the principal 
investigator. The role of these Steering Committee members is to assess the scientific 
merit of proposals and approve the use of trial data. The criteria employed in this 
process include assessment of originality, scientific quality, potential value to the wider 
scientific community and publication potential. All subsequent manuscripts are also 
reviewed by the Steering Committee prior to submission for publication.
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Steering committee members (representing contributed trials) Collaborators 
K.R. Lees- 5Uk.r.lees@clinmed.gla.ac.ukH  B. Ovbiagele- 5UOvibes@mednet.ucla.eduH  
L. Claesson- 5ULennart.Claesson@astrazeneca.comH  J. Prosser- 5UJane.Prosser@mh.org.auH  
E. Bluhmki- 5Uerich.Bluhmki@bc.boehringer-ingelheim.comH  M. Hill- 5UMichael.Hill@CalgaryHealthRegion.caH  
B. Gregson  5UBarbara.Gregson@newcastle.ac.uk  J. Fink- 5Ujohn.fink@chmeds.ac.nzH  
G. Donnan- 6Ugdonnan@unimelb.edu.au J. Whitehead- 6Uj.r.whitehead@reading.ac.ukH  
H. C. Diener- 6Uh.diener@uni-essen.deH  K. Kucher- 6Uklaus.kucher@novartis.comH  
J. Grotta- 6Ujames.c.grotta@uth.tmc.edu M. Ali- 6Umyzoonali@clinmed.gla.ac.uk 
J. Marler 6Umarlerj@ninds.nih.gov H  S. Atula- 6Usari.atula@kolumbus.fiH  
J. Curram- 6Ujohn.curram@bayerhealthcare.comH   BrainsGate/S.Weiss/ N. Bornstein- 6Usagit.weiss@Brainsgate.comH  
P. Teal - 7Uteal@interchange.ubc.ca J. Diedler  7UJennifer.Diedler@med.uni-heidelberg.deH  
M.G. Hennerici- 7Uhennerici@neuro.ma.uni-heidelberg.deH   L. Gray  7Ulaura.gray@nottingham.ac.uk H  
N.G. Wahlgren- 7Unils-gunnar.wahlgren@cns.ki.seH  H. Hallevi  7UHen.Hallevi@uth.tmc.eduH  
P. Lyden- 7Uplyden@ucsd.eduH  H. Altman 7Uhernan.altman@brainsgate.comH  
P.W. Bath- 7Uphilip.bath@nottingham.ac.ukH  J. Dawson 7Ujd168c@clinmed.gla.ac.uk H   
R. Sacco- 8Urls1@columbia.eduH  H. Kamel 8Uhooman.kamel@ucsf.eduH   
S.M Davis- 8Usdavis@ariel.its.unimelb.edu.auH  C. Johnston 8UClay.Johnston@ucsfmedctr.orgH  
W. Hacke- 8Uwerner_hacke@med.uni-heidelberg.de H  A. Aleu 8Uaitziberaleu@gmail.com 
S. Warach- 8UWarachS@ninds.nih.govH  D. Toni 8UDanilo.Toni@uniroma1.it 
M. Fisher- 8UFisherM@ummhc.orgH  M. Saini 8Umsaini@ualberta.caH  
M. Hommel- 9UMarc.Hommel@ujf-grenoble.fr H  G. Sare 9UMsxgs1@nottingham.ac.ukH  
M. Kaste- 9Umarkku.kaste@hus.fi J. Morris 9UMorriJ05@ummhc.orgH  
K. Muir 9U-k.muir@clinmed.gla.ac.uk T. Chou Utchou@vertical-group.com 
A. Shuaib 9Uashfaq.shuaib@ualberta.caH   
C. Weimar 9Ustroke.med@uni-due.deH   
  
Table 2-1 VISTA Steering Committee members and collaborators who have contributed to the establishment of VISTA
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2.2.2 Selection of trials 
The criteria for trial entry into VISTA are summarised in Table 2-2. We developed 
eligibility criteria to facilitate data comparability and validity of analyses. However, 
datasets that do not completely conform to all of the stated criteria may still be 
considered for entry into VISTA: the intention is to be inclusive. We encourage 
contribution of clinical trials from all areas of stroke research; diversity of data 
enhances the potential for the collaboration to meet the needs of investigators. 
However, in the nascent stage of trial recruitment, priority was given to intervention 
trials in the acute stroke care setting due to the availability and homogeneity of 
prognostic and outcome variables.  
 
 
 
 
 
 
Eligibility Criteria for Trial Recruitment 
Minimum dataset of 100 patients 
Documented entry criteria 
Documented consent or waiver of consent following local Institutional Review Board-approved 
procedure 
Baseline assessment within 24 hours of stroke onset 
Baseline assessment includes recording of neurological deficit by Oxford, National Institutes of 
Health Stroke Scale, Scandinavian Stroke Scale or similar 
Confirmation of stroke diagnosis by cerebral imaging within 7 days 
Outcome assessed between 1 and 6 months after stroke onset 
Outcome assessment includes recording of at least one of National Institutes of Health Stroke 
Scale, Scandinavian Stroke Scale, Rankin, Barthel or Glasgow outcome scale 
Monitoring procedures existed to validate data 
 
Table 2-2 Eligibility for trial recruitment into VISTA 
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2.2.3 Confidentiality 
Confidentiality issues have been at the forefront of VISTA development. Researchers 
may argue that informed consent should not be applicable for patient participation in 
clinical databases due to the substantial benefit to society from the research 
conducted, and the very low risk to the patients involved (133). It may also be 
impracticable and costly to approach all patients for consent (133). Tu et al. (2004) 
recommended the collation of de-identified data without obtaining consent from 
individual patients, but with implementation of appropriate safeguards to protect data 
as a viable alternative to tackle barriers to consent (133). The methods employed to 
safeguard confidentiality within VISTA have an advantage over other stroke databases as 
VISTA retains the element of informed consent whilst holding only anonymised data. 
The majority of the informed consent and Institutional Review Board (IRB) approvals 
that have been gathered restrict storage and transmission to anonymised data.  
All collaborators and investigators have been made aware that data provided to the 
VISTA group must be held as confidential. Investigators are not privy to trial source 
unless a specific application had been accepted by the VISTA Steering Committee. 
Investigators are asked to sign an agreement stating that data provided will only be 
used for the stated purpose, and will be removed from all computer hard drives after 
the agreed analysis period, (Appendix Chapter 10.2: Data Use Agreement).  
2.2.4 Data Storage and Documentation 
The data are stored for the VISTA group within the Robertson Centre for Biostatistics, 
University of Glasgow, UK. Trial representatives also have the option to retain their own 
converted or annotated data and merely to provide the data to investigators at the time 
of agreed analyses. Trial data are not collected first -hand, therefore issues of integrity 
and validity are paramount. We require documentation that describes the data and the 
protocols implemented for its collection. Case Report Forms (CRF) and data dictionaries 
are requested from trial contributors. If these are not readily available, details of the 
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trial are requested from investigators so that a basic description of variables and 
conditions applied can be elucidated (Table 2-3). Additionally we request details on the 
format of the data being transferred, ethics approval documentation, and consent to 
hold or collect original data. 
2.2.5 Data Compatibility 
The issue of data compatibility is addressed by the conversion of all datasets into a 
standardised form using the SAS 9.1™ statistical package (SAS Institute, Inc). SAS 9.1™ 
permits transfer and import of data in other formats such as Microsoft Excel, Access, 
SPSS and other versions of SAS™, as well as performing data management tasks. Data 
comparability is addressed through documentation of variables, and the inclusion of 
data dictionaries alongside analysis datasets to explain the type, range and units of 
each variable.  
2.2.5.1 Depth of Data 
Kush et al. (2008) reported that data standards for health care and medical research 
could permit integration and analysis of patient observations in a dataset that was 
sufficiently robust to inform valid decision making (154). We have implemented this 
concept within VISTA by combining data from different trials under standard headings to 
generate a richer dataset within which to carry out novel analyses. 
2.2.6 Compilation of Analysis Datasets 
Datasets that are used in proposed VISTA analyses are compiled on the basis of data 
availability; data from single or identified trials are not released without prior consent 
by the principal investigators of these trials. Additionally, investigators are asked to 
identify named variables that are essential to their analyses, and subsequent datasets 
are compiled by a third party with no vested interest in the proposed study. This 
eliminates selection bias on the part of the investigator. VISTA trials include positive, 
neutral and negative trials; but since the data of interest are those from placebo-
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treated patients, and since the actively treated groups would be disregarded in any case 
where treatment effect was present, the issue of bias becomes less relevant.
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Necessary Variables for Data collection 
Primary Objectives 
Secondary Objectives 
Study Period 
Duration of intervention 
Primary outcome measures 
Frequency of data collection (monthly, annually) 
Stroke Scales used 
Lists of file names 
Variable names 
Number of records in each file provided 
Key identifier fields, such as subject number 
Number of subjects 
Type of stroke 
Intervention 
Study Design 
Secondary outcome measures 
Source(s) used to create the data collection, relationships between the data collection and the source(s), coding systems used, algorithms defined 
Data collection methods, hardware/software, audit trail available for any data changes, validation methods 
Variable description and format 
Categorical variable decodes, if a coding system is used then this data should be included. 
Relationships between files 
Format of data, including delimiters used 
 
Table 2-3 Basic information required for data collection if completed Case Report Forms were unavailable 
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2.3 Establishment of VISTA 
2.3.1 Initial Promulgation   
We initially developed VISTA through collation of patient data from clinical trials that 
were chaired and conducted by known investigators and founding Steering Committee 
members. Thereafter, advancement of VISTA progressed from word- of –mouth to a 
larger scale promotion facilitated by the publication of a manuscript describing the 
project (155). Subsequent investigations and contributions of new trials to VISTA have 
been facilitated through our expanding network of collaborators.  
2.3.2 The VISTA Website 
The VISTA project now accepts the submission of proposals and the transfer of data 
electronically. A web portal is currently under construction (156) where anonymised 
data can be accessed. Investigators can examine whether the resource has the ability to 
accommodate specific endpoints or variables, and potential investigators may use the 
site to select and request specific variables for their proposed project. The website will 
also provide a forum through which the Steering Committee can review proposed 
projects to assess their viability, scientific merit and relevance to VISTA aims. Following 
acceptance of a written proposal, data are compiled, anonymised, and can either be 
sent through a secure web space to the investigator for local analysis, or analyses can 
be carried out centrally under the direction of the proposing author(s). This medium 
enhances participation and inclusion of new collaborators, and reduces the timeframes 
for research projects.  
2.3.3 Content of VISTA   
Description of the contents of VISTA is integral to the promotion of the database as a 
clinical resource. As of June 2008 the VISTA database contains information from 28 
clinical trials and 1 stroke registry which meet the VISTA eligibility criteria (Table 2-2) 
with individual data on more than 27, 500 patients (Table 2-4). The accumulation of 
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these data took several years and involved collaborations amongst medical health 
professionals, trial coordinators in industry and statisticians worldwide.  
Twenty six trials contain data on patients who had experienced an ischaemic stroke; 7 
trials also contain data on patients who had experienced an intracerebral haemorrhage. 
Currently data are held for 24, 208 (90.7%) patients with index ischaemic stroke, and 
2438 (9.1%) patients with index intracerebral haemorrhage (ICH).  
VISTA contains data on patients aged between 18 and 103 years, with data on 15,103 
men and 12,502 women (Table 2-4). Patient data also include 90 day Scandinavian 
Stroke Scale (SSS), Barthel index (BI), modified Rankin Scale (mRS), National Institutes 
of Health Stroke Scale (NIHSS), Orgogozo, Mathews, and European Stroke Scales (ESS). 
All 29 clinical trials/ registries in the archive include the BI as a means of classifying 
functional ability following stroke; 15 trials include the NIHSS, 11 trials included the 
SSS, while 19 describe the original or modified Rankin Scale. Twenty one out of the 29 
trials/registries in the archive have a primary endpoint at 3 months and 6 trials continue 
follow up to 6 months. One trial ended at 21 days and one ended at 30 days (Table 2-5). 
Measures of the SF-36 Health Survey (SF-36), Orgogozo, Glasgow Coma Score and 
European Stroke Scales are also selectively available.  
Additional baseline data are available, including Computed Tomography (CT) imaging 
indicating the nature and cause of the stroke, hemispheric location, any corresponding 
midline shift, and evolution of the infarct or haemorrhagic transformation. Medical 
histories are also available including such items as incidence of prior strokes or 
myocardial infarction, smoking history and presence of diabetes and hypertension. The 
date of stroke onset, time between ictus and intervention, race, height, weight and 
baseline blood pressure are also available for selected trials. Control group data alone 
are also available for some studies.  
Recruitment into VISTA is ongoing and we aim to build this database further with the 
contribution of the MAXI-POST and Citicoline trials, and addition of CT and Magnetic 
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Resonance Imaging (MRI) files from the CHANT, GAIN International, GAIN Americas and 
IMAGES trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Frequency (%) Median [IQR] 
Age - 71 [61, 78] 
Sex  M=15,503 (54.7%) 
F= 12,502 (45.4%) 
- 
Onset to Treatment Time (OTT) - 4.7 [3.5, 6.2] 
Stroke Type  Ischaemic=24,208 
(90.7%) 
ICH= 2438 (9.1%) 
Other= 54 (0.2%) 
- 
Baseline NIHSS - 11 [6, 17] 
NIHSS at 90 days - 4 [1,9] 
mRS at 90 days - 3 [1,4] 
BI at 90 days - 85 [40, 100] 
Mortality at 90 days Alive=22,060 (83.6%) 
Dead= 4332 (16.4%) 
- 
   
Table 2-4 Summary of baseline demography and outcome measures for patients contained 
within VISTA
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Trial Number of 
Patients 
Sex Age Onset to 
Treatment 
Time (h) 
Medical 
History 
CT 
Imaging 
BI SSS NIHSS mRS/ 
RS 
Ischaemic 
Stroke 
ICH Follow 
Up 
Additional
A20 (157) 132 ⌧ ⌧ <6 ⌧ ⌧ ⌧ ⌧   ⌧  180 days  
A2 20 ⌧ ⌧ N/A ⌧ ⌧ ⌧ ⌧   ⌧  180 Days  
STAT (158) 500 ⌧ ⌧ <3 ⌧ ⌧ ⌧ ⌧   ⌧  90 Days  
ESTAT (159) 1222 ⌧ ⌧ <10 ⌧ ⌧ ⌧ ⌧  ⌧ ⌧  90 Days RDRS 
ECASSI (85) 701 ⌧ ⌧ <6 ⌧ ⌧ ⌧ ⌧ ⌧ ⌧ ⌧  90 Days  
ECASSII (86) 814 ⌧ ⌧ <6 ⌧ ⌧ ⌧ ⌧ ⌧ ⌧ ⌧  90 Days SF-36 
GAINAM (160) 1605 ⌧ ⌧ <6 ⌧  ⌧  ⌧ ⌧ ⌧ ⌧ 90 Days OCSP 
GAININT (161) 1808 ⌧ ⌧ <6 ⌧  ⌧  ⌧ ⌧ ⌧ ⌧ 90 Days TOAST,  OCSP 
SEL07 (162) 138 ⌧ ⌧ <6 ⌧  ⌧ ⌧ ⌧  ⌧  90 Days  
SEL10 (162) 432 ⌧ ⌧ <6 ⌧  ⌧ ⌧ ⌧  ⌧  90 Days  
CMZ (163) 599 ⌧ ⌧ <12 ⌧ ⌧ ⌧ ⌧ ⌧ ⌧ ⌧  90 Days ADAMS 
ASK (100) 340 ⌧ ⌧ <4 ⌧ ⌧ ⌧    ⌧  90 Days CNS, GCS 
IMAGES (108) 2589 ⌧ ⌧ <12 ⌧  ⌧   ⌧ ⌧ ⌧ 90 Days  
INWEST (120) 100 ⌧ ⌧ <24 ⌧  ⌧    ⌧  21 Days Orgogozo,  
Mathews, GCS 
TAIST (164) 491 ⌧ ⌧ <48 ⌧ ⌧ ⌧ ⌧  ⌧ ⌧  180 days SF-36 
TRUST (121) 608 ⌧ ⌧ <48 ⌧  ⌧    ⌧  180 days Orgogozo, 
Nottingham Scale 
LUB-INT-5  360 ⌧ ⌧ <7 ⌧  ⌧    ⌧  90 Days ESS 
LUB-INT-4 69 ⌧ ⌧ <6   ⌧  ⌧ ⌧ ⌧  30 days ESS 
LUB-INT-7 15 ⌧ ⌧ <36       ⌧  7 days ESS 
LUB-INT-9 (118) 353 ⌧ ⌧ <8 ⌧  ⌧  ⌧ ⌧ ⌧  90 Days  
LUB-INT -13 (109) 885 ⌧ ⌧ <8 ⌧  ⌧   ⌧ ⌧  90 Days ESS 
LUB-INT-15 55 ⌧ ⌧ <6 ⌧  ⌧   ⌧  ⌧ 90 days  
STICH (122) 389 ⌧ ⌧ <72 ⌧ ⌧ ⌧   ⌧  ⌧ 180 days GOS, GCS 
mRECT 826 ⌧ ⌧ <4.5 ⌧ ⌧ ⌧  ⌧ ⌧ ⌧  90 Days SIS-16 
 NINDS (81) 624 ⌧ ⌧ <3 ⌧ ⌧ ⌧  ⌧ ⌧ ⌧  90 Days GOS 
ASTIN (165) 997 ⌧ ⌧ <8 ⌧  ⌧ ⌧ ⌧ ⌧ ⌧   90 Days Ace/ Statin Use 
SAINT (110;143) 4946 ⌧ ⌧ <6 ⌧ ⌧ ⌧  ⌧ ⌧ ⌧  90 Days Thrombolytics,  
SIS-16 
CHANT (166) 603 ⌧ ⌧ <6 ⌧ ⌧ ⌧  ⌧ ⌧  ⌧ 90 days Thrombolytics,  
GCS 
GSDB 5783 ⌧ ⌧ N/A ⌧ ⌧ ⌧  ⌧ ⌧ ⌧ ⌧ 90/180 
days 
Only BI @ 6m,  
TOAST 
               
Table 2-5 Data availability within VISTA 
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Trial Treatment 
Type 
Placebo 
Type 
Placebo 
Only 
Lesion 
Volume 
NIHSS 
Intervals 
NIHSS 
Individual 
Categories 
Labs BI 
Intervals 
mRS 
/RS 
Intervals 
Concomitant 
Medication  
rt-PA AE CT 
Intervals 
Year 
Published 
 A20 Ancrod Normal 
Saline 
No  ⌧ N/A N/A ⌧ N/A N/A ⌧  ⌧  1994 
A2  Normal 
Saline 
No  ⌧ N/A N/A ⌧ N/A N/A ⌧ ⌧ ⌧   
 STAT Ancrod Normal 
Saline 
No  ⌧ N/A N/A ⌧ Baseline, 
7, 90 & 
360  
N/A ⌧  ⌧  2000 
 ESTAT Ancrod Normal 
Saline 
  N/A N/A ⌧ Pre-
Stroke, 
90 Days 
N/A ⌧  ⌧  2006 
 ECASSI  Alteplase Lylophilised 
powder in 
sterile water 
No  6h, 24h, 
90 Days 
⌧ ⌧ 90 Days 90 Days ⌧ ⌧ ⌧ Baseline, 
24h, 7 
Days 
1995 
ECASSII Alteplase Lylophilised 
powder in 
sterile water 
No ⌧ Baseline, 
24h, 90 
Days 
⌧ ⌧ 30 & 90 
Days  
30 & 90 
Days 
⌧ ⌧  ⌧  Baseline, 
24h, 7 
Days 
1998 
GAINAM Gavestinel Dextrose No  Baseline, 
30 Days, 
90 Days  
⌧ No 
Glucose 
Available 
7, 30 & 
90 Days 
Baseline, 
30 &  90 
Days 
⌧ ⌧  ⌧  2001 
GAININT Gavestinel Dextrose No  Baseline, 
30 & 90 
Days  
⌧ No 
Glucose 
Available 
7, 30 & 
90 Days 
Baseline, 
30 & 90 
Days 
⌧ ⌧  ⌧  2000 
SEL07 Selfotel  No  Baseline, 
7, 30 & 
90 Days 
⌧ ⌧ 24h,  90 
days 
N/A ⌧    2000 
SEL10 Selfotel  No  Baseline, 
7, 30 & 
90 Days 
⌧ ⌧ 7, 30 & 
90 Days 
N/A ⌧  ⌧  2000 
CMZ Clomethiazole Saline ⌧ ⌧ Baseline, 
7, 30 & 
90 Days 
⌧ ⌧ 7, 30, 60 
& 90 
Days 
30 & 90 
Days 
⌧  ⌧ Days 33-
800 
(Varied) 
2002 
ASK Streptokinase Saline     N/A   N/A     1996 
IMAGES MgSO4 Saline   N/A N/A   N/A N/A ⌧ ⌧  2004 
               
 
Table 2-5 Data availability within VISTA 
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Trial Treatment 
Type 
Placebo 
Type 
Placebo 
Only 
Lesion 
Volume 
NIHSS 
Intervals 
NIHSS 
Individual 
Categories 
Labs BI Intervals mRS /RS 
Intervals 
Concomitant 
Medication  
rt-PA AE CT 
Intervals 
Year 
Published 
INWEST Nimodipine  ⌧   N/A ⌧ Baseline, 7, 
30 & 90 
Days 
N/A     1994 
TAIST Tinzaparin Aspirin ⌧  No BNIH N/A ⌧ 90 Days Pre 
Stroke,  
90 Days  
⌧ 
No Heparin/ 
Warfarin  
 ⌧  2001 
TRUST Nimodipine  ⌧  N/A N/A ⌧ 7, 21 & 180 
Day 
N/A N/A    1990 
LUB-INT-5  Lubeluzole  Saline ⌧   N/A N/A ⌧ 5, 30 & 90 
Days 
N/A N/A  ⌧  1998 
LUB-INT-4 Lubeluzole Saline ⌧  Baseline, 
3, 5, 14 & 
30 Days  
⌧ ⌧ 7 &28 days 7 & 28 
Days 
  ⌧  1995 
LUB-INT-7 Lubeluzole Saline ⌧    ⌧     ⌧  - 
LUB-INT-9 Lubeluzole  Saline ⌧  ⌧ ⌧ N/A Pre-Stroke, 
30 & 90 
Days  
Pre-
Stroke, 30 
& 90 Days 
N/A    1997 
LUB-INT -13 Lubeluzole  Saline ⌧  N/A N/A ⌧ Pre-Stroke, 
5 30 & 90 
Days 
Pre-
Stroke, 5 
30 & 90 
Days 
⌧  ⌧  2000 
LUB-INT-15 Lubeluzole Saline     ⌧ Pre-Stroke, 
5 30 & 90 
Days 
Pre-
Stroke, 5 
28 & 90 
Days 
⌧  ⌧  - 
STICH Early 
Surgery  
Best  
Medical 
Care 
⌧ ⌧ N/A N/A N/A  180 Days  Pre-
Stroke, 
180 Days 
Thrombolytic 
Therapy- No 
Details 
   2005 
               
Table 2-5 Data availability within VISTA 
 
 
 
Myzoon Ali, 2008   Chapter 2, 53 
 
 
 
 
 
Trial Treatment 
Type 
Placebo 
Type 
Placebo 
Only 
Lesion 
Volume 
NIHSS 
Intervals 
NIHSS 
Individual 
Categories 
Labs BI 
Intervals 
mRS 
/RS 
Intervals 
Concomitant 
Medication  
rt-PA AE CT 
Intervals 
Year 
Published 
mRECT Repinotan  No N/A Baseline,  
24-48h, 
48-72h, 
72-96h, 
30 &90 
Days 
⌧  ⌧ 3-4, 30 & 
90 Days 
3-4, 30 & 
90 Days 
⌧ ⌧ ⌧   - 
 NINDS rt-PA  No ⌧ Baseline, 
2h, 24h, 
7-10  & 
90 Days 
⌧ ⌧ 7-10, 90, 
180 & 360 
Days 
7-10, 90, 
180 & 
360 
Days 
⌧ ⌧   Baseline, 
24 Hrs,  
7-10 & 90 
Days 
1995 
ASTIN UK-279,276 
Neutrophil 
Inhibitory 
Factor 
Saline  No ⌧ Baseline, 
1, 7 & 21 
Days 
No ⌧ 7, 21, 90 
Days 
Prior 
stroke,  
1, 21 & 
90 Days  
 ⌧  Day 5 2003 
SAINT NXY-059 Saline  No ⌧ Baseline, 
24h, 7 & 
90 days 
⌧ ⌧ 7, 30 & 90 
days 
7, 30 & 
90 days 
⌧ ⌧ ⌧ Baseline, 
72 h 
2006 
CHANT NXY-059  No  ⌧ Baseline, 
7 & 90 
days 
⌧ ⌧ 7, 30 & 90 
days 
7, 30 & 
90 days 
⌧  ⌧ Baseline, 
5 & 10 
days 
 
GSDB - - -  Baseline, 
48-72h 
⌧  90 days Prior 
stroke, 
48-72h 
⌧    - 
               
Table 2-5 Data availability within VISTA 
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2.4 The Role of VISTA in Current Electronic Resource- 
Based Research 
As mentioned in chapter 1, other databases such as the German Stroke Databank (167) 
and the Database of the German Stroke Unit Register Study Group (168) are available to 
carry out analyses. Similarities exist in principle between the German Stroke Databank 
(GSDB) and VISTA. The GSDB, which was added to VISTA in November of 2007, is a 
multicentre hospital based registry of stroke patients who were registered between 
1998 and 1999. It has been used as a resource for epidemiology, aetiology, management 
and outcome in stroke patients. VISTA has similar aims, but includes specific subsets of 
patients who have been enrolled in international clinical trials of various therapies.  
Mohr et al. (1986) described limitations of conventional stroke registries. These 
included an ill defined population due to prospective entry of all patients at a given 
institution, missing data due to insufficient follow up protocols and a diminished 
number of patients for a particular stroke subtype, or set of prognostic factors (169). 
Spitzer et al. (1989) (170) further added that in order for a stroke registry to be used in 
a multicentre study of stroke data, items and follow up periods should be well defined. 
VISTA addresses all of these issues and builds on the previous stroke registry model to 
create a well defined patient population that is comparable with patients who are likely 
to be enrolled in clinical trials.  
The international relevance of the VISTA data, the larger sample, and the concentration 
on trial-eligible patients are unique but complementary features. Certain Cochrane 
review groups also hold individual patient data for meta-analysis purposes: unlike these 
groups, VISTA does not plan for or permit examination of treatment effects, nor are the 
data restricted to a single trial topic. Again, the meta-analysis groups provide 
complementary opportunities; VISTA is distinct through encouraging data sharing and 
having a mechanism for handling external proposals.  
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In 2005 the International Committee of Medical Journal Editors (ICMJE) initiated a policy 
whereby investigators were required to deposit information about trial design into a 
clinical trials registry before commencing patient enrolment (171;172). Their aim was to 
encourage dissemination of new research and promote collaboration with other 
investigators. Many institutional review boards or national ethics committees apply 
similar rules. There can be little prospect of harm and substantial potential for 
universal gain from lodging trial data for at least the control group in a resource that 
will be used to improve future research and clinical care for the participating patient 
community. Some national grant awarding bodies such as the UK Medical Research 
Council expect completed trial data to be available to their community. VISTA provides 
a mechanism for securely lodging, maintaining and accessing such data for approved 
purposes.  
2.5 Potential Uses of VISTA 
VISTA facilitates access to a wide range of patient data from randomised trials. For each 
case in VISTA we can examine the relationship between baseline prognostic factors 
including concomitant treatments, and outcome measures. Thus, natural history 
analyses can be adjusted from many covariates. Investigators can specify whether their 
dataset contains placebo and /or treatment group data and if necessary these data can 
be used to conduct sensitivity analyses with output made available to VISTA 
investigators in a form that does not compromise the anonymity of the trial(s).  
Gray (2006) (173) recommended the development of models to assess the cost-
effectiveness of interventions based on data from clinical trials and observational 
studies. This can be facilitated using patient prognostic and outcome variables available 
within VISTA. The lack of validated and comprehensive prognostic models to chart 
stroke recovery (174) is also an area where use of VISTA could be beneficial. To that 
end, a predictive model for survival and functional outcome after acute ischaemic 
stroke was recently developed by König et al. (2008) using VISTA (175). 
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The failure of so many acute stroke interventions has highlighted the need for a method 
to assess the futility of an intervention before committing resources to further study. 
Tilley et al. (2007) (176) commented on the feasibility of using clinical resources to aid 
the selection of effective therapeutic agents. The study of multiple interventions for 
acute stroke may take years and consume vast resources in the process. VISTA could be 
used as a source of historical comparator data to assess futility of a novel intervention 
before assessment in a costly phase III trial.  
Mandava & Kent (2008) (177) successfully demonstrated the use of pooled placebo 
groups from previous clinical trials to predict success of future trials. They found that 
patient outcomes in both the treatment arms of the SAINT I and ABESST trials fell within 
prediction bands generated using pooled placebo data (predicting futility of these 
interventions), while patient outcomes from the treatment arm of the NINDS rt-PA trial 
fell above the prediction band, indicating a successful outcome of the latter 
intervention. VISTA can be used in a large-scale version of this study to inform futility of 
a novel intervention.        
Data from the nascent VISTA were used to develop the forced allocation system that 
was employed to achieve an average onset to treatment time of under 4 hours in the 
SAINT I trial (110). Currently VISTA has 29 ongoing or completed projects involving 
natural history data which may inform future trials. Questions under investigation 
include the incidence of congestive heart failure following index stroke in placebo 
treated patients to provide guidance on use of fluids early after stroke, the importance 
of stroke lateralisation on clinical outcomes, the safety and efficacy of heparin 
treatment in patients with cardioembolic stroke and the incidence of delayed diagnosis 
of atrial fibrillation after acute ischaemic stroke.   
Subsequent chapters demonstrate the proposed uses of VISTA to investigate stroke 
epidemiology, methods of improving clinical trial design and finally the potential for use 
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of data from VISTA as a source of historical comparators to inform phase II and phase III 
clinical trials.   
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3 Stroke Outcome in Clinical Trial Patients 
Deriving from Different Countries 
3.1 Background 
Epidemiological studies based on data from clinical registries have contributed to 
advances in modern medicine by enhancing our understanding of the natural history of 
disease (133). The depth of data and the multinational nature of clinical trials within 
VISTA make this resource well suited for an examination of the natural history of stroke 
recovery in patients recruited from various countries.  
3.1.1 Variance in Stroke Prevalence and Outcomes 
Worldwide, stroke is one of the leading causes of morbidity and mortality and 
constitutes a major global disease burden (178). As mentioned in chapter 1, 
geographical variations in stroke subtype exist: 67-80% of strokes in developed countries 
are ischaemic and 6-19% are haemorrhagic in nature (20), contrasting with the Asian 
population where up to 35% of all strokes are haemorrhagic (23;24).  
Comparisons of stroke incidence and mortality have shown prominent geographical 
variations (144-149). Stroke incidence in Asia is generally higher than in the USA (43-
45). Avendano et al. (2008) reported that adults in the USA had a higher stroke 
prevalence than their European counterparts (179). This difference remained after 
adjustment for risk factors, and the authors hypothesised that differing health care 
policies could have played a role in determining prevalence.  
Within the USA, stroke mortality varies by race and geographical location, with 
increased incidence in the ‘Stroke Belt’ states (180). Strokes are more frequent in 
Eastern than in Western Europe, with incidence varying from 660 per 100 000 men in 
Russia to 303 per 100 000 men in Sweden (48). Stroke mortality is also five times higher 
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in Eastern Europe compared with Western Europe (48;50). This phenomenon could also 
be attributed to a higher frequency of risk factors such as hypertension and smoking in 
the Eastern European population (181;182). These patients tend to suffer more severe 
strokes, from which the recovery is poorer.  
Differences in stroke risk are not confined to the East-West European axis, but are also 
found amongst countries in Western Europe. Stroke incidence is lower in France and the 
United Kingdom compared with Germany. One-year mortality for stroke is lowest in 
France and highest in the United Kingdom (48). Over the past 20 years stroke-related 
mortality has decreased in Japan and Western Europe, and increased in Eastern Europe 
(50;183).  
3.1.2 Causes of Regional Variation 
Although the regional variations in stroke morbidity and mortality have been well 
established, the underlying causes are not well understood (184;185). Variation may be 
due to factors such as socioeconomic status (186) distribution of risk factors (187) 
access to and use of health care resources (188;189). Voeks et al. (2008) described 
stroke incidence in the ‘Stroke Belt’ states of North and South Carolina, Georgia, 
Alabama, Mississippi, Tennessee, Louisiana and Arkansas (180). They reported that 
regional differences in diabetes prevalence followed a similar pattern to stroke 
mortality and this variation was independent of patient hypertensive status, indicating 
that diabetes prevalence may influence regional differences in stroke prevalence.     
The availability of resources for acute stroke care and rehabilitation can influence 
functional outcome and survival (190). The standard of stroke care between or within 
countries can vary widely (191). There were 5.7 million stroke related deaths in 2005 
and of these, 87% occurred in low and middle income countries (192;193). Asplund et al. 
(2003) reported that rehabilitation such as physiotherapy and speech therapy was 
provided more often in the Netherlands, Belgium, Australia and New Zealand compared 
with other regions (188).  
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The International Stroke Trial investigators observed the lowest case fatality rates in 
Scandinavian stroke patients. This was attributed to the availability of acute stroke 
units for these patients (194) though a confounding effect of case-mix cannot be 
excluded. The location of acute stroke treatment centre can influence the standard of 
care, and therefore the outcome. Read & Levy (2005) reported significant differences in 
stroke care practices between smaller, regional hospitals and larger, metropolitan 
hospitals (195). Patients who were initially admitted to community hospitals and 
subsequently transferred to dedicated stroke centres had a higher in-hospital mortality 
rate when compared with similar patients who were initially assessed and treated in 
dedicated stroke centres (196). Stroke trial centres usually deliver the highest standards 
of care in the country and are associated with improved outcome (197). A confounding 
impact of stroke care on an assessment of geographical variation in outcome should be 
minimized by utilizing patients treated in this setting. Nevertheless, adjustment of 
outcome for multiple case mix and service quality variables did not remove substantial 
differences in functional outcome and death between countries in the Tinzaparin in 
Acute Ischaemic Stroke Trial (TAIST) (198).  
3.1.3 Aims 
We intended to examine the impact of geographical location on index stroke severity, 
stroke outcomes and mortality, after adjusting for case-mix, amongst different trial 
centres using the Virtual International Stroke Trials Archive (VISTA). 
3.2 Methods 
3.2.1 Eligibility Criteria 
We collated anonymised data from VISTA on patients who were recruited into clinical 
trials across various geographical locations. Anonymity agreements for use of VISTA 
preclude identification of the trial sources. However, we identified eligible patients 
who were at least 18 years old, had documented National Institutes of Health Stroke 
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Scale (NIHSS) and modified Rankin Scale (mRS) scores available for baseline and at 90 
days. We examined patients with an ischaemic stroke, for whom previous medical 
history variables were available, and for whom no thrombolysis or active intervention 
was performed. Variables of interest for our study included baseline NIHSS score, age, 
sex, medical history, geographical region, mortality, mRS and NIHSS score at 90 days. In 
order to examine regional influences, whilst accounting for low sample numbers in some 
regions, countries within a similar geographic location were grouped together into 
datasets of at least 40 patients. Data from patients enrolled in the USA & Canada were 
used as a reference against which we compared index stroke severity, neurological and 
functional recovery in other regions, as this group had the largest sample size and 
therefore offered the strongest statistical power for comparison. 
3.2.2 Statistical analyses 
We described the distribution of 90 day modified Rankin Scale (mRS) scores amongst 
constituent trials, stratified by region of patient recruitment, in an attempt to examine 
whether the differences in individual trial eligibility criteria could have confounded 
outcome measures. We then investigated the NIHSS scores at baseline, and the mRS, 
NIHSS and survival at 90 days following index stroke.  
3.2.2.1 Regional Variation in Stroke Severity 
We used logistic regression to examine whether the geographical region of trial 
recruitment was a significant predictor of mild index stroke, defined as NIHSS score at 
baseline of ≤ 5. We included age and medical history as covariates in this model. We 
accounted for potential shifts in treatment patterns over time by including a binary 
covariate in our logistic regression analyses, representing patient recruitment between 
1994 and 1997 or 1998 and 2000 respectively.  
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3.2.2.2 Regional Variation in 90 -Day Outcomes  
We defined good functional outcome at 90 days as attainment of a mRS score of ≤ 1, 
and good neurological outcome as attainment of a NIHSS score of ≤ 1. We performed 
logistic regression using these functional and neurological outcomes to determine 
whether recruitment region was a significant predictor of good outcome after 
accounting for age, initial stroke severity, medical history and year of trial recruitment. 
Finally, we used a Cox Proportional Hazards model to examine whether survival differed 
amongst regions after accounting for year of recruitment, initial stroke severity, age, 
and medical history.  
Missing data were handled by imputing the worst possible outcome where the patient 
had died within the follow up period. All analyses were performed using a SAS 9.1™ 
statistical package.  
3.3 Results 
3.3.1 Demography 
We extracted anonymised data on 3284 patients who met the stated eligibility criteria. 
The majority of patients in this dataset were from USA & Canada (58%), 5% were from 
Australia, New Zealand Hong Kong or Singapore, and 36% were from European countries 
(Figure 3-1). Details of case mix across the different regions are presented in Table 3-1. 
Median age across the regions ranged from 66 (IQR [58, 72]) in Germany, to 76 (IQR [64, 
81]) in Greece & Israel. Median baseline NIHSS score ranged from 10.5 (IQR [6, 15]) in 
Austria & Switzerland, to 15 (IQR [10, 20]) in the USA & Canada. The most frequent 
stroke risk factor present was hypertension. Greece and Israel had the highest 
proportion of patients with hypertension (76%) and atrial fibrillation (41%).  
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3.3.2 Bias from Trial Source  
We accounted for the possibility that the original trials’ eligibility criteria could 
confound analyses by examining the distribution of mRS across regions, stratified by 
trial source. These distributions revealed that eligibility criteria did not contribute to an 
overall difference in outcomes amongst the regions examined (Figure 3-2).     
3.3.3 Variation in Initial Stroke Severity 
We examined the variation in initial stroke severity in patients who were recruited into 
clinical trials from different regions after accounting for age, medical history and year 
of enrolment. Patients who were enrolled in Austria & Switzerland had the mildest 
index stroke in our sample (p=0.0001, adjusted odds ratio for mild stroke=72.8, 95% 
confidence interval [22.0, 240.4]), closely followed by patients enrolled in Germany 
(p=0.01, adjusted odds ratio for mild stroke=52.3, 95% Confidence Interval [15.0, 
182.9]) (Figure 3-3). In this analysis patients who were recruited after 1998 had more 
severe index strokes (p= 0.006, adjusted odds ratio for mild stroke =0.22, confidence 
interval [0.07, 0.64]
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Region  Frequency 
(n) 
Frequency 
(%) 
Age 
(Median 
[IQR]) 
Baseline 
NIHSS 
(Median 
[IQR]) 
Sex 
(%Male) 
Hemisphere 
(% Right) 
Atrial 
Fibrillation 
(%present) 
Hypertension 
(% present) 
MI 
(%present)  
Diabetes 
(%present) 
Australia & New Zealand 102 3.1 70 [62, 77] 13 [9, 19] 56.9 48.0 31.4 64.0 16.3 16.7 
Austria & Switzerland 82 2.5 68 [59, 77] 10.5 [6, 15] 59.8 51.3 20.3 55.4 9.5 18.5 
Belgium & Netherlands 99 3.0 71 [63, 78] 13 [8, 18] 62.6 45.9 38.5 48.4 15.4 14.9 
Denmark, Iceland & Norway 78 2.4 67.5 [57, 73] 11 [7, 16] 60.3 42.5 11.9 32.2 17.0 5.8 
Finland 133 4.1 69 [64, 75] 12 [7, 18] 51.1 54.7 19.6 32.1 10.7 10.5 
France 194 5.9 68 [55, 74] 14 [10, 19] 62.9 51.9 24.7 54.6 5.2 10.2 
Germany 161 4.9 66 [58, 72] 12 [7, 15] 61.5 64.2 14.18 50.8 9.7 15.5 
Greece & Israel 43 1.3 76 [64, 81] 12 [7, 17] 58.1 55.8 41.5 75.6 9.8 22.0 
Hong Kong & Singapore 66 2.0 74 [68, 79] 12 [8, 18] 48.5 43.9 40.4 66.7 3.5 28.1 
Italy 130 4.0 72 [65, 78] 12 [7, 18] 62.3 45.4 22.1 61.1 6.2 14.4 
Spain & Portugal 158 4.8 70 [64, 76] 14 [9, 19] 55.7 43.6 26.3 48.3 8.5 20.3 
Sweden  66 2.0 73 [69, 77] 13 [6, 19] 74.2 47.7 33.3 43.9 15.8 21.9 
UK 53 1.6 71 [64, 77] 14 [8, 19] 43.4 52.8 35.7 54.8 26.2 10.9 
USA & Canada 1919 58.4 72 [63, 79] 15 [10, 20] 49.4 47.4 25.9 71.7 20.2 24.6 
     
Table 3-1 Baseline characteristics and concomitant diseases in patients enrolled in different regions 
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Figure 3-1 Proportion of patients from each region included in analyses 
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Figure 3-2 Distribution of mRS Scores stratified by country and trial source 
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Figure 3-2 Distribution of mRS scores stratified by country and trial source 
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Figure 3-3 Odds ratio for mild index stroke (NIHSS ≤ 5) amongst different regions (adjusted 
for age, medical history and year of trial enrolment) 
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3.3.4 Variation in 90 Day Outcome Measures 
3.3.4.1 Functional Outcome 
In our analysis dataset only 3% of patients were lost to follow up at 90 days. Functional 
outcome at 90 days after stroke varied by region, even after adjusting for initial stroke 
severity, age, medical history and year of enrolment. Patients who were recruited in 
Austria & Switzerland attained a significantly better functional outcome at 90 days 
compared with those recruited in USA & Canada (p=0.023, adjusted odds ratio for good 
functional outcome=1.96, 95% confidence interval [0.90, 4.27]), closely followed by 
patients enrolled in Italy, (p=0.036, adjusted odds ratio for good functional 
outcome=1.78, 95% confidence interval [0.85, 3.75]). Patients recruited in Germany had 
a significantly worse functional outcome at 90 days (p=0.013, adjusted odds ratio for 
good functional outcome=0.31, 95% confidence interval [0.13, 0.76]) (Figure 3-4). Trial 
recruitment after 1998 was not a significant predictor of good functional outcome at 90 
days (p=0.42).  
3.3.4.2 Neurological Outcome 
Patients enrolled in Austria & Switzerland had a significantly better neurological 
outcome at 90 days (p=0.034, adjusted odds ratio for good neurological outcome= 2.42, 
95% confidence interval [1.08, 5.41]) when compared with those enrolled in the USA & 
Canada (Figure 3-5). Likewise, trial recruitment after 1998 was not a significant 
predictor of good neurological outcome at 90 days (p=0.87).   
3.3.4.3 Survival 
We examined survival at 90 days following acute ischaemic stroke to determine whether 
mortality varied between geographical locations after adjusting for case mix. A Cox 
Proportional Hazards model showed that patients enrolled in Australia, New Zealand, 
Austria, Switzerland, Belgium, Netherlands, Finland, Germany, Greece, Israel, Spain and 
Portugal had a significantly better survival rate when compared with those enrolled in 
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USA & Canada (p<0.05) (Figure 3-6), with those enrolled in Spain & Portugal having the 
best survival rate in our sample (p<0.0001 hazard ratio for survival=1.70, 95% 
confidence interval [1.31, 2.20]).  
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Figure 3-4 Odds ratio for good functional outcome at 90 days (mRS ≤1) amongst different 
regions (adjusted for case mix and year of trial enrolment) 
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Figure 3-5 Odds ratio for good neurological outcome at 90 days (NIHSS ≤1) amongst 
different regions (adjusted for case mix and year of trial enrolment). 
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Figure 3-6 Hazard ratio for survival at 90 days amongst different regions, (adjusted for case 
mix and year of trial enrolment). 
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3.4 Discussion  
Investigating stroke incidence in different parts of the world increases our 
understanding of aetiology and prevention (23). Epidemiological studies form the basis 
for future research (199); knowledge of disease patterns and regional differences assist 
the targeting of programs which could help reduce risk factors and distribute resources 
for stroke management (200). We aimed to identify region specific differences in index 
stroke, outcome and mortality after accounting for case-mix.  
In our analysis dataset, patient observations from some countries were under-
represented, therefore some analyses lacked power. We overcame this by grouping 
countries together according to geographical location. We recognise that the 
participating centres may represent some of the more organised hospitals in their 
country and that this may diminish country-specific differences; however, this 
strengthens rather than weakens our conclusions as the impact of standard of care on 
outcome is minimised.  
After accounting for initial stroke severity, age, year of recruitment and medical 
history, we found that trial recruitment in Austria, Switzerland and Italy was a 
significant predictor of good functional outcome at 90 days when compared with the 
USA & Canada (p<0.05). This trend towards better recovery was also reflected in the 
neurological outcomes of patients recruited in Austria & Switzerland (p=0.03). 
Interestingly, Austria has a universal health care system and low levels of income 
inequality (201;202), which may have contributed to our observations. Adjustment for 
period of trial recruitment revealed a trend for more severe stroke in trials conducted 
after 1998, with no improvement in functional or neurological outcome when compared 
with earlier trials. This may be a reflection of the lack of clinical impact of new drugs 
since the licensing of recombinant tissue plasminogen activator (rt-PA) (81). Moreover, 
it is possible that the increased use of rt-PA within the 3 hour time window could have 
led to some selection of more severe patients for trials after 1998. Survival across the 
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different regions varied, with patients enrolled in Australia, New Zealand, Austria, 
Switzerland, Belgium, Netherlands, Finland, Germany, Greece, Israel, Spain and 
Portugal all reporting a significantly better survival rate than those enrolled in USA & 
Canada.  
Our dataset did not contain any patients who were enrolled in the Far East or South 
America. Our findings are therefore only applicable to a subset of stroke trial patients; 
these are typical of internationally conducted trials over the last decade.  
Disparity in outcome could be partially explained by variations in stroke care (198) per 
capita expenditure on health care, health care policy and availability of rehabilitation 
resources amongst the regions examined. It has been previously documented that 
dedicated stroke units can reduce disability (197). For example, the Scandinavian stroke 
unit model combines both acute and rehabilitation stroke units nationwide and this was 
reflected in low case fatality (203). However not all stroke patients have access to 
these units (198). Despite the established benefits, it is still uncommon for patients to 
be admitted into stroke units in many Italian regions: patients are most commonly 
admitted into general wards (204).  
Variations in case –fatality may also be influenced by differing accuracies of stroke 
diagnoses, stroke subtypes, severity or different methods of management, for example, 
use of CT scanning in the MONICA centres varied between 0- 76% (205). The proportion 
of patients who receive brain imaging, neurosurgery, physiotherapy, speech and 
occupational therapy (206) and the degree of governmental expenditure on health care 
can also influence outcome. For example, the United States government in 2003 spent 
USD $2548 per capita on health care. In contrast government expenditure on health 
care in Singapore in 2003 was USD $348 (207). In some countries such as Japan, 
residents are covered by Ministry of Health and Welfare –sponsored health insurance 
(208). This level of coverage is often unavailable in other countries. Distribution of 
health care workers also differ amongst regions, with Belgium reporting a greater 
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number of physicians per 1000 people (4.49) compared with Canada (2.13) (209). These 
factors in combination can impact the standards of care available and contribute to 
disparity. We lacked data on the standard of stroke care available to each patient and 
therefore could not consider this as a covariate in this analysis.  
Although we noted a variation in functional outcome at 90 days between different 
regions, we are unable to draw inferences regarding its cause. Data on socio-economic 
status, a predictor of stroke both in poor and developed countries (186;210;211), were 
not available and may have influenced outcome. Socio-economical factors are complex 
in their nature and influence both risk factors and standards of care (186;212). Risk 
factors vary across the lifespan, and show regional and international variations (200). 
Recording of patient lifestyle is imperfect in its nature, and particularly in our series, 
some lifestyle and social factors that may have impacted outcome, such as the degree 
of family support available (213), were not recorded. The degree of family support and 
social network structure is more extensive for some ethnic minority groups, and can 
permit increased home placement after stroke rehabilitation (214). Absence of these 
variables may have confounded our results. In addition, factors such as ethnicity (150-
152), and stroke subtype may have had an impact on outcome in our sample. Both 
stroke subtype and ethnicity were not included as covariates in our analyses, but should 
be taken into account when interpreting outcome.  
We found significant differences in mortality in many European countries compared with 
the USA & Canada. This finding was supported by Asplund et al. (2003) (188) Gray et al. 
(198) and Holland (1991) (215). Both Grieve et al. (2001) (216) and Holland (215) 
reported that stroke outcome was worst in the UK. Our findings are congruent with 
these investigations. We found no significant difference in the outcome or survival of 
patients enrolled in the UK compared with those recruited in the USA & Canada, which 
had the worst survival rate in our study. Our mortality results could also be explained by 
the use of optimal patient selection during the trial recruitment phase; the trials may 
have excluded patients with a poorer prognosis.    
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Read & Levy (2005) described differences in stroke management practices between 
regional and metropolitan hospitals, and identified a need to limit this variation (195). 
Additionally, Sudlow et al. (1997) (23) reported that comparisons of stroke incidence in 
different regions are only meaningful if investigations utilise standard definitions and 
methods. The strengths of our analyses lay in the robust data collection protocols 
implemented within VISTA, the similar standard of care in trial centres and the depth of 
patient variables available. However data were extracted from trials that were 
primarily concerned with the treatment of ischaemic stroke using a novel therapy, and 
as such, data collection was not specifically tailored for an epidemiological 
investigation. Numerous socio-economic factors that impact stroke recovery were not 
recorded within VISTA. 
3.4.1 Conclusion 
We concluded that recruitment in recent trials was associated with more severe index 
stroke, but not with significant difference in outcome when compared with earlier trial 
enrolment. Variation in stroke outcome across different geographical regions was 
evident after adjustment for case mix. Patients recruited in the USA & Canada had the 
worst index stroke severity. Patients recruited in Austria & Switzerland had the best 
functional and neurological outcome at 90 days after adjusting for case mix. Patients 
enrolled in Spain and Portugal had the best survival rate.  
Since the differences in outcome between countries are larger than the expected 
treatment effects of some interventions, the findings here echo the need for rigorous 
randomisation practices for active and control groups within multinational trials so as to 
avoid false treatment effects in regions where placebo treated patients achieve a good 
outcome after accounting for case mix (217). Our findings may be pertinent to trials 
that do not include ethnicity or country of recruitment as a covariate in analyses. We 
consider it unlikely that these findings would explain discrepant results between 
consecutive trials of the same drugs, for example, the Lubeluzole North American trial 
(118) and the subsequent neutral European Lubeluzole trial (109), or the failure of 
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SAINT II (143) compared with SAINT I (110). These trials randomised patients within 
centres or countries and some included geographical site or country as a covariate in 
analysis (110;143); overall severity and outcomes were similar between trials. 
We demonstrated here the use of VISTA to elucidate stroke severity and outcome trends 
in clinical trial patients. Further investigation of the causes of regional differences in 
outcome would be beneficial particularly in developing countries which are under 
represented within VISTA. This could include an investigation of stroke subtypes, time 
from stroke onset to treatment, the underlying socio-economic influences, access to 
and use of health care resources within countries which have reported a poorer 
outcome. Continued recruitment of acute stroke and rehabilitation trials to VISTA will 
allow us to address these questions.  
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4 Primary Endpoint Times, Functional Outcome 
and Adverse Event Profile after acute Ischaemic 
Stroke. 
4.1 Background 
Many clinical trials of putative neuroprotectants have failed. There is a need for data 
with which to optimise aspects of stroke clinical trial design. Trials contained within 
VISTA utilised rigorous data collection protocols, making this resource ideal for an 
investigation of stroke outcomes. This chapter illustrates how VISTA can be used to 
examine aspects of clinical trial design such as the optimisation of stroke endpoints.  
Stroke can be complicated by a number of adverse events such as recurrent stroke, 
raised intracranial pressure (ICP), pulmonary embolism (PE), pneumonia and deep vein 
thrombosis (DVT). Such events are major sources of morbidity and mortality in stroke 
patients. We used data from VISTA to investigate the relationship between types of 
post-stroke complications and attainment of good functional outcome.  
4.1.1 Post-Stroke Complications 
Although early mortality can result from the direct effects of stroke, the majority of 
deaths after the first week are due to non-neurological factors (218). Viitanen et al. 
(1987) (219) attributed mortality within 1 week of index stroke to the direct effects of 
stroke, subsequent mortality in the first month may occur as a consequence of 
potentially preventable causes (218;220).  
The risk of mortality after ischaemic stroke increases with time: Vernino et al. (2003) 
(221) reported that survival after first ischaemic stroke was 92% at 1 week, 83% at 30 
days and 77% at 6 months. History of a previous stroke confers a 7-fold increase in risk 
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of recurrent stroke when compared with the general population (222). After a transient 
ischaemic attack (TIA) or mild ischaemic stroke, the overall risk of recurrent stroke is 
about 5% within the first 2 days, 10% within the first week and 18% within the first 3 
months (223). The risk of mortality from pulmonary embolism is increased 25–fold in 
patients who survive for 8 or more days following a stroke, compared with those who 
survive for less than seven days (224). The overall risk of DVT in patients following 
acute ischaemic stroke is between 22 and 75% (225) though aggressive modern 
management reduces this risk (226-228). Medical complications such as these may 
impact outcome by delaying or preventing aggressive rehabilitation (229), causing 
general deterioration of health and can result in a poor outcome after stroke (230;231). 
The scope of care is limited in patients who are medically unstable due to the 
occurrence of complications. This may increase their length of hospitalisation (231). 
Preventable medical complications may be a source of long term morbidity and 
mortality (232) and could confound assessment in clinical trials.   
4.1.2 Rationale for Shortening Clinical Trial Follow Up Period 
Many strokes occur in the context of other serious medical diagnoses and this increases 
the chances for developing medical complications in stroke survivors (233). Johnston et 
al. (1998) (230) described medical and neurological complications after acute ischaemic 
stroke to assess the impact of these complications on functional outcome and mortality. 
The direct effects of stroke were reported to be the principal cause of disability in 86% 
of patients, new stroke or extension of stroke was the primary cause of disability in 3% 
of patients, and ‘other’ factors were the primary cause of disability in 9% of patients. In 
that investigation disability in at least 12% of patients was not directly linked to index 
stroke severity. Similarly Vernino et al. (2003) reported that in patients who survived 30 
days after index ischaemic stroke, cardiac (28%) and respiratory events (26%) were the 
primary causes of subsequent death (221). The results of these investigations indicate 
that the presence of some types of preventable complications may have a confounding 
effect on outcome. These effects need to be minimised in order to create an accurate 
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representation of outcome based on stroke severity, therapeutic intervention and 
rehabilitation.  
Stroke itself clearly carries some direct risk of complications and whilst the rate of 
complications may to some extent depend on stroke severity (231;234-236), a number 
of later events are possible that may be unrelated to the severity of the index stroke 
and that could greatly influence or confound assessment of outcome. The incidence and 
timing of such complications could have a bearing on clinical trial outcomes that use 
later follow up periods. The longer the period between clinical assessments, the more 
likely it is that the patients will deteriorate due to the length of assessment period 
(237).  
Clinical trial investigators aim to measure as accurately as possible the impact of their 
novel treatment on disability at a given end point. We postulated that largely 
preventable factors such as secondary complications which were not a direct 
consequence of index stroke could influence the outcome of clinical trials. Case in 
point, Johnston et al. (1998) (230) reported that disability in at least 12% of patients 
was not attributed to index stroke severity. We sought to investigate whether the 
presence of such avoidable complications at later time points could confound outcome, 
and if this confounding effect could be minimised through altering the study endpoints. 
The duration of follow up usually chosen for efficacy trials is 3 months, based on largely 
empirical grounds; however, shorter follow up periods are possible (124). We postulated 
that a shorter follow up duration of 30 days could potentially limit the variability in 
clinical outcomes due to extraneous factors, i.e. to factors not directly related to 
stroke. Under our hypothesis, the extension of follow-up to three months could 
potentially expose a trial population to numerous competing influences that render 
their outcomes insensitive to real and important clinical benefits, just as follow-up for a 
20 year period in elderly people would inevitably lead to similar but extremely high 
mortality in all groups. Our investigation was based on the assumption that there are 
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two types of post-stroke event: those that are related to stroke severity and/or acute 
treatment, and which rightly reflect the outcome of treatment; and those that are 
simply markers of recent stroke and stroke risk (such as age and cardiovascular disease) 
but which could not reasonably be influenced by early intervention.  
4.1.3 Aims 
We intended to describe the complications encountered over a 90 day period after 
acute ischaemic stroke, categorise these complications into those which arose as a 
direct consequence of index stroke (‘stroke-related’) or those which occurred due to 
extraneous factors (‘unrelated to initial stroke severity’). We aimed to ascertain 
whether complications arising from comorbidities or of idiopathic aetiology could 
influence disability at 30 or 90 day follow up periods.  
4.2 Methods 
4.2.1 Eligibility Criteria 
We identified and included placebo –treated patients from VISTA who had experienced 
an acute ischaemic stroke, in whom thrombolysis was not administered, where 
documentation of adverse events and modified Rankin Scale (mRS) scores were 
available for the duration of the 90 day trial period.   
Variables of interest included age, sex, type of stroke, baseline National Institutes of 
Health Stroke Scale (NIHSS) score, type of complications, time to onset of complication 
relative to start of clinical trial, and mRS at 30 and 90 days. 
4.2.2 Categorisation of complications 
We reviewed and categorised complications from physicians’ case notes with the aid of 
previous literature (167;232;238-245); these were verified separately. Within VISTA the 
frequencies of complications were prospectively monitored and events were coded using 
the Medical Dictionary for Regulatory Activities (MedDRA) or World Health Organisation 
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(WHO) classification schemes. We termed events that had occurred due to a pre-
existing condition, (those that could be reasonably assumed not to have arisen due to 
the onset of symptoms), as ‘unrelated to initial stroke severity.’ These included events 
that were simply markers of recent stroke and stroke risk such as vascular stenosis, 
hypertension and cardiovascular disease. We also included in this category late onset 
complications (>7 days after index stroke) such as cerebral oedema, raised ICP, 
haemorrhagic transformation and evolution of stroke; these were determined to have 
occurred as a consequence of a recurrent stroke. Complications that had occurred as a 
direct consequence of the onset of symptoms were coded as ‘related to initial stroke 
severity/ hospitalisation.’ These included complications such as early neurological 
deterioration, infection and depression.   
4.2.3 Follow up 
Literature has reflected variation in what is considered to be early follow up after index 
stroke. For example in the case of recurrent stroke, the first 14 days have been 
selected as a margin between early and long-term recurrence especially in ischaemic 
stroke of cardioembolic aetiology (124;246). Some series have also extended the 
definition of early recurrent stroke to 90 days, (246-248) however the cut off point of 30 
days is used in most studies when referring to short term recurrent stroke 
(238;239;249). Using the above definitions as a guideline, we examined the incidence of 
complications and outcomes over 30 and 90 days. 
4.2.4 Statistical Analyses 
4.2.4.1 Types and Frequencies of Complications 
We described the risk of complications encountered over the 90 day period, and 
examined the time to first event using a Kaplan Meier analysis. Modified Rankin Scale 
scores at 30 and 90 days, stratified by type of complication were presented as median 
[IQR], to give an indication of subjective changes in outcome as a result of fluctuating 
risk of complications.  
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4.2.4.2 Functional Outcome at 30 and 90 Days 
We defined poor functional outcome as attainment of a mRS >1 at 30 or 90 days. We 
used logistic regression to analyse the association between a) the occurrence of 
unrelated complications and poor outcome (disability and death) and b) the occurrence 
of unrelated complications and disability (mRS>1, excluding death) at 30 and 90 days. 
We examined death and disability separately to ascertain whether any associations were 
being driven by mortality rates. We accounted for age and index stroke severity in the 
logistic regression, but omitted medical history variables as we hypothesised that 
patients with an eventful medical history would already be associated with an increase 
in ‘unrelated’ complication rates due to comorbidities, and adjustment for these 
variables may confound the analyses. 
Missing data were handled by imputing the worst possible outcome where the patient 
had died within the 90 day follow up period. All analyses were carried out using the SAS 
9.1 statistical package according to a pre-specified analysis plan. 
4.3 Results 
4.3.1 Demography 
We identified 531 eligible placebo-treated patients with acute ischaemic stroke, in 
whom thrombolysis was not administered, who had experienced at least one 
complication during the study period. Table 4-1 summarises the baseline characteristics 
and outcomes of these patients. The median age was 75 (IQR [68, 81]), 52.7% were 
male, 73% of patients had been diagnosed with hypertension and 40% had atrial 
fibrillation.  
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4.3.2 Complications 
4.3.2.1 Categorisation 
Tables 4-2 and 4-3 detail the categorisation of types of complications into ‘stroke- 
related’ and ‘stroke –unrelated’ categories. Complications deemed to be ‘stroke-
related’ included immediate consequences of index stoke such as cerebral oedema, 
cerebral herniation, progression of stroke and respiratory complications including 
aspiration pneumonia and bronchial infections. ‘Stroke-related’ complications were 
most commonly neurological in nature (39.4%), followed closely by respiratory 
complications (32.9% Figure 4-1). 
 ‘Stroke-unrelated’ events included cardiac arrhythmias, recurrent/ new strokes, 
miscellaneous pain and cancer. The majority of ‘stroke-unrelated’ events consisted of 
cardiac complications (38.9%), (Figure 4-2). In total, 35% of patients experienced a 
complication deemed ‘unrelated’ to initial stroke severity, and 16% of patients 
experienced both ‘stroke –related’ and ‘stroke-unrelated’ complications (Figure 4-3). 
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Variable Median [IQR] Frequency (%) 
Age 75 [68, 81] - 
BNIH 16 [11, 20] - 
mRS at 30 days 5 [4, 6] - 
mRS at 90 days 6 [4, 6] - 
Day of death 5 [2, 23] - 
Gender - Male=52.7 
Atrial fibrillation - YES= 40.0 
Hypertension - YES= 73.0 
MI - YES= 24.0 
Diabetes - YES= 26.5 
Mortality at 90 days - ALIVE=43.5 
Stroke-Unrelated  Complication  Yes=51.0 
Stroke-Related Complication  Yes=65.0 
Time To First Stroke-Related Event 6 [1, 27]  
Time To First Stroke- Unrelated Event 16 [5, 35]  
   
Table 4-1 Baseline characteristics and outcomes in patients with at least one complication 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 Incidence of ‘stroke-related’ complications 
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Figure 4-2  Incidence of ‘stroke-unrelated’ complications 
 
 
 
 
 
 
 
 
Figure 4-3 Risk of stroke-related, unrelated and combination of both complication types 
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Stroke-Related Complication Reason for inclusion Frequency Percentage 
Increased ICP Consequence of stroke 1 0.23 
Aggressiveness Consequence of hospitalisation 1 0.23 
Anaphylaxis Consequence of medication 2 0.47 
Aspiration of feeding tube Intubation 1 0.23 
Aspiration pneumonia Intubation 28 6.57 
Bacteraemia Consequence of hospitalisation 1 0.23 
Bleeding from urethra Consequence of catheterisation 1 0.23 
Bleeding- Gastrointestinal (GI) Consequence of medication 3 0.70 
Bronchial infection Intubation 2 0.47 
Bronchitis Intubation 2 0.47 
Bronchopneumonia Intubation 5 1.17 
Cerebral herniation Consequence of stroke 23 5.40 
Cerebral oedema Consequence of stroke 27 6.34 
Cerebral haemorrhage (petechial) Consequence of stroke 1 0.23 
Chest infection Consequence of hospitalisation 1 0.23 
Clostridium difficile Consequence of hospitalisation 1 0.23 
Colitis Consequence of hospitalisation 2 0.47 
Coma Consequence of stroke 2 0.47 
Cranial contusion Due to weakness induced fall 1 0.23 
Cystitis Consequence of hospitalisation 1 0.23 
Decreased consciousness Consequence of stroke 1 0.23 
Dehydration Consequence of hospitalisation 4 0.94 
Dementia Consequence of stroke 1 0.23 
Depression Consequence of stroke 2 0.47 
Deterioration of stroke Consequence of stroke 3 0.70 
DVT Due to immobility 6 1.41 
Edema -legs Due to immobility 1 0.23 
Elbow fracture Due to weakness induced fall 1 0.23 
Elevated International Normalised 
Ratio (INR) 
Consequence of hospitalisation 1 0.23 
Evolution of stroke Consequence of stroke 1 0.23 
Extension of stroke Consequence of stroke 2 0.47 
Fall Due to weakness induced fall 1 0.23 
Febrile Consequence of hospitalisation 4 0.94 
Foot swelling Due to immobility 1 0.23 
GI bleed Consequence of medication 14 3.29 
Haemorrhagic transformation Consequence of stroke 1 0.23 
Hematuria Consequence of medication 2 0.47 
Hemiparesis worsening Consequence of stroke 1 0.23 
Hemorrhagic transformation Consequence of stroke 9 2.11 
Hip dislocation Due to weakness induced fall 1 0.23 
Hip fracture Due to weakness induced fall 4 0.94 
Hyponatremia Consequence of hospitalisation 1 0.23 
Hypotension Consequence of stroke 5 1.17 
Hypoxia Consequence of stroke 2 0.47 
ICH Consequence of stroke 9 2.11 
Infection- unknown Consequence of hospitalisation 1 0.23 
Insomnia Consequence of hospitalisation 1 0.23 
Leg fracture Due to weakness induced fall 1 0.23 
Leukocytosis exacerbation Consequence of hospitalisation 1 0.23 
Lipothymia Consequence of stroke 1 0.23 
Low prothrombin rate Consequence of hospitalisation 1 0.23 
Malnutrition Consequence of hospitalisation 1 0.23 
Melaena Consequence of medication 3 0.70 
Nerve palsy Consequence of stroke 1 0.23 
Orthostatic hypotension Consequence of stroke 1 0.23 
Paraesthesia Consequence of stroke 1 0.23 
Parenchymal haemorrhage Consequence of stroke 1 0.23 
Pelvic abscess Due to immobility 1 0.23 
Pneumonia Intubation 37 8.69 
Pneumonitis Intubation 1 0.23 
Pneumopathy Intubation 1 0.23 
Poor nutrition Consequence of hospitalisation 1 0.23 
Possible pneumonia Intubation 1 0.23 
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Stroke-Related Complication Reason for inclusion Frequency Percentage 
Possible pulmonary embolus Consequence of stroke 1 0.23 
Probable sepsis Consequence of hospitalisation 1 0.23 
Progression of stroke Consequence of stroke 57 13.38 
Pulmonary aspiration Intubation 1 0.23 
Pulmonary embolus Consequence of stroke 22 5.16 
Pulmonary infection Intubation 1 0.23 
Pulmonary oedema Consequence of hospitalisation 19 4.46 
Pyelonephritis Consequence of catheterisation 1 0.23 
Respiratory arrest Consequence of stroke 12 2.82 
Respiratory distress Consequence of stroke 3 0.70 
Respiratory infection Intubation 2 0.47 
Seizure Consequence of stroke 18 4.23 
Sepsis Consequence of hospitalisation 11 2.58 
Septic shock Consequence of hospitalisation 6 1.41 
Septicaemia Consequence of hospitalisation 5 1.17 
Shock Consequence of stroke 1 0.23 
Suicide Consequence of stroke 1 0.23 
Syncope Consequence of stroke 4 0.94 
Toxic infection shock Consequence of stroke/ 
hospitalisation 
1 0.23 
Unconsciousness Consequence of stroke 1 0.23 
Urinary retention Consequence of catheterisation 1 0.23 
Urosepsis Consequence of catheterization 5 1.17 
Urinary Tract Infection (UTI) Consequence of catheterisation 7 1.64 
Vertigo Consequence of stroke 2 0.47 
Weakness Consequence of stroke 1 0.23 
Withdrawal of all life support Consequence of stroke 1 0.23 
Withdrawal of life support Consequence of stroke 1 0.23 
    
 
Table 4-2 Classification of complications into ‘stroke-related’ events 
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Stroke-unrelated complication Reason for categorisation Frequency Percentage
Abdominal pain Unlikely due to index stroke 1 0.30 
Angina Pre-existing risk/ condition 7 2.08 
Aortic aneurysm Unlikely due to index stroke 1 0.30 
Asthma Pre-existing risk/ condition 2 0.59 
Asystole Unlikely due to index stroke 3 0.89 
Atlantoaxial subluxation Unlikely due to index stroke 1 0.30 
Bowel obstruction Unlikely due to index stroke 2 0.59 
Bronchospasm Unlikely due to index stroke 2 0.59 
Cancer Pre-existing risk/ condition 13 3.86 
Cardiac arrest Unlikely due to index stroke 13 3.86 
Cardiac arrhythmia Pre-existing risk/ condition 35 10.49 
Cardiac decompensation Unlikely due to index stroke 1 0.30 
Cardiac insufficiency Unlikely due to index stroke 3 0.89 
Cardiogenic shock Unlikely due to index stroke 2 0.59 
Cellulitis Unlikely due to index stroke 1 0.30 
Cerebral tumour Pre-existing risk/ condition 1 0.30 
Chest pain Unlikely due to index stroke 2 0.59 
Congestive Heart Failure (CHF) Pre-existing risk/ condition 30 8.90 
Conduction block Unlikely due to index stroke 1 0.30 
Constipation Unlikely due to index stroke 1 0.30 
Conversion disorder Unlikely due to index stroke 1 0.30 
Conversion reaction Unlikely due to index stroke 1 0.30 
Chronic Obstructive Pulmonary 
Disease (COPD) exacerbation 
Pre-existing risk/ condition 1 0.30 
Coronary artery embolism Pre-existing risk/ condition 1 0.30 
Delirium tremens Pre-existing risk 1 0.30 
Deterioration of stroke Due to recurrent stroke 2 0.59 
Diabetic decompensation Pre-existing risk/ condition 1 0.30 
Diabetic nephropathy Pre-existing risk/ condition 1 0.30 
Diarrhoea Unlikely due to index stroke 1 0.30 
Duodenitis Unlikely due to index stroke 1 0.30 
Dyspnea Unlikely due to index stroke 1 0.30 
Edema No known location 1 0.30 
Electrolyte imbalance Unlikely due to index stroke 1 0.30 
Elevated sed rate Unlikely due to index stroke 1 0.30 
Emesis Unlikely due to index stroke 1 0.30 
Emphysema Pre-existing risk/ condition 1 0.30 
Endocarditis Pre-existing risk/ condition 2 0.59 
Evolution of stroke Due to recurrent stroke 2 0.59 
Exitus letalis No known cause 1 0.30 
Extension of stroke Due to recurrent stroke 1 0.30 
Femoral artery insufficiency Unlikely due to index stroke 1 0.30 
Functional paralysis No known cause 1 0.30 
Gall stones Unlikely due to index stroke 3 0.89 
Gastric erosions Unlikely due to index stroke 1 0.30 
Gastroenteritis Unlikely due to index stroke 1 0.30 
Gastroparesis Unlikely due to index stroke 1 0.30 
GI polyp Unlikely due to index stroke 1 0.30 
GI ulcer Unlikely due to index stroke 6 1.78 
Haematemesis Unlikely due to index stroke 1 0.30 
Haemorrhagic transformation Due to recurrent stroke 1 0.30 
Heart failure Pre-existing risk/ condition 2 0.59 
Hemopthoic expectoration Unlikely due to index stroke 1 0.30 
Hemoptysis Unlikely due to index stroke 1 0.30 
Hemorrhagic transformation Due to recurrent stroke 1 0.30 
Hydroelectrolithic disturbance Unlikely due to index stroke 1 0.30 
Hyperglycaemia Pre-existing risk/ condition 5 1.48 
Hyperosmolarity Unlikely due to index stroke 1 0.30 
Hypertension Pre-existing risk/ condition 3 0.89 
Hypoglycaemia Pre-existing risk/ condition 3 0.89 
ICH Due to recurrent stroke 4 1.19 
Ischaemic Heart Disease (ICH) Pre-existing risk/ condition 1 0.30 
Ileus paralytic Unlikely due to index stroke 1 0.30 
Intracranial mass Pre-existing risk/ condition 1 0.30 
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Stroke-unrelated complication Reason for categorisation Frequency Percentage
Ischaemic bowel Unlikely due to index stroke 1 0.30 
Ischaemic bowel syndrome Unlikely due to index stroke 1 0.30 
Ischaemic colitis Unlikely due to index stroke 1 0.30 
Kidney infection Unlikely due to index stroke 1 0.30 
Left hemithoracalgia Unlikely due to index stroke 1 0.30 
Metabolic encephalopathy Unlikely due to index stroke 1 0.30 
Myocardial Infarction (MI) Pre-existing risk/ condition 21 6.23 
Multiple organ failure Unlikely due to index stroke 2 0.59 
Myelodysplastic syndrome Unlikely due to index stroke 1 0.30 
Myocardial ischaemia Pre-existing risk/ condition 1 0.30 
Myocardial necrosis Pre-existing risk/ condition 1 0.30 
Neuroalgodystrophy Unlikely due to index stroke 1 0.30 
Obstructive sleep apnea Unlikely due to index stroke 1 0.30 
Oesophageal bleeding Unlikely due to index stroke 1 0.30 
Pain No known cause 1 0.30 
Pancreatitis Unlikely due to index stroke 1 0.30 
Peripheral vascular disease Pre-existing risk/ condition 1 0.30 
Peritonitis Unlikely due to index stroke 1 0.30 
Phlebothrombosis Unlikely due to index stroke 1 0.30 
Pneumothorax Unlikely due to index stroke 3 0.89 
Possible cardiac rupture Unlikely due to index stroke 1 0.30 
Probable cardiac death Unlikely due to index stroke 1 0.30 
Probable recurrent stroke Pre-existing risk 1 0.30 
Progression of stroke Due to recurrent stroke 7 2.08 
Pulmonary AVM Pre-existing risk/ condition 1 0.30 
Pulmonary fibrosis Pre-existing risk/ condition 1 0.30 
Rectal bleed Unlikely due to index stroke 3 0.89 
Recurrent stroke Pre-existing risk 49 14.54 
Renal failure Pre-existing risk/ condition 6 1.78 
Renal insufficiency Pre-existing risk/ condition 7 2.08 
Respiratory insufficiency Unlikely due to index stroke 5 1.48 
Ruptured ventricle Unlikely due to index stroke 1 0.30 
Septic arthritis Pre-existing risk/ condition 2 0.59 
Spinal epidural hematoma Unlikely due to index stroke 1 0.30 
Spondylodiscitis Unlikely due to index stroke 1 0.30 
Subclavian thrombus Unlikely due to index stroke 1 0.30 
Sudden death No known cause 5 1.48 
Tachypnea Unlikely due to index stroke 1 0.30 
TIA Pre-existing risk/ condition 2 0.59 
Unknown cause of death No known cause 1 0.30 
Unstable blood sugar levels Pre-existing risk/ condition 2 0.59 
Vascular occlusion Pre-existing risk/ condition 2 0.59 
Vascular stenosis Pre-existing risk/ condition 4 1.19 
Viral hepatitis C Unlikely due to index stroke 1 0.30 
Wound infection Unlikely due to index stroke 1 0.30 
    
 
Table 4-3 Classification of complications into ‘stroke-unrelated’ events 
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4.3.2.2 Time of Adverse Event Presentation  
We investigated the time course for onset of events. The median time to first ‘stroke- 
related’ adverse event was 6 days (IQR [1, 27], while ‘stroke- unrelated’ adverse events 
had a slightly later onset (16 days IQR [5, 35]). Our Kaplan- Meier analysis revealed a 
significant difference in time to first complication with ‘stroke-related’ complications 
occurring more frequently in the acute period after index stroke (Figure 4-4, Logrank 
p=0.01, Figure 4-5, 30.2%). Between 8 and 30 days after index stroke, a greater 
proportion of events were ‘stroke-unrelated’ (13.3%), however in the 31-90 day period 
incidence of ‘stroke-related’ and ‘unrelated’ events was indistinguishable (Figure 4-5).  
4.3.3 Short and Long-Term Follow Up Outcomes 
We examined the relationship between time of complication presentation and follow up 
at 30 and 90 days. Patients did not appear to have a better death and disability profile 
(median mRS Score) at 30 days when compared with 90 day outcomes, regardless of the 
type of complication experienced. This was also evident when disability alone was 
examined as an end point (Figures 4-6 – 4-9). Attainment of good functional outcome by 
mRS marginally favoured assessment at 90 days, exemplified by a slightly broader mRS 
distribution (Figures 4-8, 4-9).  
We used logistic regression to determine whether the absence of ‘stroke- unrelated’ 
events influenced functional outcome at 30 and 90 days. We found that the absence of 
unrelated complications was associated with a worse outcome at 30 days (p=0.04, 
adjusted odds ratio for good functional outcome=0.54, 95% confidence interval [0.3, 
0.96]), and had no significant effect on outcome at 90 days (p=0.07). When examining 
disability separately, we found that the absence of unrelated complications was not a 
significant predictor of good functional outcome at either 30 or 90 days (p>0.05).  
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These findings suggested that shortening the follow up period in clinical trials to 30 
days, with a view to minimising the risk of ‘stroke-unrelated’ complications, was not 
associated with better functional outcomes. 
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Figure 4-4 Kaplan –Meier analysis of time to first type of complication 
 
 
 
Figure 4-5 Risk of complications over 90 days 
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Figure 4-6 Death and disability at 30 and 90 days in patients with ‘stroke-related’ 
complications 
 
 
 
 
 
Figure 4-7 Death and disability at 30 and 90 days in patients with ‘stroke unrelated’ 
complications 
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Figure 4-8 Disability at 30 and 90 days in patients with ‘stroke- related’ complications 
 
 
 
Figure 4-9 Disability at 30 and 90 days in patients with ‘stroke-unrelated’ complications 
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4.4 Discussion 
We sought to determine whether a longer follow up period in clinical trials increased 
the trial exposure to idiopathic adverse events that in turn would negatively influence 
functional outcome. Fewer idiopathic events or a beneficial mRS profile at earlier time 
points may give an indication of whether early follow up could provide a more valid 
assessment of outcome. 
Stroke-related complications were most frequent in the early acute period after stroke. 
We were unable to find an association between the absence of stroke-unrelated 
complications and a beneficial functional outcome profile. Early follow up (30 days) did 
not appear to confer a beneficial outcome when compared with late follow up (90 day) 
perhaps because later follow up allowed the patient more time to improve (237), or 
perhaps there was under-reporting of later events, simply because patients are not 
supervised in an acute ward. Langhorne et al. (2000) reported that incidence of 
complications at later time points may be subject to over or underestimation by both 
patients and caregivers (250).   
Our study builds on previous studies by Johnston et al. (1998) (230) and Birschel et al. 
(2004) (251). Authors of the former study investigated the extent to which medical and 
neurological adverse events affected outcome (230). Their study categorized 
complications into medical and neurological subtypes; we expanded these categories to 
include events that were related to index stroke, and those that occurred due to 
comorbidity. Birschel et al. (2004) classified patients who died within the first 3 days 
after index stroke as having early neurological deterioration, but no distinction was 
made between deaths that were caused by index stroke and those that occurred as a 
result of comorbidities (251).  
A previous investigation of the occurrence of infectious complications (238), revealed 
that the majority of adverse events under examination occurred within the first week 
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following index stroke; a finding which was concurrent with our study. It was also 
previously reported that both pneumonia and urinary tract infection (UTI) were 
predictive of a poor outcome at 3 months, after correction for baseline NIHSS, age, 
gender, history of diabetes, previous stroke, smoking and Oxfordshire Community Stroke 
project (OCSP) types (238). Pneumonia and UTI were both defined as ‘related to initial 
stroke severity,’ in our study. Kwan & Hand (2006) reported that dependency due to 
index stroke severity was linked to an increased need for catheterisation in the first 5 
days after stroke (237); this contributed to the development of UTI. Their findings 
supported our classification of UTI as a ‘stroke-related’ complication. 
Our classification of infections in the ‘stroke-related’ category was supported by 
Langhorne et al. (2000), who linked an increased risk of infection with high dependency 
after stroke (250). Stroke also induces immunodepression, making the patient more 
susceptible to infection (252). These observations give credence to our findings, as the 
above mentioned complications were correctly identified as being ‘related’ to index 
stroke in our study.  
We found that the absence of ‘stroke-unrelated’ events was associated with a worse 
outcome at 30 days. This finding is congruent with previous investigations which stated 
that early neurological deterioration was correlated with poor functional outcome 
(230;253;254). Many of the events that contributed to early neurological deterioration 
were categorised as ‘stroke-related’ in our study. 
The strengths of our analyses lie in the depth of clinical trial data available. Kalra et al. 
(1995) commented on the need to ensure that comparisons of patient groups were 
undertaken at the same stage in their management (255). This was facilitated within 
VISTA through systematic documentation of outcomes at various time points. Studies 
using data from patients who were not offered stroke unit care may not be 
representative of modern stroke management (229), however within VISTA each patient 
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was treated in a trial centre which represented the best possible care for the region of 
recruitment.  
The limitations of this investigation include the categorisation and documentation of 
adverse events. We postulated that medical and neurological complications could be 
separated into ‘stroke-related’ and ‘stroke-unrelated’ categories. However, 
classification of these complications into either one category or the other is subjective 
and patients could experience more than one complication in each category. Previous 
literature (167;232;238-245) reported results from which we inferred the aetiology of 
complications to aid our classification, however the reliability of this classification 
method should be studied further. We made logical inferences regarding the aetiology 
of these complications. For example we defined late onset cerebral complications as a 
consequence of recurrent stroke based on the unlikelihood of these events occurring 
due to index stroke at the given time point. This assumption was supported by Aslanyan 
et al. (2004) (240). We also proposed that pneumonia and respiratory infections were 
likely caused by intubation or aspiration of feeding tubes, and thromboembolic 
complications and oedema were likely complications of immobility. Although 
hypertension can develop after stroke, we defined this event as ‘stroke-unrelated’ as 
there were insufficient data to distinguish whether this developed in an attempt to 
increase blood flow to damaged areas of the brain, or as a consequence of underlying 
comorbidity.  
VISTA is a resource that consists predominantly of raw data from clinical trials. These 
data were therefore subject to inter-observer bias as they concerned the identification 
of complications from case notes. Differing diagnostic criteria would have affected the 
frequency of adverse events observed in this study. Additionally, ‘stroke- related’ 
adverse events did not occur in isolation in a group of patients. In fact many patients 
experienced both ‘stroke-related’ and ‘stroke–unrelated’ complications. This could also 
have confounded outcome at an individual level.   
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Although we found no benefit of shortening the follow up period or excluding patients 
with ‘stroke-unrelated’ complications, investigation into the feasibility of shorter follow 
up periods should not be entirely abandoned. Other investigations have provided 
evidence for the potential benefits of shortening follow up. Brown et al. (2005) (239), 
reported that over a 30 day follow up period, stroke recurred in 2.5% of patients and 
cardiac events had occurred in 0.8% of patients in their series. At 6 months, this 
incidence had increased to 6.6% for stroke, and 2.6% for cardiac events. Similarly, 
observational studies indicated that stroke recurrence had arisen between 3-6% at 1 
month follow up (256-258) and 7% at 3 months follow up (259). These findings were also 
supported by Dhamoon et al. (2006) who reported that amongst patients who had 
survived at least 30 days after index stroke, the risk of recurrent stroke was greater 
than the risk of a cardiac event occurring during the follow up period, and this risk 
increased with follow up time (260). Bronnum-Hansen et al. (2001) also reported that 
cumulative risk for mortality after index stroke was 28%, 41% and 60% at 28 days, 1 year 
and 5 years respectively (261). These findings highlight the importance of investigating 
an early follow up period in clinical trials and improving prophylaxis for common post- 
stroke complications.  
4.4.1 Conclusion 
Post-stroke complications impact functional outcome in complex ways. We utilised 
clinical trial data from VISTA to identify complications that we deemed not to have 
occurred as a direct consequence of index stroke. Although we found the elimination of 
stroke unrelated adverse events to be associated with a worse functional outcome at 30  
days, further investigation into our adverse event classification scheme and the impact 
of specific unrelated adverse events on outcome would be warranted before making 
inferences about shortening clinical trial follow up. The depth of data available within 
VISTA permits the examination of many different patient populations and study 
endpoints. Chapter 5 further illustrates how VISTA can be used in a different patient 
population to inform safety in clinical trials.   
101 
 
5 Natural History of Complications after 
Intracerebral Haemorrhage. 
5.1 Background 
Therapies available for intracerebral haemorrhage (ICH) remain limited. There is a need 
for accurate data with which to plan future ICH studies. Current research focuses on the 
attenuation of haematoma growth through early re-bleeding; minimisation of 
haematoma expansion would have beneficial effects on outcome. Novel interventions 
that promote coagulation risk causing systemic thromboembolic events and 
characterisation of these events in a natural history population would inform safety in 
future trials of ICH interventions. This chapter describes the characteristics of ICH, 
current therapies available, therapeutic targets and the natural history of post-stroke 
complications in patients with ICH.  
5.1.1 Intracerebral Haemorrhage (ICH) 
Intracerebral haemorrhage (ICH) is estimated to affect over 1 million people worldwide 
each year (24;262). ICH is the least treatable form of stroke (11;25;263) and constitutes 
10-15% of all stroke cases in the USA and Europe, and 20-30% of stroke in Asian 
populations (12;25;26). The incidence of ICH is expected to grow as the population ages 
(264). Prognosis is poor: of 37 000 patients who presented with ICH in the USA, 35-52% 
had died within one month of ictus, only 10% were living independently at 1 month, and 
only 20% were independent at 6 months (12;265). Flaherty et al. (2006) also reported a 
1 year survival rate of less than 50% in patients with ICH (266).  
Primary ICH occurs most commonly in men and in African or Asian populations (13;14). 
Patients with smaller haematomas may present only with headaches, nausea or 
vomiting, whereas those with larger haematomas exhibit depressed mental status, poor 
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Glasgow Coma Scale (GSC) scores and neurological deficits related to the location of the 
haemorrhage (79).   
5.1.1.1 Pathology of ICH 
Knowledge of ICH pathology helps to identify therapeutic targets. Historically, it was 
postulated that the bleeding associated with ICH was completed within minutes of onset 
and the neurological deterioration observed during the first 24 hours after ictus was a 
consequence of cerebral oedema and mass effect around the haematoma (267). 
However, it has since been ascertained that early re-bleeding into the congested peri-
haematoma region contributes to haematoma growth within the first 24 hours and 
subsequent neurological deterioration (268-270). Haematoma expansion is a dynamic 
process with re-bleeding occurring at multiple sites over several hours (269). It is 
relatively common after ICH, found in almost one third of cases (265). The extent of 
haematoma growth is an independent predictor of poor outcome in patients (271), and 
it is therefore of importance to investigate interventions that attenuate haematoma 
expansion.  
5.1.2 Current Management for ICH 
While there have been rapid advances in acute therapy for ischaemic stroke and 
aneurysmal subarachnoid haemorrhage, therapies for ICH have not progressed past the 
supportive care stage (272). Current management involves blood pressure reduction, 
monitoring of intracranial pressure, control of fever, osmotherapy, prophylaxis for 
seizures, and nutritional supplementation (79;80). A recent investigation of the benefit 
of early surgery compared with best medical care for the treatment of ICH found no 
beneficial effect on functional outcome (122).  
5.1.3 Therapeutic Targets 
Haematoma expansion is a critical determinant of functional outcome (271) and is 
therefore an important therapeutic target. Becker et al. (1999) reported that the 
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majority of re-bleeding occurs within the first few hours after ictus (270), indicating a 
narrow therapeutic time window for a potential intervention. Promotion of clotting at a 
local level to attenuate early re-bleeding has been investigated to varying degrees of 
success. An ideal haemostatic agent would encourage coagulation locally, while limiting 
systemic thromboembolic events.  
Agents that have been developed include ε- aminocaproic acid and tranexamic acid, but 
these agents have not attained clinical success (273). Piriyawat et al. (2004) reported 
that although administration of ε- aminocaproic acid within 12 hours of ICH onset was 
safe, the risk of haematoma enlargement did not significantly differ from that observed 
in the natural history of ICH progression (273).  
Tranexamic acid has been successfully used to treat menorrhagia, upper gastrointestinal 
bleeding and mucosal bleeding, and to decrease blood loss in surgical patients (274): 
administration suppresses fibrinolysis. Sorimachi et al. (2005) supported the use of 
tranexamic acid in combination with rigorous control of blood pressure after ICH (275). 
However individual administration of tranexamic acid has not yielded positive results 
(276). Both ε- aminocaproic acid and tranexamic acid prevent dissolution of existing 
clots but do not promote or accelerate the formation of new clots to stop the active re-
bleeding in the early acute phase after ICH (277). This may account for their failure as 
an intervention for ICH.   
Recombinant factor VIIa [rFVIIa, ‘NovoSeven®’]) was proposed as a therapy for use in 
the ultra-early period after ICH – when haematoma growth occurs (278). Previously 
developed for the treatment of spontaneous or surgical bleeding in haemophiliacs, 
rFVIIa was found to promote haemostasis in the central nervous system in patients with 
coagulopathy (279), which led to its investigation as a therapy for ICH.  
An initial proof of concept study revealed a beneficial effect on haematoma volume, 
haematoma growth and mortality in patients receiving rFVIIa compared with those 
receiving placebo (11). However, investigators of this phase IIb study noted a higher 
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incidence of thromboembolic complications amongst patients receiving rFVIIa (7% for 
rFVIIa compared with 2% in the placebo group). Positive results from this trial lead to 
the expansion of the trial population to fully examine efficacy of rFVIIa administration 
in the subsequent FAST trial. The latter trial recently confirmed a reduction of 
haemorrhage growth and showed some early clinical benefit but no sustained benefit on 
functional outcome at 3 months (123).  
Despite the failure of many haemostatic interventions for ICH, this form of therapy may 
still have potential. A recent post- hoc analysis of data from the FAST trial revealed that 
a subpopulation of patients - those without massive haemorrhage, intraventricular 
haemorrhage or advanced age - may benefit from treatment with rFVIIa. However, as 
with any intervention that promotes local coagulation there is an increased risk for 
systemic thromboembolic complications.  
5.1.4 Aims  
Our aim was to document the natural history of thromboembolic complications in 
placebo treated patients with ICH from VISTA. We sought to characterize the risk of 
these complications after intracerebral haemorrhage for use in the design of safety and 
efficacy trials of ICH therapies. In addition, we aimed to examine whether the 
occurrence of these complications influenced the attainment of good functional 
outcome at 90 days. Natural history data on disease progression and common 
complications after ICH would aid prophylactic measures and could reduce morbidity 
and mortality at final follow up.  
5.2 Methods  
5.2.1 Eligibility Criteria 
We analysed pooled clinical trial data from VISTA. Confidentiality agreements prohibit 
identification of the trial sources from which data were extracted; however, we 
restricted our dataset to placebo-treated patients with documented spontaneous 
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intracerebral haemorrhage and a randomisation time of up to 4 hours, for whom adverse 
event and 90 day functional outcome data were available. Variables of interest included 
age, sex, time to randomisation, level of consciousness at admission, medical history, 
initial stroke severity, types of complications, time from ictus to onset of complication, 
and mortality, functional and neurological outcome at 90 days.  
The phase IIb (11) and FAST (123) trials of rFVIIa, and the STICH trial of haematoma 
evacuation for ICH (122) excluded patients with a baseline Glasgow Coma Scale (GCS) 
score of <6, (corresponding to deep coma). Where GCS scores were unavailable, we 
used the Level of Consciousness (LOC) 1A category on the National Institutes of Health 
Stroke Scale (NIHSS) scale to exclude patients with a LOC1A score of 3; we sought to 
provide data for a trial-eligible ICH patient population.  
5.2.2 Statistical analyses 
5.2.2.1 Natural History  
We documented the risk of post-ICH complications over a 90 day period. We examined 
the time to onset of various complications and stratified occurrence by initial stroke 
severity to provide an indication of the types of complications predominant in patients 
with mild (baseline NIHSS score 0-10), moderate (baseline NIHSS score 11-20) and severe 
stroke (baseline NIHSS score 21-30).  
5.2.2.2 Impact of Complications on Outcome 
We used logistic regression adjusting for age, initial stroke severity (baseline NIHSS) and 
medical history variables, to investigate whether the absence of thromboembolic 
events, infection, neurological, respiratory or cardiac complications influenced the 
attainment of good functional outcome, defined as a modified Rankin Scale Score (mRS) 
of ≤ 4 at 90 days. Similarly, we used a Cox Proportional Hazards model to examine 
whether the absence of each of these complications influenced mortality at 90 days 
(adjusting for age, index stroke severity and medical history).  
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Missing data were handled by imputing the worst possible outcome where patients had 
died within the 90 day follow up period. Analyses were carried out using the SAS 9.1 
statistical package.  
5.3 Results 
5.3.1 Demography 
We analysed data from 201 patients who met our eligibility criteria. In this patient 
population the median age was 65 (IQR [55, 75]) and 70% were male (Table 5-1). The 
median NIHSS score at baseline was 14 (IQR [10, 18]) and the median baseline 
assessment time was 3.5 hours (IQR [2.9, 3.8]). The vast majority of patients had 
hypertension (79%) and 19% had experienced a prior stroke.  
 
 Full dataset (FAST n=201) 
Variable Median [IQR∗] Frequency (%) 
Age  65 [55, 75] - 
Sex - Male =141 (70.2) 
Onset to Treatment time (h) 2.91 [3.5, 3.8] - 
Baseline NIHSS 14 [10, 18] - 
NIHSS at 90 days 5 [2, 8] - 
mRS at  90 days 4 [2, 5] - 
Atrial Fibrillation - Yes=11 (5.8) 
Hypertension - Yes=150 (79.0) 
Previous Myocardial Infarction - Yes=7 (3.7) 
Smoking Status - Non smoker= 115 (60.5) 
Past smoker=33 (17.4) 
Current smoker=36 (19.0) 
Previous Stroke - Yes=36 (18.7)  
Diabetes - Yes=37 (19.5) 
Mortality at 90 days - Alive=154 (76.6) 
Patients who experienced adverse 
events 
 Yes=141 (70.2)  
Thromboembolic complications - Yes= 4 (2.0) 
   
Table 5-1 Demographic data for 201 patients with ICH  
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5.3.2 Risk of Complications after ICH 
5.3.2.1 General Complications 
Amongst these 201 patients, 141 patients (70%) experienced at least one adverse event 
during the 90 day follow up period (Figure 5-1). Of the complications experienced, the 
most common were neurological in nature, including extension of the haemorrhagic 
stroke, increased intracranial pressure and cerebral herniation (Table 5-2). Infective 
complications were the second most frequent event (11.4%). The majority of 
complications arose within the first 20 days after index ICH, with only respiratory 
complications persisting beyond this point. Neurological complications were confined to 
the first 16 days after ictus and cardiovascular complications persisted until 26 days 
after index ICH (Figure 5-2). 
5.3.2.2 Risk of Thromboembolic Complications 
We observed only 4 thromboembolic events in our dataset, affecting only 2% of 
patients. These events were ischaemic stroke, myocardial infarction (MI), transient 
ischaemic attack (TIA), and pulmonary embolism (PE). Each of these complications 
occurred only once during the study period and their time to onset was confined to the 
first 22 days after index ICH (Figure 5-3) with ischaemic stroke being the first 
thromboembolic event to emerge at 9 days, and pulmonary embolism emerging last at 
22 days.  
5.3.3 Index Stroke Severity and Type of Complication 
In patients with mild index stroke (baseline NIHSS score of between 0 and 10), 
neurological complications were most frequent, and psychological complications had 
the longest duration of presentation (Figure 5-4). In patients with moderate index 
stroke (baseline NIHSS score of 11-20), neurological complications were again most 
frequent, however respiratory complications had the longest duration of presentation 
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(Figure 5-5). The latter observations were also evident in patients with a baseline NIHSS 
score of 21-30 (Figure 5-6).  
 
 
 
 
 
 
 
 
Figure 5-1 Frequency of complications after index ICH 
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Event Frequency Percentage 
Acute Respiratory Distress                   1 0.50            
Acute Respiratory Failure                    2 1.00 
Aggravation Of Hematoma Cerebral             1 0.50            
Agitation                                    1 0.50            
Anemia Aggravated                            1 0.50            
Anxiety Disorder                             2 1.00 
Asthmatic Attack                             1 0.50            
Back Pain                                    1 0.50            
Bundle Branch Block Left                     1 0.50            
Cardiac Arrest                               2 1.00            
Cellulitis                                   1 0.50            
Cerebral Hematoma Ingravescent               1 0.50            
Cerebral Herniation                          3 1.50 
Cerebral Oedema                              3 1.50 
Coma                                         1 0.50            
Constipation                                 3 1.50 
Contact Dermatitis                           1 0.50            
Corneal Erosion                              1 0.50            
Depressive Disorder                          3 1.50 
Diabetes Mellitus Aggravated                 1 0.50            
Diarrhoea                                     2 1.00 
Diplopia                                  1 0.50            
Diuresis                                     1 0.50            
Drowsiness                                   1 0.50            
Dyspnea                                      1 0.50            
Extension Of Cerebral Haemorrhage           28 14.0 
Fever                                       20 10.0 
Fluid Retention                              1 0.50            
Folate Deficiency                            1 0.50            
Glucose Increased                            1 0.50            
Headache                                     6 3.00 
Hematuria                                    1 0.50            
Hydrocephalus                                1 0.50            
Hyperpyrexia                                 1 0.50            
Hypertension                                 4 2.00 
Hyperthermia                                 1 0.50            
Hypokalaemia                                 3 1.50 
Hyponatremia                                 1 0.50            
Increased Intracranial Pressure              1 0.50            
Infusion Site Swelling                       1 0.50            
Ischaemic Stroke 1 0.50 
Leg Cramps                                   1 0.50            
Lethargy                                     2 1.00 
Muscle Spasm                                 1 0.50            
Nausea                                       2 1.00 
Obstipation                                  2 1.00 
Pedal Oedema                                  1 0.50            
Petechia                                     1 0.50            
Pneumonia                                    4 2.00 
Possible Myocardial Infarction               1 0.50            
Pulmonary Embolism                           1 0.50            
Recurrent Stroke                             1 0.50 
Respiratory Infection                        4 1.00 
Seizure                                      1 0.50            
Sinus Bradycardia                            1 0.50            
Sleep Disorder                               2 1.00 
Somnolence                                   1 0.50            
Transient Ischaemic Attack                   1 0.50            
Traumatic Hematoma                           1 0.50            
Urinary Retention or Urinary Tract Infection                       3 1.50            
Viral Infection                              1 0.50 
   
Table 5-2 Frequency of complications experienced in 201 patients with ICH 
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Figure 5-2 Time to onset of post- ICH complications 
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Figure 5-3 Thromboembolic complications after index ICH and time from ictus to occurrence
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Figure 5-4 Frequency and time to onset of complications in patients with a baseline NIHSS score of 1-10
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Figure 5-5 Frequency and time to onset of complications in patients with a baseline NIHSS score of 11-20
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Figure 5-6 Frequency and time to onset of complications in patients with a baseline NIHSS score of 21-30 
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5.3.4 Impact of Complications on 90 –Day Functional Outcome   
 
5.3.4.1 Thromboembolic Complications 
No patient was lost to follow up in our analysis dataset. Our logistic regression analysis 
(adjusting for index stroke severity, age and medical history) revealed that the absence 
of thromboembolic complications was not a significant predictor of good functional 
outcome at 90 days, (p=0.23, adjusted odds ratio for good functional outcome= 0.19, 
95% confidence interval [0.01, 2.28]). Similarly our Cox Proportional Hazards modelling 
(CPHM) revealed that the absence of a thromboembolic complication did not 
significantly influence survival at 90 days (p=0.27).   
5.3.4.2 Extension of Cerebral Haemorrhage 
The absence of haemorrhagic extension was a significant predictor of good functional 
outcome at 90 days (p<0.0001, adjusted odds ratio for good functional outcome=21.9, 
95% confidence interval [5.5, 88.3]). Similarly the absence of haemorrhagic extension 
contributed to survival at 90 days (p<0.0001, adjusted hazard ratio for survival=6.8]. 
5.3.4.3 Infection  
Infection occurred in 11.4% of patients in our dataset. Our logistic regression and Cox 
Proportional Hazards analyses revealed that the absence of these complications did not 
significantly influence the attainment of good functional outcome at 90 days (p=0.8, 
odds ratio for good functional outcome=0.88, 95% confidence interval [0.26, 2.97]) and 
did not significantly affect survival at 90 days (p=0.7). 
5.3.4.4 Respiratory Complications 
Respiratory complications affected 7.5% of patients in our dataset. We found that the 
absence of these complications was not a significant predictor of good functional 
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outcome at 90 days (p=0.33 odds ratio for good functional outcome=0.51 95% confidence 
interval [0.13, 2.02]) and did not significantly influence survival at 90 days (p=0.2). 
5.3.4.5  Cardiac Complications 
Cardiac complications affected 4% of the patients in our dataset and logistic regression 
and CPHM analyses revealed that absence of these complications did not appear to 
influence attainment of good functional outcome (p=0.4) or survival at 90 days (p=0.4). 
5.4 Discussion 
We found that the most common post-ICH complication was extension of the 
haemorrhage and that the absence of this complication significantly influenced 
attainment of good functional outcome at 90 days. Complications such as infection did 
not appear to influence 90 –day mRS scores, despite frequent occurrence. Neurological 
complications were most frequent in all stroke severity stratifications and respiratory 
complications persisted for the longest duration in patients with mild to moderate 
stroke. 
The risk of thromboembolic complications after ICH was low. Only 4 such complications 
were encountered (affecting 2% of patients) in our natural history analysis, and did not 
significantly influence 90- day functional outcome. Our observation of a 2% risk of 
thromboembolic complications was consistent with previous data (11) which also 
reported a 2% risk of thromboembolic complications in placebo treated patients. These 
events were infrequent, however our findings may inform post -ICH prophylaxis. 
We observed respiratory complications in 7.5% of patients. Aslanyan et al. (2004) 
reported the occurrence of post stroke pulmonary complications in up to 10% of patients 
with ischaemic stroke (238), an observation that was similar to our findings. However 
we found that the absence of these complications did not influence attainment of good 
functional outcome or survival at 90 days. The latter result contrasted with that of 
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Maramatton et al. (2006), who reported that occurrence of pulmonary complications 
after ICH increased morbidity and mortality (280). In their series, all pulmonary 
complications occurred within the first 10 days after stroke onset, contrasting with the 
wide time frame for occurrence observed in our study. One explanation could be the 
categorisation of pulmonary complications in our dataset. We included respiratory 
distress, respiratory arrest and asthmatic attack as respiratory complications. Only one 
instance of pulmonary embolism and 4 instances of pneumonia were observed in our 
dataset, which would not have realistically influenced attainment of good functional 
outcome or survival in our series.  
Contrary to reports of increased risk of raised intracranial pressure after ICH (281), we 
observed only one instance of this in our dataset. Similarly seizure, estimated to affect 
8% of patients within 30 days of ICH (282), was observed at a much lower frequency in 
our dataset; affecting only 0.5% of patients. Venous Thromboembolism (VTA) was 
previously estimated to affect 2-3% of patients after index ICH, however we only 
observed one instance of deep vein thrombosis in our dataset, corresponding to 0.5% of 
the patient population. Because the trials in VISTA generally were closely monitored, 
the incidence of serious adverse events such as seizure is unlikely to have been under-
reported. Our observations could be explained by the exclusion of some patients with 
severe stroke from our dataset if investigators considered them ineligible for research 
studies. We sought to investigate the natural history of post- ICH complications in a set 
of patients who would be eligible for entry into a clinical trial. Therefore patients who 
were more likely to require intubation and catheterisation may have been excluded, 
thus minimising some immobility –related complications such as urinary tract infections, 
aspiration pneumonia, deep vein thrombosis and pulmonary embolism. Despite some of 
the differences in complication rate observed in our sample, our results provide a good 
indication of the complications likely to arise after index ICH in a trial eligible patient 
population.  
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There are some limitations to our report. Some of the patients identified from VISTA 
were included in large, randomized, multicentre trials assessing therapies for ischaemic 
stroke; ICH patients were included incidentally. Haematoma volume and development 
of intraventricular haemorrhage (283;284) are critical determinants of mortality and 
functional outcome. These variables were not available for 76 of the 201 patients 
included in our analysis, and where available (n=125) there were no instances of 
thromboembolic complications. As a result we were unable to include these as 
covariates in our analyses, despite their importance in predicting outcome.  
Adverse events were derived from physicians’ case notes and documentation of 
incidence following discharge may have over or underestimated frequency (250). In 
addition, the high standard of care available to the VISTA population may have 
minimised the observed frequency of preventable complications. However, this 
strengthens our findings as the same standard of care would be available to patients’ in 
future clinical trials.   
5.4.1 Conclusion 
Our natural history observations are limited to non-comatose patients with ICH who 
were randomized within 4 hours of index stroke, and are therefore pertinent to clinical 
trials which target early re-bleeding within this time frame. Our findings should inform 
prophylaxis for general post-ICH complications. However, in order to gain a fuller 
picture of the natural history of thromboembolic complications after ICH in the wider 
population, analysis of data from a comprehensive disease -based registry is required 
(285). 
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6 Use of Historical Comparators in Clinical Trials 
6.1 Background 
There is a wealth of stroke patient data within VISTA that could be used to inform the 
natural history of disease progression for many different stroke subtypes. Collation of 
patient data within this resource has resulted in a rich volume of clinical trial data, 
which is ideal for use as historical comparators.  
This chapter describes the process of drug development from phase I, first- in –man 
studies to phase III efficacy trials and identifies a key area in the drug development 
process where use of VISTA as a historical comparator resource could be of benefit: 
phase II studies. This chapter details the difficulties associated with drug development, 
the types of conventional comparator groups available for use in a phase II 
investigation, advantages and disadvantages of using each of these comparator groups, 
the potential for use of historical comparators in some scenarios where use of 
conventional comparator groups is infeasible, and possible solutions to address the 
limitations associated with use of historical comparators.   
6.1.1 Development of Novel Stroke Treatments 
Currently drug development trends reflect health care needs for specific populations. 
For example, chronic disease states such as cardiovascular disease have been the most 
recent target for drug development (286). Preclinical testing of an intervention is a 
requirement of regulatory authorities such as the Food and Drug Administration (FDA) 
before progression towards efficacy assessment in clinical trials (76). Safety information 
from preclinical studies can be used to support the translation of investigations from 
animal studies to first –in –man studies. Figure 6-1 illustrates the complexity of the drug 
approval process and highlights the time frames involved in proceeding from preclinical 
studies to approval and marketing of an intervention. 
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Following identification of a potential therapeutic intervention for stroke, clinical 
testing usually progresses through three main phases. In phase I trials, assessment of 
the initial safety and practicality of the drug or device takes place in subjects who are 
relatively stable from a medical point of view and who usually have little to gain from 
exposure to the treatment but in whom reliable evidence of the basic effects can be 
quickly and cheaply assessed (76). Phase I may take place in a small number of healthy 
volunteers. The main aim is to elucidate the pharmacokinetics of the drug under study 
(287). It may also seek to identify or exclude dose-limiting non-serious adverse effects, 
elucidate their nature and relationship to dose.    
 
Figure 6-1 New drug development timeline. Source: 
www.fda.gov/fdac/graphics/newdrugspecial/drugchart.pdf 
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Phase II moves assessment to patients with the condition under study (76) and begins to 
examine the treatment under realistic clinical circumstances. The dose, duration of 
exposure and frequency of treatment may be ascertained in phase II trials. It may even 
be possible to explore the outcomes of patients to estimate treatment efficacy to plan 
pivotal trials. However in some disease areas, affordable phase II trials may be too small 
to give realistic estimates of treatment effect, leaving safety, tolerability and surrogate 
efficacy measures as endpoints; stroke is such a condition.  
Efficacy and safety are usually examined together in phase III trials (76;287), often 
termed pivotal if these will inform regulatory decisions. Phase III trials are the final, 
pre-approval phase of investigation (287) and usually utilise much larger sample sizes 
and can include many treatment centres worldwide. These trials require rigorous 
attention to design issues such as blinding and randomisation to avoid bias, and are 
particularly expensive and time-consuming to undertake. Regulators usually demand 
two positive phase III trials, or at least one positive trial supported by additional 
evidence of efficacy in a similar population before proceeding with licensing. 
In some cases, regulatory authorities require a phase IV trial, which is performed as a 
post- marketing surveillance study (76) after a drug has been approved for use. The aim 
of this type of investigation is to gather additional information about the risks, benefits 
and optimal use of the drug, or to examine its efficacy on a new, previously undefined 
patient population.    
6.1.2 Difficulties Associated with Drug Development  
Development of treatments to improve outcome from acute stroke is associated with 
several difficulties. First, outcome from acute stroke is variable. Initial severity, stroke 
aetiology, age and comorbidity of the patient have a profound influence on outcome. 
Attitudes and access to treatment also vary regionally and can affect outcome 
(58;148;149). The influence of novel treatments directed at stroke recovery must be 
measured against a common standard or control, and control groups should be 
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comparable to the treatment group in terms of known prognostic factors. Estimations of 
efficacy of a given intervention depend on the strength of evidence from the data 
collected. Implementation of procedures to combat bias will strengthen the conclusion 
which can be drawn (76). 
Costs of stroke care and stroke research are high (288) and development of 
independent, low cost studies is increasingly problematic (289). The development of 
new therapeutic interventions requires substantial investment of capital, human 
resources, technological proficiency and adherence to regulatory stipulations for testing 
and manufacturing standards (286). These factors in combination contribute to 
incremental costs for research and form a barrier to effective drug development 
especially for investigators with a promising intervention but limited resources. As a 
result, trials addressing important issues are at risk of becoming impractical or 
unaffordable (289).  
Since stroke affects older patients who may have some cognitive decline and since 
stroke can itself cause communication difficulty, recruitment into clinical trials can be 
compromised through barriers to consent. An investigation of participation in a stroke 
registry where patients gave informed consent revealed that participants were more 
likely to be younger, alert at admission and many patients who were unable to give 
consent were cognitively impaired (133). Tu et al. (2004) also found that imposing the 
requirement for informed consent reduced participation to about half of all eligible 
patients (133). Barriers to consent can significantly delay attainment of the required 
sample sizes in a randomised controlled trial (RCT), thus increasing the recruitment 
period and subsequently placing a greater financial burden on sponsors.  
The time between synthesis of a drug intervention to approval of a new drug application 
has increased over the past 5 decades. Estimated time from initiation to regulatory 
approval in the 1960’s was 7.9 years, compared with 12.8 years in the 1990’s (290). This 
was attributable to increasing clinical trial length, regulatory requirements, increasing 
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difficulty and need for additional recruitment of patients for clinical trials (287). The 
widening time frame between laboratory assessments and regulatory approval increases 
the likelihood that competing pharmaceutical companies will make a discovery first and 
diminish the return on investment for sponsors (286): an unattractive proposition for 
many investors. In addition more investors are requesting evidence of cost –
effectiveness of an intervention in their target population before funding agreements 
for further research are in place (286) and this serves to deter even more proof -of -
concept investigations. This has implications for small research and development 
companies; unless they can develop a ‘blockbuster’ drug or intervention frequently, 
funding to support exploratory research will diminish (291). 
Financial issues such as the cost of drug development, the relatively limited benefits 
that individual treatments may achieve, and restrictions on the potential market as a 
consequence of limited selection criteria for the initial trials, all conspire to limit the 
potential return on investment for sponsors. This can inhibit investment in promising 
interventions which are still at the early development phase. In the UK only 2-8% of 
government research funding is devoted to RCT’s and it is estimated that the cost of a 
RCT has tripled or quadrupled for studies sponsored by industry, making further 
research difficult (288). Finally, the track record of potential treatments for stroke is 
discouraging: only thrombolysis with rt-PA (81) and the MERCI Retriever device (90) 
(141) have so far been approved for use.  
It is currently estimated that the cost of research and development for an intervention 
is $802m (USD), mainly due to the increased cost of animal testing, and conducting 
clinical trials (287). It is also estimated that a reduction in clinical phase length by only 
25% would reduce capitalised drug development costs by $129m (USD) (287). These 
observations highlight the need to reduce timeframes for clinical research with a view 
to improving the feasibility of continued research. Because it may be years before the 
results of a RCT are published (292) exploration of alternative avenues of phase II 
research is vital to maximise the potential of new interventions within a shorter time 
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frame. For developers of potential treatments who have access to a limited budget, 
there are many reasons to seek to limit costs and to speed up the research process. 
6.1.3 Area for Improvement: Phase II Studies  
There are insufficient resources in terms of finances and manpower to provide patients 
with every available health care intervention in the form of a RCT. Hence there is a 
need to maximise health gain obtained from the limited resources available (173). Due 
to the enormous commitment of resources associated with a phase III programme in 
stroke, most sponsors will seek reassurance of potential efficacy (“proof of concept”) 
during the phase II programme. They may also wish to pilot aspects of the design of the 
trial before moving into phase III. Due to an increase in estimated capitalised phase cost 
by up to $10m USD for the transition from phase II research to a phase III clinical trial 
(Figure 6-2) (287), sponsors and trialists need to be certain that interventions under 
investigation are viable and potentially efficacious. Rigorous phase II investigation 
would be beneficial to minimise the chances of proceeding with a costly venture which 
could ultimately prove futile. Ideally, a proof of concept trial should employ a 
randomised, blinded design that pilots every aspect of the intended phase III trial; this 
method is the most rigorous in terms of avoiding bias (293;294). However this carries a 
substantial cost overhead. It can be difficult to gain informed consent from patients for 
exposure to an untested treatment in an early phase trial. Non –participation increases 
the cost of recruitment per patient, which is a serious concern when resources are 
limited (295). It is even more difficult to randomise patients to a suitable control group 
if an invasive procedure such as a sham operation for a device trial may be involved. 
These issues become particularly relevant for investigators who wish to examine safety 
and tolerability but have limited resources with which to test a novel, promising 
intervention. As an alternative to concurrent controls which would be used in a RCT, 
comparison with historical controls may be considered, especially if the phase II trial is 
intended to offer proof -of -concept rather than to act as a pivotal trial or even as 
‘supporting evidence.’ We hypothesised that historical comparator data from VISTA may 
have utility in phase II studies to determine success or futility of potential interventions 
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in an economic manner, before progression into costly phase III trials. This may be 
particularly relevant in situations where randomisation to a control group is not possible 
due to financial or ethical constraints.  
 
 
Figure 6-2 Estimated capitalised phase cost for new interventions entering each phase. 
Adapted from DiMasi et al. Journal of Health Economics 2003; 22:162 
 
 
6.1.4 Aims 
We aimed to describe here the types of comparator groups available for proof –of –
concept studies, discuss the benefits and drawbacks of these options, describe the 
potential for use of historical comparators in a phase II investigation and provide 
solutions to address the limitations associated with use of historical comparators. These 
solutions may make the use of historical comparators more appealing, especially to 
smaller research and development companies that have limited resources with which to 
carry out proof –of -concept studies.  
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6.2 Types of Control Groups Available  
The main purpose of a control group is to allow investigators to ascertain whether the 
observed efficacy in a trial is a true reflection of the experimental intervention, or if 
other confounding factors such as the natural history of disease progression, observer 
participation or concomitant treatments are responsible (296). The European Agency for 
the Evaluation of Medicinal Products (EMEA) (297) and the Food and Drug Administration 
(298) describe the various control groups that may be considered for use in clinical 
trials.  
6.2.1 Concurrent Control Groups 
‘Placebo concurrent control groups’ are used in randomised clinical trials. Patients 
receive an identical appearing treatment, that does not contain the test drug or 
treatment (297). This method represents the most rigorous effort to combat bias; 
patients in each treatment group undergo the same randomisation practices, there are 
no temporal delays in recruitment when compared with the active group, and 
investigators are blinded to the treatment allocation.  
However there are many barriers to a randomised trial with a concurrent control group. 
Each additional patient will cost $2,000-$20,000 depending on the nature of the trial, 
the location of the centre and the details of the protocol. For a trial of 100 patients, 
the addition of concurrent randomised controls will add between $0.2M and $2M in 
investigator fees, a similar amount in monitoring fees via a contract research 
organisation, plus the costs of a randomisation service and statistical help. The true 
extra cost is likely between $0.5M and $5M. Even non-randomised concurrent controls 
would cost $0.4 - $4M (299). In addition, each control patient slows recruitment of 
actively treated patients: the trial will take at least twice as long to complete. In 
practice, the true additional time is greater due to delays in obtaining ethics approvals, 
setting up randomisation systems, failure of randomisation, or patient reluctance to 
receive placebo.  
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If financial costs and expenditure of time can be sustained, then despite the ethical and 
scientific difficulties, the use of a randomised trial design with concurrent controls is 
the optimal approach. If resources preclude the use of concurrent controls then 
alternatives are needed. 
6.2.2 Uncontrolled Studies 
‘No-treatment’ controls offer no active treatment to the control group; however the 
key difference between ‘no-treatment’ controls and a placebo- controlled design is that 
both patients and investigators are not blinded to the treatment allocations (297). This 
design can pose problems for patient recruitment. Uncontrolled studies are the least 
expensive and the simplest to conduct but deliver the weakest answer. In light of 
natural variation in stroke recovery, no conclusion may be drawn about the 
effectiveness of treatment. This could lead to continued development of ineffective but 
well tolerated treatments or to abandoned development of highly effective measures 
that carry modest side effects. Uncontrolled studies are notoriously difficult to publish 
in reputable journals. This can be relevant when later trying to recruit key investigators 
to participate in later trials and diminishes the reputation of the treatment approach.  
6.2.3 Dose-response Concurrent Controls 
‘Dose-response concurrent controls’ are randomised to receive one of several fixed 
doses of a therapeutic intervention (297). This method compares outcomes in patients 
allocated to different doses to establish the best dose for administration. Again, this 
method can extend the recruitment period, delay recruitment into the active treatment 
groups and increase the cost of conducting a phase II trial as recruitment into more than 
2 groups is necessary.   
6.2.4 Positive Concurrent Controls 
Finally, if acting as positive concurrent control groups, patients are treated with an 
alternative active therapy (297). For example rt-PA and aspirin are considered as active 
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treatments for stroke patients. This method increases randomisation costs per patient 
as the control group also receives an active therapy.  
It has become increasingly difficult to conduct trials of important questions at a 
reasonable cost (137); many questions of clinical or public health importance may not 
be addressed adequately. If rigorously controlled studies are not an option then it 
remains desirable to identify an alternative comparator group to assist interpretation of 
data from phase II clinical trials. Use of external comparators may be a viable option in 
some circumstances.  
6.3 External Comparators 
External comparators are a group of patients who are separate from the population 
tested in the active arm of a trial. External comparator groups may comprise patients 
who were treated at an earlier time, termed historical comparators, or those who are 
treated concurrently in another setting (297).   
6.3.1 Advantages of Historical Comparators 
Quite apart from avoiding the disadvantages of cost and time, the use of historical 
comparators can also deliver some benefits. A small phase II study will inevitably lack 
statistical power. To detect even a large benefit, as seen with thrombolysis in acute 
stroke, a sample size of 300-400 per group would usually be recommended to deliver 
80% power. Use of historical comparators can expand the comparator group beyond the 
1:1 ratio. Whilst power is greatly influenced by the size of the smaller group and there 
is ever-diminishing advantage in ratios much greater than 2:1, power may be slightly 
greater with a 3:1 ratio than the 1:1 ratio usually chosen for a RCT. 
The use of historical comparators allows a range of covariates to be examined for their 
influence on the outcome, and models can be developed based on adequate sample 
sizes to permit adjustment according to such variables. Comparisons between current 
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active treatments and historical comparators may be beneficial if the historical 
comparators are derived from previous clinical trials conducted in the same 
environment, or by the same investigators (76); these factors reduce bias (300).  
Historical comparator databases may be used to gauge whether therapies are promising 
enough to justify further investigation in a phase III trial. In the field of cancer, this 
approach is employed to identify treatments that appear to have the greatest potential 
for efficacy (301). Historical comparators also provide investigators with data with 
which to run simulations. For example, these simulations may be used to develop 
algorithms to identify stroke subtypes based on presentation at baseline, or to produce 
regression equations to describe recovery. Historical data may represent viable control 
group alternatives when ethical issues preclude the use of concurrent controls. 
The collection of patient data is expensive. The use of historical comparators reduces 
overall costs, permitting resources to be focussed on collecting active treatment data 
(302). Consequently, smaller research and development companies in particular will 
benefit from a reduction in the cost of conducting proof-of-concept investigations. The 
use of historical comparators also allows all of the patients recruited to receive the 
potentially beneficial new therapy.  
The use of historical comparators is suboptimal for a phase III clinical trial in stroke; 
however, they can provide information on the natural history of stroke prognosis. 
Natural history findings may be used as a baseline with which to compare the outcomes 
of patients who receive an active treatment in a proof -of -concept study. 
6.3.2 Disadvantages of Historical Comparators 
There are some concerns with use of historical comparators. These data are 
independent from any treatment group and since patients are neither concurrent nor 
treated at the same sites, there may be real concerns about the degree of similarity 
between the patients in the treatment and control groups; Yen et al. (2004) commented 
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on differing mortality rates in historical comparators patients with motor neuron disease 
compared with those receiving an active treatment. This was thought to be due to the 
recent introduction of new medications and wider use of supportive therapies (301). 
In clinical trials patients are typically randomised to one of two treatment groups: 
active therapy and control. Through randomisation, investigators attempt to balance 
entry into the two groups with respect to baseline variables. Provided that the sample 
size is sufficiently large, patients with similar characteristics should be recruited into 
the treatment and control groups so that the baseline variables in each group remain 
comparable. With the use of historical comparators, patients are not randomised to 
either group and the impact of case mix becomes important. Differences in 
interventions, patient population or duration of follow up (293) may contribute to bias 
and should be accounted for. 
Potential temporal differences in diagnostic criteria and concomitant therapy may also 
lead to bias. These issues affect data comparability and could confound treatment 
effects. Treatments have evolved over time, and this coupled with epidemiological 
changes in the incidence and intensity of stroke could mean that historical comparator 
patients have differing outcomes when compared with current patients. Known changes 
in treatment, for example the use of thrombolysis, can be measured and controlled; 
unknown factors are more difficult to handle. The inability to identify or collect all 
necessary data and difficulty in measuring or quantifying subjective factors such as 
clinical judgment also contributes to bias (293). Even so, exploratory analyses may 
provide reassurance on many points. We proposed methods to optimize VISTA when 
used as a source of historical comparators. 
6.4 Recommendations 
We proposed 5 principal measures to address our initial concerns about the use of 
historical comparators for proof- of –concept studies. First, historical comparators from 
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VISTA should be selected by applying the same eligibility criteria as the active 
treatment group. This would generate a pool of patients with similar baseline 
characteristics in the two groups. Previous investigations have reported that the use of 
external comparators may overestimate (303) or underestimate the efficacy of an 
intervention (304). These biases can be accounted for by selecting the comparator 
group before commencing assessment of the intervention (76), and ensuring that the 
comparator group is similar to the active group with respect to baseline characteristics.  
Second, in some instances, the pool of potential historical comparators may be large, 
while the corresponding active treatment group is small (76). In these instances data 
comparability could be further addressed by prospectively matching each treated 
patient with historical comparators based on the principal prognostic factors. This 
should also ensure that baseline patient characteristics in each group would remain 
comparable.  
Third, any potential historical comparator resource needs to employ consistent and 
objective definitions of outcomes appropriate to the patient population (305). Within 
VISTA, outcomes have been measured using standardised stroke scales such as the 
modified Rankin Scale (mRS) and National Institutes of Health Stroke Scale (NIHSS). 
These scales are widely used by physicians and training materials such as DVDs and 
online tutorials (306) are available to ensure correct scoring of patients. Use of these 
defined stroke scales would ensure the comparability of VISTA data with those from 
active treatment groups.  
Both the active treatment and historical comparator groups need to use similar follow 
up periods for a valid comparison (302). This could be facilitated within VISTA, as follow 
up periods of between 3 weeks and 1 year are available for patients recruited between 
1989 and 2006.  
Last, bias could be limited by engaging an independent group to undertake the 
matching process, by undertaking the matching prospectively before outcomes of 
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treated patients are known, or by stratifying final analysis according to the main 
prognostic factors (307).  
6.4.1 Conclusions 
Despite our concerns about the use of historical comparators, these may represent the 
most viable control group option for investigations where time, financial or ethical 
constraints preclude the use of a RCT. Having established and performed both natural 
history analyses and investigated methods of improving clinical trial design, we 
postulate that VISTA has the potential to provide excellent comparator data for a phase 
II proof- of –concept study owing to a wealth of data available for comparison with any 
prospective treatment cohort.   
While we do not advocate the use of historical comparators from VISTA as an alternative 
to the definitive RCT in a phase II or phase III study, we can demonstrate the ability of 
VISTA to provide an alternative to the RCT for a phase II study, using the example of the 
NeuroPath™ Device in chapter 7. 
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7 Use of Historical Comparators for a Proof -of -
Concept Device Trial 
7.1 Background 
BrainsGate, a medical device company sought to pilot the NeuroPath™ Device for use in 
patients with acute ischaemic stroke affecting the anterior cerebral circulation. Due to 
limited resources with which to carry out a phase II randomised controlled trial (RCT) to 
investigate efficacy, a collaborative project with VISTA was established whereby 
historical comparators selected from the resource would be used in a proof- of –concept 
study. This collaboration was later scaled back: VISTA provided regression equations to 
inform the progress of device –implanted patients in place of matched and covariate 
adjusted analyses. All initial work for this collaboration was completed, however, and 
this chapter describes the example of a device in early phase testing, where VISTA was 
primed for use as a resource for historical comparators. The limitations associated with 
the use of historical comparators, how these limitations could be overcome in practice, 
and the measures taken to ensure the validity of results are discussed here.  
7.1.1 Current Treatments for Ischaemic Stroke 
As mentioned previously, there are limited treatment options available for acute 
ischaemic stroke. Only the administration of rt-PA within 3 hours of stroke onset (81) 
and use of the MERCI device (90;141) have been approved. Both of these interventions 
rely on early restoration of perfusion to ischaemic areas of the brain. To date, the use 
of rt-PA within 3 hours of ictus remains the most effective therapy after acute 
ischaemic stroke. 
The MERCI device was developed to restore cerebral blood flow following stroke (90) by 
ensnaring the thrombus and pulling it out of the blocked artery. The Multi MERCI trial 
investigators found that recanalisation could be achieved in 57% of patients with 
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treatable vessels, and when used in adjunct with rt-PA recanalisation could be achieved 
in up to 69.5% of patients (89). Amongst patients who were recanalised with the MERCI 
device, survival was increased two-fold and a higher proportion of patients were 
without significant disability. Mechanical thrombectomy plays an important role in 
acute stroke care; recanalisation of cerebral vasculature is a significant predictor of 
good clinical outcome (308-310). However this intervention has yet to be rigorously 
examined in a RCT. 
The European Stroke Initiative (EUSI) recommendations (228) emphasise the need for 
fast and efficient diagnosis and treatment of stroke. The treatment window for therapy 
with rt-PA is narrow (within 3 hours of stroke onset). Similarly the recent Multi MERCI 
trial used an onset- to -treatment time of 8 hours (89). Some patients may miss out on 
potential therapies due to delays in diagnosis and hospital admission. It is therefore of 
interest to develop treatments which have efficacy at slightly later time points in order 
to maximise patient benefit.     
7.1.2 Areas for Further Research 
Local enhancement of blood flow during the recovery period may confer benefit, 
according to some experimental reports (311). The sphenopalatine ganglion (SPG) 
(Figure 7-1) is the source of parasympathetic innervations to the nasal and eye mucosa, 
as well as most of the anterior part of the cerebral vasculature (312). Stimulation of the 
parasympathetic fibres of the sphenopalatine ganglion appears capable of enhancing 
blood flow to the ipsilateral hemisphere in rats (313), cats (314) and dogs (315). 
Vascular dilatation can increase arterial diameter by 15-20% (316), however this is short 
lived (311). Stimulation can be achieved through implantation of electrodes, and a 
device to provide this stimulation, the NeuroPath™ Device, was developed and is 
currently being tested by the biotechnology company, BrainsGate.  
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7.1.2.1 BrainsGate/ VISTA collaboration 
BrainsGate proposed use of the NeuroPath™ Device within the first 24 hours after index 
stroke. This longer time window for treatment initiation means that more patients are 
eligible to receive a potentially beneficially therapy. This device (Figure 7-2) was 
designed to stimulate the SPG thereby causing vasodilatation of the cerebral 
vasculature with the aim of increasing blood flow to the ischaemic areas of the brain 
after stroke. Data from 23 patients who were implanted with the NeuroPath™ Device 
were presented at the International Stroke Conference, New Orleans, 2008 (317). 
Patients were eligible for device implantation if they had an ischaemic stroke affecting 
the anterior circulation, were aged between 18 and 85 years, had a baseline National 
Institutes of Health Stroke Scale (NIHSS) score of between 7 and 20 and if implantation 
was feasible within 24 hours of ictus. Treatment consisted of device implantation and 
stimulation for 3 hours per day, over 7 days. Outcome data from device implanted 
patients were compared with outcomes from the placebo arm of the NINDS rt-PA trial 
(81). The NeuroPath™ investigators reported that 57% of device implanted patients 
achieved a favourable outcome, defined as attainment of a modified Rankin Score 
(mRS) score of 0-2, compared with 29% of placebo –treated patients from the NINDS 
trial. They concluded that stimulation of the SPG was safe, feasible, and device 
implantation may be a promising therapy (317). 
In the planning phase of this open label study, representatives from BrainsGate sought 
to collaborate with VISTA, the latter providing historical comparator data, data 
management and statistical consultation through the Robertson Centre for Biostatistics. 
Our objective was to provide comparator data, with which outcomes in device- 
implanted patients could be assessed. In addition, statistical consultation would guide 
the planning of this pilot, open -label trial, so that a pivotal trial could be planned using 
these data and if necessary, the pilot trial outcomes could be put forward as supporting 
evidence for regulatory authorities, having met their standards for analyses.  
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7.1.3 Aims 
We aimed to optimise VISTA data for use in a comparison with device –implanted 
patients from BrainsGate, examine the feasibility of matching patients based on data 
availability, and detail the best statistical analyses for this type of investigation. We 
aimed to address each of these issues using the eligibility criteria and design 
specifications provided by BrainsGate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Myzoon Ali, 2008  Chapter 7, 137 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-1 Location of the sphenopalatine ganglion (SPG). Adapted from BrainsGate 
protocol number: CLP1000410 
 
Figure 7-2 The NeuroPath™ Device. Adapted from BrainsGate protocol number: 
CLP1000410 
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7.2 Methods 
7.2.1 Choice of Comparator Group 
We discussed the available comparator group options with representatives from 
BrainsGate. For the purposes of the NeuroPath™ Device trial, ‘placebo concurrent 
controls’ would be infeasible as an identically appearing treatment would require 
surgery, with the attendant risks and ethical barriers. The choice between sham 
operation, dummy device and active device with inactive stimulation was unappealing 
and the risk/benefit assessment would raise ethical dilemmas that were soluble but 
unattractive for a phase II trial. Additionally, blinding or masking of investigators is 
difficult where devices are concerned; without masking, the assessment of outcome is 
open to bias which is unquantifiable. Bias could however be minimised through a 
prospective, randomized, open-label, blinded end point (PROBE) design (318), in which 
the outcome assessments are blinded though the treatment is given in an open manner. 
To achieve this properly with a stroke trial would require central adjudication of 
outcomes, now possible using video links and digital video recordings (319) but this 
would carry further costs and complexity for BrainsGate. The main deterrent for this 
design was the financial constraints of the project, which precluded the randomisation 
of patients to a placebo group.  
Similarly, ‘no-treatment’ controls (297) would pose problems for patient recruitment, 
though the major barrier was one of cost. ‘Dose-response concurrent controls’, in whom 
efficacy of various doses of a treatment is examined, would be ineligible for use since 
ethical barriers limit implantation of a device that would be switched on rarely and 
since detection of differences amongst active doses is even more impractical than 
distinguishing treatment from no treatment. Additionally, this would require a large 
sample size and the attendant costs for randomisation. ‘Positive concurrent control’ 
groups in which patients are treated with an alternative active therapy (for example, rt-
PA), would be inappropriate; this control group would contain an additional variable for 
Myzoon Ali, 2008  Chapter 7, 139 
 
  
which one could not adjust in the device implantation group, and in any case patients 
who were administered with rt-PA were excluded under BrainsGate’s entry criteria 
(Table 7-1).  
 Comparison of the surgical group with a control group that receives conservative 
medical care rather than a historical comparator group would increase the costs of 
patient monitoring and data collection. Within a fixed budget, this would result in a 50% 
smaller sample size or the same sample size with only half the potential information 
about the experimental treatment, low statistical power to detect device efficacy and 
limited information on tolerability.  
We concluded that the use of an ‘external control group’ (297) would best address the 
needs of this early stage of the device development program. As mentioned in 6.3.1, 
bias could be reduced through the use of historical comparators from previous trials 
conducted in the same environment (300). We postulated that the standard practices 
employed in clinical trials of ischaemic stroke within VISTA would provide a uniform 
measure of outcomes which could be comparable to patient outcomes from an active 
arm of a current trial. Potential differences in diagnostic criteria between treatment 
and historical control groups could be overcome by utilising standardised diagnostic 
tools such as NIHSS score at baseline, and outcome measures such as the Barthel Index 
(BI) and modified Rankin Scale Score (mRS) in the two groups. These criteria are 
commonly implemented and easily understood. Training tools such as DVDs (319) 
demonstrating the correct use of the mRS and online assessment for the NIHSS (306) are 
available to ensure that outcome measures are consistent with those collected in VISTA.    
7.2.2  Maximising Data Comparability  
Our first objective was to maximise data comparability between the historical 
comparators and the device -implanted patients. We narrowed the VISTA data pool 
according to the same eligibility criteria stipulated for patients with NeuroPath™ device 
implantation. This generated a pool of patients with similar baseline characteristics to 
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the device implanted patients (Table 7-1). Briefly, patients aged between 18 and 85 
years, with an ischaemic stroke affecting the anterior cerebral circulation, and for 
whom no active treatment was administered were eligible for inclusion. Variables of 
interest included baseline National Institutes of Health Stroke Scale Scores (NIHSS), 
hemisphere of infarct, medical history, mortality, NIHSS, Barthel Index (BI) and 
modified Rankin Score (mRS) at 90 days.  
7.2.2.1  Identification of Anterior Circulation Strokes  
The identification of anterior circulatory stroke was imperative in order to eliminate 
unnecessary observations from the comparator patient data pool. Anterior circulation 
involvement can be determined using classification schemes based on clinical history 
and examination (320) such as TOAST, used in the Trial of Org 10172 in Acute Stroke 
Treatment (5). Bamford et al. (1991) (9) developed the Oxfordshire Community Stroke 
Project (OCSP) classification scheme for ischaemic stroke which categorised stroke into 
one of four subtypes (Table 7-2). These included Total Anterior Circulatory Syndrome 
(TACS) and Partial Anterior Circulatory Syndrome (PACS) subtypes; classifications which 
were ideal for use in narrowing the VISTA data pool.   
Out of the 28 clinical trials, and one stroke registry contained within VISTA, only 2 trials 
contained data on stroke subtypes using the OCSP classification, and an additional 2 
trials stated the presence or absence of anterior circulatory stroke. In order to 
maximise patient data available for this project, we sought to produce a classification 
system for anterior circulatory stroke in trials which did not use an OCSP classification. 
We examined the association between stroke characteristics at admission (NIHSS at 
baseline) and OCSP classifications in the same patient using an algorithm which was 
previously developed for the IMAGES trial (108).   
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7.2.2.2 The IMAGES Algorithm 
The IMAGES trial (108) utilized a method of stroke classification based on the National 
Institutes of Health Stroke Scale (NIHSS). This was expanded and used to create an 
algorithm to determine TACS and PACS classification (Table 7-3). Baseline 
characteristics were used in equation form to identify stroke subtypes according to the 
OCSP classification (Table 7-4). We applied this algorithm in a test dataset to identify 
patients who had suffered an anterior circulatory stroke based on their NIHSS score. The 
GAIN Americas trial (160) was made available through VISTA. This dataset contained 
NIHSS scores at admission and had documented stroke subtypes using the OCSP 
classification, which was ideal for our purposes as a direct comparison between NIHSS 
score and OCSP classification could be performed within this dataset.  
Those patients who had been identified by the algorithm as having a TACS subtype were 
excluded from further reclassification under another subtype. Similarly, remaining 
patients with a PACS subtype classification were excluded from further reclassification 
under another subtype. Those patients whom the algorithm had identified as having a 
TACS or PACS subtype were assigned to a ‘Cortical Stoke’ group, and those identified as 
having Lacunar Circulatory Syndrome (LACS) or ‘Other,’ subtype were assigned to a 
‘Non- Cortical Stroke’ group. Those patients who were identified as having TACS or PACS 
classification using OCSP documentation were assigned to an OCSP-defined ‘Cortical 
Stroke’ group, and all other subtypes were assigned to an OCSP- defined ‘Non-Cortical 
Stroke’ group. We then cross tabulated these occurrences to give an indication of the 
proportion of cortical strokes which were correctly identified by the algorithm.
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Inclusion Criteria 
Age: ≥ 18  years and ≤ 85 of both genders 
Patients with symptoms and signs of an acute ischemic hemispheric stroke within the anterior 
circulation.  
Treatment can be initiated within the first 24 hours following stroke onset or since last seen normal.  
NIHSS ≥ 7 and ≤ 20  
Signed informed consent has been obtained from the patient him/herself or his/her legally authorized 
representative  
Exclusion Criteria 
Time interval since onset of symptoms undetermined 
Treatment with NeuroPath™ IS System can't start within the first 24 hours post stroke onset  
Any other imaging diagnosis including tumour, abscess, primary intracranial haemorrhage (ICH) or 
secondary haemorrhage (PH1-PH2) (H1 and H2 are allowed); or symptoms suspicious for sub-
arachnoid haemorrhage, etc 
Clinical syndrome of an acute stroke due to lacunar infarct (pure motor hemiparesis, ataxic 
hemiparesis, sensorimotor stroke), unless brain imaging demonstrates a relevant lesion > 1.5 cm in 
size 
Not a stroke in the anterior circulation  
Minor stroke with non-disabling deficit or rapidly improving neurological symptoms with a high 
probably to Transient Ischemic Attack (TIA)  
Eligible to or treated with IV or IA t-PA or mechanical thrombolysis  
Baseline NIHSS >20 or < 7 
Neurological deficit that has led to stupor or coma (NIHSS level of consciousness score greater than 
or equal to 2) 
History of stroke in previous 6 months, Pre-existing disability; Modified Rankin Score > 2 upon 
screening  
Patients under oral anticoagulants or having received heparin within 48 hours, and / or with elevated 
activated partial thromboplastin time (aPTT) (or INR) 
High clinical suspicion of septic embolus 
Severe cardiac disease: evidence of congestive heart failure or has history of end-stage 
cardiovascular disease (e.g. CHF New York Heart Association Class III or IV or unstable angina)  
Uncontrolled hypertension upon enrolment (systolic >185 mmHg and/or diastolic >110 mmHg) 
Serious systemic infection  
Women known to be pregnant or having a positive or indeterminate pregnancy test  
Patients with other implanted neural stimulator, Orthodontics or non-Hygienic condition/ problems 
that prevent procedures within the mouth 
MRI contraindications, such as but not limited to: 
Central nervous system aneurysm clips, implanted cardiac pacemaker or defibrillator, Cochlear 
implant 
Ocular foreign body (e.g. metal shavings), Insulin pump, Metal shrapnel or bullet, or any implanted 
device that is incompatible with MRI. 
Patients with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.) 
Life expectancy < 1 year from other causes  
Currently participating in any other clinical trial 
Patients unable or unwilling to follow protocol requirements 
 
Table 7-1 Eligibility criteria for NeuroPath™ Device implantation 
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OCSP classification Description 
Total Anterior Circulatory Syndrome (TACS) Presentation of new higher cerebral 
dysfunction, homonymous visual defect, 
ipsilateral motor and/ or sensory deficit of at 
least two areas of the face, arm and leg 
Partial Anterior Circulatory Stroke (PACS) Presentation with two of the three 
components of TACS 
Lacunar Circulatory Syndrome (LACS) Presentation with a pure sensory stroke, 
sensory-motor stroke, or ataxic hemiparesis 
Posterior Circulatory Syndrome (POCS) Presentation of ipsilateral cranial nerve palsy 
with contralateral motor and /or sensory 
deficit; disorder of conjugate eye movement; 
cerebellar dysfunction without ipsilateral long 
tract deficit  or isolated homonymous visual 
field defect 
  
Table 7-2 Definition of OCSP classification 
 
 
 
IMAGES code NIHSS equivalent (category) 
1. Unilateral weakness of the face (4) Facial palsy  
2. Unilateral weakness of arm (5) Motor arm scores where left ≠ right  
3. Unilateral weakness of leg (6) Motor leg scores where left ≠ right  
4. Unilateral sensory loss (8) Sensory  
5. Homonymous hemianopia (3) Visual  
6. Dysphasia (9) Best language  
7. Neglect or sensory/ visual inattention (11) Extinction  
8. Brainstem signs (eg. Ataxia) (7) Limb ataxia  
  
Table 7-3 IMAGES code for clinical characteristics at baseline 
 
 
 
Algorithm definition  
Total Anterior Circulatory Syndrome (TACS) (6 or 7) + 5 + (1 or 2 or 3 in any combination) 
  
Partial Anterior Circulatory Stroke (PACS) (6 or 7) 
 (6 or 7) + (1 or 2 or 3 or any combination) 
 5 + (1 or 2 or 3 or any combination) 
 (2 or 3 alone) 
  
Lacunar Circulatory Syndrome (LACS) (1+2+3) ± 4 
 (1+2) ± 4 
 (2+3) ± 4 
  
Posterior Circulatory Syndrome (POCS) 8 + (1 or 2 or 3 or 4 or any combination) 
  
Table 7-4 Coding of OCSP classifications based on the IMAGES algorithm 
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Having identified potential VISTA historical comparators based on the eligibility criteria 
defined by BrainsGate, we sought to optimise this data pool for its proposed use. 
7.2.3 Development of a Matching Algorithm for Comparators 
Discussion with BrainsGate and statistical consultation with the Robertson Centre for 
Biostatistics highlighted the need to strengthen data comparability between the device 
implanted patients and VISTA historical comparators. This was addressed by 
prospectively matching each treated patient with three VISTA historical comparators 
based on principal prognostic factors, namely age, baseline NIHSS and hemisphere of 
infarct. Compromise was struck between employing numerous comparators that were 
loosely matched to treated patients and choosing a small number of comparators per 
patient that instead were closely matched on several prognostic factors.   
Within our historical comparator data pool we combined the initial stroke severity 
variable indicated by the baseline NIHSS score and the hemisphere of the infarct, into 
one variable (NIHSS/side). This variable was matched exactly for each comparator group 
patient, while patient age was matched ± 4 years. Medical history and outcome data 
were recorded for each of the historical comparator patients.  
7.2.4 Feasibility of Matching Historical Comparator Patients  
We tested the integrity and validity of our historical comparator data pool for its 
proposed use. BrainsGate had previously specified that they would adhere to an onset 
to treatment time (OTT) of within 24 hours for device –implanted patients. Many trials 
in the comparator data pool had an onset to treatment time of less than 12 hours and it 
was therefore imperative that we optimise the comparator group data to avoid bias 
associated with later treatment. A later onset- to -treatment time could influence the 
baseline NIHSS measures, which would in turn confound the matching of device 
implanted patients with appropriate comparators. We postulated that this could be 
overcome by matching patients who had a later OTT (nearer 24 hours) with patients in 
the comparator data pool based on their NIHSS score at 24 hours. We examined whether 
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this comparison was feasible by determining the proportion of VISTA patients who had 
undergone a neurological assessment at 24 hours.  
We tested the depth of the comparator dataset by running a matching simulation with a 
test batch of 100 patients derived from the ECASSI trial, to simulate a treatment group 
for which appropriate matches were sought using the comparator dataset. The test 
batch had a good mix of onset- to- treatment times ranging between 0.6 hours to 23.5 
hours. We matched NIHSS at baseline or 24 hours (if applicable) and hemisphere of 
infarct preferentially, followed by age ± 4 years to narrow the field down to only those 
patients who were compatible. Where insufficient matches were available, the 
matching criteria were expanded to include NIHSS score ± 1. Implementation of the 
matching criteria based on initial stroke severity, age and hemisphere of infarct 
resulted in the identification of a smaller subset of potential matches. The onset- to -
treatment times in this subset were then sorted in descending order, so as to 
preferentially select those patients who were recruited latest. The first three patients 
were then selected, and a marker attached to the unique identifier to remove these 
patients from re-selection in subsequent match searches. This process was carried out 
for all 100 patients. 
7.2.5 Statistical Analyses 
We conducted a logistic regression analysis, accounting for age and initial stroke 
severity, to investigate the impact of trial recruitment year on attainment of good 
functional outcome at 90 days. We defined good functional outcome as attainment of a 
mRS of 0 or 1 at 90 days. We used trial recruitment in 2006 as a baseline with which to 
compare outcomes from earlier recruitment.  
Last, we developed statistical analyses in consultation with BrainsGate and the 
Robertson Centre for Biostatistics, which would be performed for an interim analysis 
and a final analysis at the end of the study.  
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We proposed to limit bias by engaging an independent group to undertake the matching 
process prospectively before outcomes of treated patients were known and by 
stratifying the final analysis according to the main prognostic factors that were used for 
matching purposes. We postulated that bias could also be limited through use of VISTA 
data, since comparators that were derived from trial populations were treated within 
academic centres and according to current standard of care: this group was likely to be 
more representative of the treated group than controls chosen from observational 
sources.  
7.3 Results 
7.3.1 Selection of the Control Group 
We determined that the use of external controls in the form of historical comparators 
was best suited to the trial design and financial constraints of this study. We used the 
eligibility criteria specified by BrainsGate to select and optimise a comparator dataset 
from VISTA.  
7.3.1.1 Identification of Anterior Circulatory Stroke 
We used the GAIN Americas dataset to investigate an algorithm to identify anterior 
circulation stroke from baseline NIHSS scores. Patients in this dataset had a median age 
of 72 (IQR [62, 79]), 53.4% were male, 85.2% had experienced and ischaemic stroke and 
14.8% had experienced an intracerebral haemorrhage. In this dataset we were 
accurately able to identify cortical strokes in patients with ischaemic stroke with 86.2% 
sensitivity and 65.1% specificity (Table 7-5).   
7.3.1.2 Comparator Group Population 
As of June 2008, VISTA contained in excess of 27 000 patient records from 28 acute 
stroke clinical trials and one acute stroke registry. Of these, only 8 trials (11 109 
patients) had sufficient diagnostic and outcome data for use in the proposed study of 
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the NeuroPath™ Device. The size of the potential pool of patients was restricted by 
several factors. VISTA contains only patients who were enrolled in acute stroke trials 
over the past two decades. The source population was restricted by the inclusion and 
exclusion criteria of participating clinical trials, and was limited to participating centres 
and countries. The population was further restricted by our conscious choice to exclude 
comparator patients who were treated with an active investigational medical product 
even if results from the source trial were neutral: only placebo-treated patients were 
considered. The greatest restriction occurred when eligibility criteria for the 
NeuroPath™ Device trial were applied to the VISTA population. Following 
Implementation of BrainsGate’s eligibility criteria, a total of 2083 patients remained. A 
breakdown of patient eligibility per trial is detailed in Table 7-6. Within this dataset 
51% of all comparator group patients were recruited between 2000 and 2006, 36% were 
recruited between 1998 and 1999 and 13% were recruited in 1994. Table 7-7 describes 
the demography of comparator group patients. The median age of patients in the 
comparator pool was 71 and 52.7% were male. NIHSS scores were available for all 
patients at baseline and for 1084 patients (52%) at 24 hours. There was little difference 
between NIHSS scores at admission (14 IQR [11, 17]) compared with NIHSS at 24 hours 
(13 IQR [10, 17]). A total of 2.6% of patients were lost to follow up.  
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Algorithm 
Freq 
% 
Row % 
Col % 
OCSP 
  
Cortical Non- cortical Total 
Cortical 923 
72.11 
92.67 
86.18 
73 
5.70 
7.33 
34.93 
996 
77.81 
Non Cortical 148 
11.56 
52.11 
13.82 
136 
10.63 
47.89 
65.07 
284 
22.19 
Total 1071 
83.67 
209 
16.33 
1280 
100.00 
    
Table 7-5 Accuracy of anterior circulatory stroke identification 
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Trial BNIH between 
7-20  
Placebo No rt-PA Age between 
18-75 
Anterior Circulation 
Stroke 
Ischaemic 
Stroke 
Total  
ECASSI (1994) 357 311 311 707 472 685 144/701 
ECASSII (1998) 627 391 391 814 593 800 165/800 
GAINAM (1999) 1092 790 1267 1460 1160 1360 233/1605 
GAININT (1999) 1255 900 1808 1673 1210 1446 354/1808 
CMZ (2000) 436 599 599 546 591 596 380/599 
NINDS (1994) 397 312 312 606 522 624 126/624 
mRECT (2004) 684 365 295 766 764 826 88/826 
SAINT (2006) 1997 2535 1546 2407 1831 2535 593/4946 
        
Table 7-6 Breakdown of data availability for the BrainsGate collaboration 
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Variable Median [IQR] Frequency (%) 
Age  71 [62, 77]  
Male  52.7 
Hemisphere of Infarct  Left=46.8 
Location of Infarct  Cortical=39.0 
Cortical/ Subcortical=58.8 
Subcortical=2.2 
Onset to Treatment Time 4.7 [3.7, 6.2]  
Baseline NIHSS 14 [11, 17]  
NIHSS at 24 hours 13 [10, 17]  
mRS at 90 Days 4 [2, 5]  
NIHSS at 90 Days 6 [2, 11]  
Death Day 20 [5, 72]  
Mortality at 90 Days Alive= 81.6  
   
Table 7-7 Demographic data for the VISTA comparator group 
 
 
 
 
 
 
 
7.3.2  Feasibility of Matching Historical Comparators 
For the proposed study with the NeuroPath™ Device, we undertook extensive modelling 
and simulation work to assess probabilities of finding matches for an example treatment 
group (derived from the ECASS I trial). Table 7-8 details the results of our matching 
simulation. Where appropriate, expansion of the matching algorithm to include NIHSS 
score ± 1 provided sufficient matches, without requiring further alteration to the 
algorithm. Only 2 patients (numbers 30 and 80) could not be matched, however these 
patients were from an extreme of the patient age spectrum. We determined that VISTA 
contained sufficient data to offer a high probability that each treated patient could be 
matched with at least three historical comparators who were aged within 4 years of the 
treated patient and had an identical NIHSS total score and hemisphere of infarct. 
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  Number of Matches Available  
Test 
Patients 
Number 
Parameters 
(Age, 
NIHSS/Side) 
Age ± 2 
years 
Age ± 3 
years 
Age ± 4 
years 
NIH ±1 point 24 hour 
NIHSS used 
1.  73, 19/LEFT 11     
2.  33, 9/LEFT 0 0 0 1 (NIHSS11 /LEFT) 
1 (NIHSS07 /LEFT) 
 
3.  64, 15/RIGHT 9     
4.  73, 14/RIGHT 14     
5.  34, 13/LEFT 0 0 0 1 (NIHSS14/ LEFT)  
6.  70, 15/RIGHT 12     
7.  62, 10/LEFT 6     
8.  58, 8/LEFT 3     
9.  65, 14/RIGHT 7     
10.  75, 18/RIGHT 10     
11.  66, 11/LEFT 5     
12.  51, 20/RIGHT 1 2 2 1 (NIHSS19/ 
RIGHT) 
 
13.  69, 16/RIGHT 9     
14.  57, 17/RIGHT 3     
15.  78, 13/RIGHT 17     
16.  74, 20/RIGHT 8     
17.  64, 17/RIGHT 5     
18.  61, 15/RIGHT 8     
19.  58, 13/RIGHT 8     
20.  67, 16/RIGHT 2     
21.  62, 18/RIGHT 6     
22.  32, 16/LEFT 0 0 0 3 (NIHSS17/ LEFT)  
23.  73, 20/RIGHT 4     
24.  45, 8/LEFT 1 1 2 2 (NIHSS16/ 
RIGHT) 
 
25.  57, 20/LEFT 2 2 3  3 
26.  67, 19/LEFT 4    3 
27.  68, 14/RIGHT 5     
28.  75, 20/LEFT 16     
29.  72, 11/LEFT 21     
30.  31, 15/LEFT 0 0 0 0 3 
31.  42, 17/RIGHT 0 0 2 1 (NIHSS 15/LEFT)  
32.  77, 14/LEFT 17     
33.  65, 8/LEFT 3     
34.  47, 16/LEFT 0 1 1 7 (NIHSS15/ LEFT)  
35.  75, 18/LEFT 7     
36.  64, 14/LEFT 4     
37.  80, 16/LEFT 7     
38.  68, 20/LEFT 5    3 
39.  71, 10/LEFT 5     
40.  74, 14/LEFT 11     
41.  73, 13/LEFT 10     
42.  79, 18/RIGHT 4    3 
43.  67, 17/LEFT 12     
44.  79, 16/RIGHT 20     
45.  76, 11/RIGHT 4    3 
46.  55, 18/LEFT 3     
47.  69, 19/RIGHT 5     
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  Number of Matches Available  
Test 
Patient 
Number 
Parameters 
(Age, 
NIHSS/Side) 
Age ± 2 
years 
Age ± 3 
years 
Age ± 4 
years 
NIH ±1 point 24 hour 
NIHSS used 
48.  77, 18/RIGHT 3    3 
49.  64, 20/RIGHT 1 3   3 
50.  68, 12/RIGHT 12     
51.  70, 11/RIGHT 10     
52.  64, 11/RIGHT 6     
53.  66, 12/LEFT 4     
54.  43, 17/RIGHT 0 0 0 1 (NIHSS16/ 
RIGHT) 
1 (NIHSS18/ 
RIGHT) 
 
55.  76, 9/RIGHT 9     
56.  67, 18/LEFT 4     
57.  73, 8/RIGHT 6     
58.  69, 17/RIGHT 11     
59.  72, 9/LEFT 6    3 
60.  64, 14/RIGHT 9     
61.  80, 10/RIGHT 12     
62.  65, 18/LEFT 6     
63.  51, 20/LEFT 3    3 
64.  79, 18/LEFT 6    3 
65.  74, 18/RIGHT 5    3 
66.  80, 10/LEFT 7     
67.  72, 15/RIGHT 12     
68.  62, 19/LEFT 9     
69.  70, 19/RIGHT 5     
70.  64, 16/LEFT 4     
71.  69, 14/RIGHT 4     
72.  77, 17/RIGHT 11     
73.  61, 9/RIGHT 3     
74.  54, 17/RIGHT 2 2 2 1 (NIHSS18/ 
RIGHT) 
3 
75.  77, 14/RIGHT 12     
76.  48, 14/RIGHT 0 0 1 4 (NIHSS15/ 
RIGHT) 
3 
77.  66, 11/LEFT 2 3    
78.  76, 18/RIGHT 8     
79.  66, 12/LEFT 1     
80.  46, 20/RIGHT 0 0 0 0  
81.  75, 12/LEFT 6    3 
82.  61, 19/RIGHT 1 1 1 3 (NIHSS18/ 
RIGHT) 
3 
83.  49, 19/RIGHT 3     
84.  76, 15/LEFT 16     
85.  64, 14/RIGHT 3    3 
86.  49, 17/RIGHT 3     
87.  42, 9/LEFT 2    3 
88.  65, 13/LEFT 3     
89.  67, 18/LEFT 3    3 
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  Number of Matches Available  
Test 
Patient 
Number 
Parameters 
(Age, 
NIHSS/Side) 
Age ± 2 
years 
Age ± 3 
years 
Age ± 4 
years 
NIH ±1 point 24 hour 
NIHSS used 
90.  73, 13/RIGHT 10     
91.  59, 15/RIGHT 6     
92.  62, 20/LEFT 7     
93.  67, 16/LEFT 4     
94.  60, 18/LEFT 3     
95.  71, 16/RIGHT 4    3 
96.  46, 13/LEFT 5     
97.  55, 12/LEFT 1 2 3  3 
98.  69, 12/LEFT 5     
99.  55, 9/RIGHT 4     
100. 47, 16/LEFT 0 0 0 3 (NIHSS15/ LEFT)  
       
Table 7-8 Results of the matching simulation 
 
 
 
 
 
 
 
Year P -value Point Estimate for attainment of good 
functional outcome at 90 days 
95% confidence 
interval 
1994 vs 2006  0.23 1.42 [0.90, 2.23] 
1998 vs 2006 0.08 2.44 [1.52, 3.92] 
1999 vs 2006 0.34 1.98 [1.42, 2.76] 
2000 vs 2006 <0.0001 3.65 [2.54, 5.23] 
2004 vs 2006 0.23 1.19 [0.53, 2.67] 
    
Table 7-9 Time course analysis showing the impact of time on attainment of good functional 
outcome after accounting for age and initial stroke severity 
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7.3.3 Quantifying Temporal Effects 
The effect of evolving therapies over time on outcome was assessed using logistic 
regression, adjusting for age and initial stroke severity. We performed this analysis on 
the whole historical control dataset. Patient recruitment in the historical comparator 
group took place between 1994 and 2006. Amongst this sample of patients aged 18-75, 
with documented anterior circulatory stroke and in whom baseline NIHSS scores were 
between 7 and 20, the year of recruitment showed no clear impact on attainment of 
good functional outcome, defined as attainment of a mRS score of 0-1 at 90 days (Table 
7-9). Only recruitment in 2000 was a significant predictor of good functional outcome 
when compared with recruitment in 2006 (p<0.0001, odds ratio for good functional 
outcome=3.7 95% confidence interval [2.5, 5.2]). Recruitment in all other years did not 
significantly affect attainment of good functional outcome when compared with 
recruitment in 2006. 
7.3.4  Recommended Statistical Analyses  
For the NeuroPath™ Device trial, we nominated a matching process with analysis based 
on adjustment for stratification (matching) variables as the primary analytic approach. 
Covariate adjustment based on the total eligible comparator population was nominated 
as the subsidiary analysis.  
7.3.4.1 Matched Analyses 
In the first instance, we proposed an interim analysis of the distribution of mRS scores 
at 90 days after approximately 40 patients had been enrolled in the BrainsGate trials. 
This would serve to optimise the matching algorithm. Following receipt of all patient 
data at the end of recruitment, we would perform a final matched analysis based on the 
full dataset. We defined attainment of good functional outcome for our statistical 
analyses as 90 -day mRS of 0-1, NIHSS of 0-1 and Barthel Index of ≥95. Final analysis at 
90 days would examine whether there was a difference between the mRS at 90 days in 
the NeuroPath™ implant group versus the VISTA comparator group. Both the interim and 
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final analyses would be assessed using the Cochran-Mantel-Haenszel (CMH) non-
parametric statistical test (321), adjusting for age, baseline NIHSS score, stroke 
location, and hemisphere of infarct. Each patient submitted by BrainsGate would have 
been matched with 3 patients from VISTA, and this would constitute one stratum. Thus 
up to 100 strata in total would be used in the CMH analysis. We would repeat this to 
assess the NIHSS score at 90 days.  
7.3.4.2 Covariate Adjusted Analyses 
Differences between the distribution of mRS at 90 days in the NeuroPath™ implant group 
and the VISTA comparator group would be analysed at the end of the study period using 
ordinal logistic regression, adjusting for age, baseline NIHSS score, hemisphere of 
infarct, and stroke location. We would repeat the logistic regression to estimate 
differences in NIHSS and Barthel Index scores (<95 vs ≥95) between the two groups at 90 
days. We would assess survival during the first 90 days using Kaplan-Meier survival 
curves and Cox Proportional Hazards modelling, accounting for the effects of age, 
baseline NIHSS score, stroke location and hemisphere of stroke. 
7.4 Discussion 
We successfully implemented an algorithm to determine the presence of anterior 
circulatory stroke with a sensitivity of 86.2% and a specificity of 65.1%. This permitted 
the identification and inclusion of patients with anterior circulatory stroke into the 
historical comparator data pool in the absence of OCSP classifications.  
We were able to implement all of the eligibility criteria specified by BrainsGate to 
create a pool of comparator group patients. We tested these data extensively to ensure 
that adequate matches could be found for potential device -implanted patients from 
BrainsGate and ascertained that the proposed matching criteria could be met. In 
situations where fewer than 3 matches per patient were found, expanding the criteria 
to include NIHSS score ± 1 was feasible in all but 2 cases. These cases were considered 
Myzoon Ali, 2008  Chapter 7, 156 
 
  
to lie outside the normal age distribution of stroke patients and were unlikely to occur 
in large numbers in the active treatment group. We also provided details on statistical 
analyses which could address bias. We provided statistical options for both matched and 
covariate adjusted analyses with separate options for interim analyses so as to address 
the needs of the device company. We were unable to identify the incidence of cortical 
stroke with 100% accuracy, however this is to be expected as discrepancies in the 
coding of TACS and PACS subtypes can occur. For example, POCS can be miscoded as 
TACS or PACS due to the presence of Posterior Cerebral Artery (PCA) mediated 
infarction of the temporal lobe, causing presentation of mild hemiparesis, aphasia and 
visual field deficits (322). These observations were seen in our series, however, the 
occurrence was low.   
It is widely acknowledged that conclusions drawn from comparison with historical 
controls may be fallible. In general, the risks are especially associated with incomplete 
data, variation in patient selection and bias in outcome evaluation (305;323). In the 
current collaboration we have made efforts to address these points by including 
patients with near complete medical histories and follow up data. This has been 
facilitated by the richness of trial data available within VISTA (155).  
Recommendations to improve the validity of historical comparators have been detailed 
by Bennett et al. (2003). These measures include the need for clear and detailed entry 
and exclusion criteria, the use of consistent and objective definitions of variables, the 
use of contemporaneous patients, and analysis of outcomes using both a cohort design 
and a matched case-control design (324). We have addressed these points during the 
development and compilation of our historical comparator dataset. VISTA has 
established clear guidelines for trial eligibility and efforts have been made to ensure 
that annotated case report forms, protocols and data dictionaries are available for 
constituent trials. We acknowledge that VISTA may have low representation of patients 
from some geographical regions, however it is anticipated that this will be rectified by 
continued recruitment of trials into VISTA. Additionally Bennett et al. (2003) reported 
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that the use of large resources from previous clinical trials would enhance the analysis 
of historical controls (324). This has provided further credence to our current pilot trial 
design. 
The use of historical comparators to evaluate the impact of new management protocols 
has been implemented over the past few years with some success in terms of regulatory 
acceptance. Watts (2002) (325) investigated the efficacy of an osteoporosis treatment. 
Patients who received 35mg of actonel once a week were compared with historical 
placebo controls from a previous actonel trial. As a result of these analyses, the 
administration of actonel once a week was approved by the FDA. In their investigation, 
historical placebo treated patients were matched with those from the active group 
according to principal baseline characteristics, similar to the protocol employed in our 
proposed study of the NeuroPath™ Device.  
Fakhry et al. (2004) (326) used historical comparators to investigate whether adherence 
to the Brain Trauma Foundation (BTF) guidelines would reduce mortality, length of stay, 
costs and disability after traumatic brain injury. They conducted a retrospective 
analysis of trauma registry data for patients recruited between 1991 and 1994, 
compared with those recruited between 1997 and 2000. Their analysis concluded that 
adherence to BTF guidelines decreased length of stay and significantly affected 
mortality and outcome.  
Martling et al. (2000) (327) examined the impact of total mesorectal excision for rectal 
cancer, using surgical historical comparators groups from two previous trials. They 
found that the implementation of a new teaching initiative had a major effect on 
cancer outcomes. These previously successful investigations have demonstrated that the 
use of historical comparators is feasible and can influence clinicians and even regulatory 
authorities. These reports have encouraged further study into comparator group options 
beyond the conventional placebo groups.   
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In the current climate of increasing costs for research and development and the 
numerous failed trials for putative neuroprotectants, it has become increasingly 
important to explore alternative methods of research, especially for smaller companies 
with limited resources.  
7.4.1 Conclusion 
We described how a resource such as VISTA could be used to inform a phase II proof –of 
–concept study. While the use of historical controls for phase III efficacy trials is not 
advocated, there can be benefits from using matched historical comparators in pilot or 
proof-of-concept studies. Most concerns arising from use of historical comparators can 
be addressed through the utilisation of a large pool of robust clinical trial data. By 
implementing optimum patient selection, matching and complete documentation of 
outcomes, historical controls can function as viable comparator groups for these types 
of investigations.    
We described here the measures that could be implemented to validate the use of 
historical comparators. The use of such a resource when examining efficacy may still be 
unappealing to some investigators. We present an alternative use for historical 
comparators in chapter 8: validation of results from a previous clinical trial and use 
when a RCT is deemed unethical or infeasible.   
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8 Assessment of Decompressive Surgery for 
Malignant MCA Occlusion using Historical 
Comparators. 
8.1 Background 
The use of historical comparators may not be optimal for a phase III efficacy trial 
however measures can be implemented to ensure feasibility and validity for use in a 
proof -of -concept study. We proposed an additional use for historical comparators in 
situations where randomisation to a placebo group is unethical or infeasible. We 
entered into collaboration with the DESTINY trial group based in Heidelberg, Germany, 
to investigate stroke outcomes after malignant middle cerebral artery occlusion 
(mMCAO). The DESTINY trial examined the impact of decompressive hemicraniectomy 
on outcome after mMCAO, compared with randomised controls. We compared the 
outcomes of operated patients from the DESTINY trial with historical comparators from 
VISTA to determine whether the findings could be replicated and if historical 
comparators could be used as an alternative in a situation where a randomised 
controlled trial (RCT) is infeasible or unethical.  
8.1.1 Malignant Middle Cerebral Artery Occlusion (mMCAO) 
Up to 10% of patients with middle cerebral artery occlusion (MCAO) experience 
progressive neurological deterioration within 2-5 days of index stroke (93;94). Malignant 
middle cerebral artery occlusion (mMCAO) occurs as a result of a large hemispheric 
infarction with poor outcome attributable to the development of cerebral oedema, 
increased intracranial pressure, cerebral herniation and death (95;328;329). Diagnostic 
criteria for malignant middle cerebral artery occlusion include infarction size of at least 
half (330) or two thirds (331) of the middle cerebral artery territory and a National 
Institutes of Health Stroke Scale (NIHSS) score of ≥ 20 (330). It occurs primarily due to 
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embolic occlusion of the internal carotid artery (ICA) or proximal middle cerebral artery 
(330). Uhl et al. (2004) described an infarction of >50% of the MCA territory and 
neuroradiological evidence of cerebral oedema such as effacement of sulci and 
compression of the basal cisterns, as indicative of mMCAO. Patients present with a 
severe hemispheric stroke syndrome, including hemiplegia, forced eye deviation, and 
progressive loss of consciousness within the first 2 days after index stroke (331).  
The prognosis for mMCAO is still poor. In unselected groups of patients, with differing 
sizes and locations of infarcts, mortality rates generally range between 30% and 66% 
(331;332). Due to development of life-threatening cytotoxic brain oedema mortality 
rates of up to 80% have been reported (95;331). 
8.1.2 Management  
8.1.2.1 Current Management 
The current focus for management of severe cerebral oedema in mMCAO, as outlined by 
the American Academy of Neurology, is prevention of further deterioration caused by 
tissue displacement and brainstem shift (333). This can be addressed through the 
restriction of free water to avoid hypo-osmolar fluid that may worsen oedema. Factors 
such as hypoxia, hypercarbia, and hyperthermia should be corrected to prevent 
exacerbation of oedema (333). Conventional therapies for complete MCA occlusion such 
as mechanical ventilation, hypothermia (94;334;335) and barbiturate administration 
(336;337) have limited effects and do little to prevent transtentorial herniation. There 
is little evidence to support these measures in reducing ICP and cerebral oedema (338-
340). 
8.1.2.2 Hemicraniectomy for mMCAO 
In order to minimise the detrimental effects of cerebral oedema, decompressive 
craniectomy was considered in mMCAO. Decompressive surgery creates space for the 
swollen cerebral tissue by removing portions of the osseous skull and performing an 
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enlarged duraplasty (341). Figure 8-1 illustrates this procedure with a computed 
tomography (CT) scan of a patient with mMCAO who underwent decompressive 
hemicraniectomy. Surgery for this patient involved the removal of portions of the 
frontal, temporal, parietal and occipital bones. 
By creating space to accommodate the swollen brain, surgery aims to interrupt the 
vicious cycle of raised ICP, further oedema and secondary infarction or brain herniation. 
Decompressive surgery allows the expansion of oedematous tissue, increases perfusion 
pressure, restores the midline position (342) and preserves cerebral blood flow by 
preventing the compression of collateral blood vessels (228;343). In some animal 
studies, decompressive surgery resulted in an increased cerebral blood flow in 
ischaemic regions, an improved outcome, and a decrease in infarct size (344).  
Authors of previous non- randomized studies hypothesized that decompressive surgery 
and duraplasty could result in decreased mortality without increasing the proportion of 
severely disabled survivors (94;345;346). The DESTINY trial included 32 patients, 17 
underwent decompressive surgery and 15 were randomized to conservative medical 
care. The study confirmed that there was a favourable mortality profile when patients 
had undergone decompressive hemicraniectomy. However, DESTINY was stopped 
prematurely as the results of a planned interim analysis favoured hemicraniectomy. A 
similar trial, the DECIMAL (97) study, was carried out to assess the effect of 
decompressive surgery on functional outcome in patients with mMCAO; however 
DECIMAL was stopped due to slow enrolment. 
In March 2007, the results of a pooled analysis of three European randomized controlled 
trials on early decompressive surgery in malignant MCA infarction were published (142). 
The three trials included the DESTINY study from Germany (96), the DECIMAL study from 
France (97), and the HAMLET trial from The Netherlands. In this pooled analysis, 
hemicraniectomy was found to double the chances of survival from 29% to 78%, and did 
not increase the risk of complete dependency (142).  
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Despite increased survival, clinicians had previously expressed concerns about outcome 
after decompressive surgery (347); they initially feared that the aggressive procedure 
may increase survival at the cost of severe disability. The effects on patient quality of 
life have not been studied in a large randomised clinical trial (94). There is no doubt 
that this procedure is lifesaving (142), however the effects on morbidity need to be 
clarified (341). Additionally, factors such as the optimal timing and patient 
characteristics for good functional outcome after decompressive hemicraniectomy need 
to be elucidated (348).  
Malignant MCAO is an example of a severe neurological disorder where a RCT is difficult 
to conduct because of ethical concerns; survival favours the surgically treated group. 
Alternative investigational methods are necessary if questions about the optimum 
patient population, time frame for intervention and assessment of quality of life after 
surgery are to be answered. Tilley and others have advocated use of historical controls 
in development of treatments for stroke (176) but caution is required when using this 
approach. 
 
 
Figure 8-1 Hemicraniectomy involving frontal, temporal, parietal and occipital bone. 
Adapted from Vahedi et al., Stroke 2007; 38:2506-17 
 
8.1.3 Aims 
We aimed to use natural history comparator data from VISTA to compare functional 
outcome with that of the original DESTINY trial, not primarily for the purposes of 
validating DESTINY per se, but instead to illustrate that historical comparators could be 
a viable alternative if the implementation of a RCT is deemed unethical or infeasible. 
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We hypothesised that patients who had undergone hemicraniectomy would have a 
better disability and survival profile than similar historical comparator patients from 
VISTA. 
8.2 Methods 
8.2.1 Eligibility Criteria 
Oppenheim et al. (2000) reported that initial stroke severity, baseline lesion volume 
and the extent of the infarct were significant predictors for the development of mMCAO 
(349). Schwab et al. (1998) (94) further stated that a baseline NIHSS score of greater 
than 20 was a significant predictor for the development of mMCAO. For the purposes of 
VISTA data extraction we defined patients with malignant MCAO as having a baseline 
NIHSS score of ≥ 20, a level of consciousness category 1A (LOC 1A) score of ≥ 1 on the 
NIHSS (specified in the original DESTINY trial [Table 8-1]) and a lesion volume of ≥ 
145cm3 between 24-72 hours after onset (specified in the pooled analysis of DESTINY, 
DECIMAL and HAMLET [Table 8-1]) (142). CT descriptions of midline shift or mass effect 
were also used to identify mMCAO. We identified historical comparators from VISTA who 
were aged between 18 and 60 years. We included eligible patients who were treated in 
the active arms of trials within VISTA, as we postulated that the effect of mMCAO would 
overwhelm any effect of an active drug treatment on outcome; in any case, many trials 
had a neutral result. Variables of interest included age, sex, baseline NIHSS score, 
lesion volume, LOC 1A score at baseline, medical history, modified Rankin score (mRS), 
Barthel Index (BI) and mortality at final assessment.  
8.2.2 Study Objectives and Outcome Measures 
Our primary objective was to examine whether decompressive surgery for mMCAO 
resulted in a beneficial disability profile when compared with natural history data from 
VISTA. We defined good outcome according to previously stated cut-points specified in 
the DESTINY trial, i.e. the attainment of a modified Rankin Scale (mRS) score of 0-3. 
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Unfavourable outcome was defined as a mRS score of 4-6. Our secondary outcome 
measures were a) survival  and b) the proportion of patients achieving a Barthel Index 
(BI) of >25 (versus 0-25) at final follow up. 
8.2.3 Follow Up Period 
Due to sparse 6 month outcome data within VISTA, we undertook a comparison between 
6 month outcomes in the DESTINY surgical patients, and 90 day outcomes in the VISTA 
historical comparators. We reasoned that though mortality usually increases slightly 
between 3 and 6 months rendering our analysis of survival conservative for the 
investigational treatment, functional outcome at the level of mRS 3 versus 4 is 
relatively stable beyond 3 months.   
8.2.4 Statistical Analysis 
We intended to compare the functional outcomes of patients enrolled in the DESTINY 
trial with an independent comparator group from VISTA according to the same 
statistical methods employed in DESTINY. Our primary efficacy analysis used a chi-
square test (χ2) test to examine whether there was a difference between the mRS at the 
last follow up assessment in the DESTINY and VISTA comparator groups. We performed 
an additional analysis using logistic regression to account for the influence of stroke 
severity in the comparator group. Due to the small sample size in the DESTINY surgical 
group, we were unable to adjust analyses for additional variables such as age, without 
confounding outcome. This method allowed a direct comparison between the DESTINY 
trial and the historical comparators, whilst still providing an indication of the influence 
of initial stroke severity on outcome in the historical comparators.  
We also used a χ2 test and logistic regression to examine the effects of hemicraniectomy 
on BI scores, (adjusting for baseline NIHSS scores in the logistic regression). Survival at 6 
months was described using Kaplan-Meier survival curves and formally assessed using 
Cox Proportional Hazards modelling (CPHM), adjusting for baseline NIHSS. Missing 90-day 
functional outcome data in VISTA comparators were handled by imputing the worst 
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possible outcome if death was known to have occurred within the 90 day follow up 
period. Complete 6 month survival data were available for all comparator group 
patients. All statistical analyses were performed using the SAS 9.1 statistical package.  
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DESTINY Trial Eligibility criteria Pooled Analysis Eligibility Criteria 
Inclusion criteria Inclusion criteria 
Age 18–60 years Age 18–60 years 
Clinical signs of infarction of the MCA 
territory with an NIHSS score ≥18 for lesions 
of the non-dominant hemisphere and ≥20 for 
lesions of the dominant hemisphere 
Clinical deficits suggestive of infarction in the 
territory of the MCA with a score on the 
National Institutes of Health stroke scale 
(NIHSS) >15 
Decrease in the level of consciousness to a 
score of ≥1 on item 1a of the NIHSS 
Decrease in the level of consciousness to a 
score of 1 or greater on item 1a of the NIHSS 
Computed tomography– documented 
unilateral MCA infarction, including at least 
2/3 of the territory and including at least part 
of the basal ganglia, with or without additional 
ipsilateral infarction of the anterior or 
posterior cerebral artery 
Signs on CT of an infarct of at least 50% of 
the MCA territory, with or without additional 
infarction in the territory of the anterior or 
posterior cerebral artery on the same side, or 
infarct volume >145 cm3 as shown on 
diffusion-weighted MRI 
Onset of symptoms ≥12 and ≤36 hours 
before a possible surgical intervention 
Inclusion within 45 h after onset of symptoms 
Possibility to start treatment/surgery within 6 
hours after randomization 
Written informed consent by the patient or a 
legal representative 
Written, informed consent by the patient or 
legal representative 
Exclusion criteria 
Exclusion criteria Pre-stroke score on the mRS ≥2 
Pre-stroke mRS score ≥2 
 
Two fixed dilated pupils 
Pre-stroke score on the Barthel Index <95 
 
Contralateral ischaemia or other brain lesion 
that could affect outcome 
Score on the Glasgow Coma Scale <6 Space-occupying haemorrhagic 
transformation of the infarct (≥parenchymal 
haemorrhage grade 2) 
Both pupils fixed and dilated Life expectancy <3 years 
Any other coincidental brain lesion that might 
affect outcome 
Other serious illness that could affect 
outcome 
Space-occupying hemorrhagic transformation 
of the infarct 
Known coagulopathy or systemic bleeding 
disorder 
Life expectancy <3 years Contraindication for anaesthesia 
Other serious illness that might affect 
outcome 
Pregnancy 
Known coagulopathy or systemic bleeding 
disorder 
 
Contraindication for anaesthesia  
Pregnancy  
  
Table 8-1 Eligibility criteria for the DESTINY trial and the pooled analysis of DESTINY, 
DECIMAL and HAMLET. 
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8.3 Results 
We identified only 32 patients within VISTA who met all of the stated eligibility criteria 
for mMCAO. Table 8-2 describes the baseline characteristics and outcomes of patients in 
the surgical and comparator groups. Despite implementation of the strict eligibility 
criteria, patients in the comparator group were older than those in the surgical group 
(surgical group median age: 43 IQR [34, 49], comparator group median age: 51 IQR [47, 
56]), and baseline stroke severity was also slightly worse (surgical group median 
baseline NIHSS: 21 IQR [20, 23], comparator group median baseline NIHSS: 23.5 IQR [21, 
26]).  
Exploratory analyses revealed no difference in outcome or survival at 30 days between 
the DESTINY surgical group and similarly selected historical comparators from VISTA. 
However, the χ2 test examining mRS at the last follow up assessment revealed that more 
patients in the DESTINY surgical group achieved a good functional outcome (47.1%), 
compared with patients in the VISTA comparator group, (18.8%, Chi-Square test p=0.04). 
This difference was also evident after adjusting for baseline stroke severity using 
logistic regression (p=0.04, odds ratio for good functional outcome in the comparator 
group=0.26, 95% confidence interval [0.07, 0.95]) (Table 8-3). 
A comparison of Barthel Index scores at the last follow up assessment in the two groups 
revealed no significant difference in outcomes (Chi-Square Test p=0.07). There was also 
no significant difference in Barthel Index scores after adjustment for baseline NIHSS 
scores (logistic regression p=0.08). Lastly, we examined survival between the two 
groups using a Kaplan-Meier analysis and a Cox Proportional Hazards Model (CPHM). We 
found no difference in 6 month survival between the surgical and comparator groups 
(p=0.42) (Figure 8-2). 
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 Surgical Group  Control Group  
 Median [IQR] Frequency (%) Median [IQR] Frequency (%) 
Age  43 [34, 49] - 51 [47, 56]  
Gender  - Male=47.1  Male=71.88 
BNIH 21 [20, 23] - 23.5 [21, 26]  
BI at final follow up 50 [20, 75] - 50 [0, 75]  
mRS final follow up 4 [3, 4] - 5 [4, 6]  
Mortality at final 
follow up 
- Alive=88.2  Alive=71.88 
Smoker  - Current=41.2  Current=42.9 
Hypertension  - Yes=52.9  Yes=59.26 
Diabetes  - Yes=11.8  Yes=15.63 
     
Table 8-2 Baseline characteristics and outcomes for patients in the DESTINY surgical and 
VISTA comparator groups 
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Group Parameter Frequency (%) of good 
outcome 
P value (Chi-Square test) P -value Logistic regression 
(accounting for Baseline NIHSS) 
Surgical vs Comparator Group mRS at last follow up DESTINY- 47.1 
VISTA- 18.75 
0.04 0.04 
Surgical vs Comparator Group BI at last follow up DESTINY- 70.59 
VISTA- 43.75 
0.07 0.08 
     
 
Table 8-3 Chi square test and logistic regression analyses comparing outcomes in the DESTINY surgical group and the VISTA comparator group
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Figure 8-2 Kaplan –Meier curve for survival between DESTINY surgical and VISTA 
comparator group 
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8.4 Discussion 
We conducted our investigation with the aim of reproducing the results of a RCT using a 
database comparator group. We hypothesised that positive results would provide 
support for the use of historical comparators as a preliminary assessment of new 
treatments in instances where a RCT is considered impractical.    
We found a significant difference in attainment of good functional outcome by mRS at 
final follow up, favouring the DESTINY surgical patients. These findings were not 
reproduced in our assessment of Barthel Index in the same patients, though the trend 
favoured surgical treatment. There was no significant difference in survival at 6 months 
between the surgical and VISTA comparator groups, contrary to our hypothesis, though 
early censoring was greater in the comparator group. 
Our mRS findings are consistent with the previous pooled hemicraniectomy analyses by 
Vahedi et al. (2007) (142). The trialists reported a significant difference in mRS 
between the surgical and conservative treatment groups at 6 months (p<0.001). 
Discrepancies between the original DESTINY findings (96) and our survival and Barthel 
Index findings could have occurred as a consequence of the difference in duration of 
follow up. Both the original DESTINY trial and the pooled hemicraniectomy analysis 
examined functional outcome after hemicraniectomy at 6 and 12 months respectively 
whereas most of our VISTA outcome data were restricted to three months. However, 
the significantly worse functional outcomes seen in patients in the historical comparator 
group are congruent with the unfavourable outcomes seen in the DESTINY control group. 
Skoglund et al. (2007) reported that use of the Barthel Index as an outcome measure led 
to underestimation of disease burden in patients with mMCAO, which may have 
contributed to our results (341). The patients in our comparator group were older and 
had worse index strokes, which may have affected the BI scores; however emphasis 
should not be given to this observation as the BI is now recognised as a less sensitive 
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measure of stroke outcome than mRS (350) and will be especially poor when a score of 
25 is used to discriminate favourable from unfavourable outcome, due to the U-shaped 
frequency distribution of Barthel Index scores usually observed after stroke. 
Previous investigations have reported a beneficial survival rate in surgically treated 
patients with mMCAO despite unfavourable outcomes (94;351-353). The early censoring 
of survivors in the comparator group limited the time for further mortality in poorly 
recovering patients. Absolute mortality would likely be at least 3% over the period from 
three to six months (81;354). However a shorter follow-up period also limited time for 
rehabilitation and recovery of function in survivors. Our comparison of survival rates 
may be conservative but the comparison of functional outcomes could favour surgical 
treatment over control. In the placebo group from the NINDS thrombolysis trial, the 
proportion with good outcome by mRS (0-1) changed from 26% at 3 months to 29% at 6 
and 28% at 12 months but the proportion with good and moderate recovery as defined 
by mRS 0-3 was 51% at 3 months and 52% at 12 months; absolute mortality increased by 
3% between 3 and 6 months in the NINDS placebo cohort (81;354). 
Patients with mMCAO are not routinely sought for clinical trials of drug efficacy due to 
the extremely poor prognosis. Indeed, they are preferentially excluded. The patients 
included in our analysis were determined to have developed mMCAO during the course 
of the qualifying VISTA trial. Our retrospective identification of these patients was 
confounded by absence of any single factor with sufficient prognostic value to 
determine mMCAO (142). We utilized clinical data such as hypodensity in the MCA 
territory (355) and NIHSS scores greater than 20 (356) to inform our selection criteria. 
We attempted to use the same eligibility criteria from the DESTINY trial (Table 8-1), 
however application of all of those criteria resulted in insufficient patients being 
identified. We compromised by choosing the presence of a lesion volume ≥ 145cm3, 
baseline NIHSS score of ≥20, LOC 1A score ≥1 on the NIHSS and age between 18 and 60 
years in combination, as our main entry criteria. We assumed that the main prognostic 
factor to identify mMCAO in VISTA was the presence of a lesion volume ≥ 145cm3, an 
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assumption which was validated by Hofmeijer et al. (2008). Their systematic review 
identified infarct size as the major determinant for the development of life-threatening 
cerebral oedema (357). Previous investigations (358-360) reported that patients aged 
over 60 years may not benefit from decompressive surgery, therefore DESTINY enrolled 
patients aged between 18-60 years. DESTINY’s narrow age criteria served to limit the 
number of patients eligible from VISTA: the median age of patients from VISTA is 71 IQR 
[61, 78]. We also included patients who received an active treatment. We hypothesized 
that the effect of mMCAO on functional outcome would overwhelm any effect of an 
active drug treatment on outcome after this type of stroke; in any case the majority of 
VISTA data are from neutral trials of putative neuroprotectants.  
Our main limitations were twofold: the sample size in the treatment group, and the 
absence of a uniform follow up period between DESTINY and VISTA. The original 
DESTINY trial was terminated as soon as a significant difference in survival was 
achieved. This restricted the number of patients who underwent hemicraniectomy. 
Subsequent investigations using data from these patients will always be limited by the 
small sample size and will lack power. Statistical comparisons that adjust for baseline 
factors cannot be applied.  
Despite our limited success in replicating the DESTINY trial results using a historical 
database, the use of such a resource for other RCT’s should not be completely 
abandoned. We postulate that the nature of the DESTINY trial precluded effective 
replication of results because patients with mMCAO were not routinely sought for 
clinical trials within VISTA. DESTINY recruited patients at one extreme of severity. A 
condition for use of historical controls should perhaps be that the trial dataset from 
which they are drawn covers a similar or broader spectrum of important prognostic 
factors such as severity and age. 
The management of patients with mMCAO remains a challenge (358) in the absence of a 
definitive RCT to optimise treatment. Expanding resources such as VISTA to include 
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more patients with mMCAO, and utilising these patients in a pooled analysis such as that 
performed by Vahedi et al. (2007) (142) may allow for design aspects such as matching 
patients based on prognostic factors, or using covariate adjusted analyses. This would 
allow broader investigation into the attainment of good functional outcome for 
different age groups, optimum time from onset to treatment and effects of surgery on 
health related quality of life measures.      
8.4.1 Conclusion 
We were unable to replicate the promising survival results from the original DESTINY 
trial with our historical comparator dataset but beneficial effects on functional outcome 
were confirmed. The difference in duration of follow-up between our groups may lead 
to underestimation of a treatment effect on survival. The use of historical comparators 
for stroke trials may be considered in selected circumstances but caution is required. 
The key advantages of using historical comparators centre on their potential to deliver 
greater statistical power with reduced cost and duration of trials. The main concerns 
relate to the potential for bias in outcome assessment. These biases can be minimised 
by use of comparators derived from similar trial populations, for example 
implementation of the same eligibility criteria, restriction to data generated using 
validated stroke scales and after similar duration of follow-up. Prospective matching of 
comparators to treated patients, independent analysis, and adjustment of the final 
analysis for prognostic covariates would also address bias, and optimise the use of a 
historical resource. Ultimately, only a randomised trial offers a reliable measure of 
treatment safety and efficacy. However historical comparators may have some utility 
for proof of concept or initial futility studies, or in circumstances where ethical and 
financial constraints preclude assessment with a randomised controlled trial.  
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9 Conclusion   
Stroke is a debilitating condition with a global impact. Therapeutic interventions remain 
limited. By broadening knowledge of clinical trial design, the natural history of patient 
progression, investigating futility of novel interventions before formal testing in costly 
phase III trials and investigating associations between patient baseline characteristics 
and outcome, the conduct of clinical trials can be optimised to increase the chances of 
eliciting a positive result.  
The STAIR group has identified the use of electronic databases as a promising tool for 
the design, implementation and performance of acute stroke therapy clinical trials 
(130). Recommendations from the Stroke Programme Review Group (131) detailed the 
need for increased collaboration and improved access to clinical resources and shared 
databases. Wide-scale sharing of meticulously controlled data is still largely a work in 
progress for many areas of research (361). Within the stroke research community the 
sharing of data has largely been addressed by the availability of the NINDS rt-PA dataset 
(81), registry data from the German Stroke Databank and the Cochrane Database, and 
now, the accessibility of clinical trial data from VISTA. A key benefit of the latter 
project is its ability to maximise health gain whilst maintaining patient confidentiality.  
Established stroke registries collate patient data using a model wherein all patients who 
presented with a stroke in participating centres are entered into a database. These 
include but are not restricted to trial –eligible patients. We sought to capitalise on the 
volume of patient data available from clinical trials to develop a comprehensive 
resource of acute stroke data on patients who are eligible for clinical trial participation. 
We provided a means of accessing these data for use in novel analyses to examine 
various aspects of clinical trial design that would aid the planning of future trials.  
We successfully collated data from 28 clinical trials and one stroke registry in VISTA. We 
initiated and implemented a method for external examiners to access data, provided 
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safeguards for data dissemination through the establishment of the VISTA Steering 
Committee and developed publication guidelines for prospective investigators (Chapter 
2). The establishment and implementation of these measures within VISTA has allowed 
the investigation of up to 30 different areas of acute stroke by both national and 
international researchers, (Appendix Chapter 10.3).   
As mentioned in chapter 3 investigation of stroke epidemiology forms the basis for 
future research (199), aiding the targeting of health interventions where they are 
needed the most. The multinational nature of clinical trial data within VISTA provided 
us with an opportunity to investigate stroke outcomes across various countries. Our 
findings indicated that there was a difference in initial stroke severity and outcomes 
amongst patients who were enrolled into clinical trials deriving from different 
countries. These differences were not fully explained by case mix. Trial patients who 
were recruited before 1998 had milder index strokes compared with those enrolled 
after 1998, and patients in this latter group did not have a significantly better 
functional outcome when compared with earlier recruitment, indicating a degree of 
stability in clinical trial outcomes over the past 14 years, after accounting for 
confounding influences.  
Our findings were supported by previous investigations into regional variation in stroke 
outcomes (198). Brainin et al. (2007) reported that stroke types and aetiology varied 
between developing and developed countries (362). Stroke mortality rates were 
investigated over the course of 10 years in China and Europe in the WHO MONICA 
project (363;364). Those investigations found that the variation in mortality observed in 
9 countries was due to changes in case fatality rather than changes in stroke incidence, 
suggesting that the standard of stroke care available in the countries examined 
impacted the stroke mortality rate. Stroke care varies within developing countries with 
some areas of excellence interspersed within areas of severe need (362). Our findings 
accounted for this confounding influence; patients enrolled in VISTA clinical trials 
received the highest standard of care in their region of enrolment. However not all 
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confounding variables could be accounted for in our analyses. Issues such as 
socioeconomic status, education and cultural belief can impact recovery after stroke, 
and absence of these confounding factors within VISTA meant that their influence could 
not be quantified. The influence of these factors on patient outcome can be resolved by 
continued recruitment of clinical trials into VISTA and standardisation of case report 
forms for data collection. The latter would also aid data comparability and aggregation.  
Mackenbach et al. (2008) remarked that the international comparability of data was 
likely to diminish with increasing geographical coverage (365). This is normally the case 
when comparing health data in the general population. However within VISTA, the 
collation of clinical trials that implement similar protocols for data collection and 
patient selection across different regions has increased rather than decreased data 
comparability. This confers a benefit for future analyses that utilise these data. 
Trialists have contributed numerous datasets to VISTA detailing many parameters 
recorded during the course of a clinical trial. We demonstrated the depth of these data 
for patients with ischaemic stroke in an investigation of the effects of shortening the 
follow up period after acute stroke intervention (chapter 4). Preventable medical 
complications that occur as a consequence of pre-existing conditions may confound 
outcome after stroke by delaying or preventing aggressive rehabilitation, worsening 
post- stroke disability and increasing mortality. Concomitant medications may aggravate 
the existing neurological impairments, or may increase the likelihood of recurrent 
stroke and subsequent deterioration (366). Previous investigators have made 
distinctions between medical and neurological complications (230). Others have 
examined the effect of medical complications on survival (366). We expanded these 
categorisations to subdivide medical and neurological complications into those that 
occurred either as a direct result of index stroke (‘stroke-related’) or as a tertiary 
factor (‘stroke- unrelated’). In our analysis ‘stroke –unrelated’ events did not appear to 
occur more frequently than ‘stroke-related’ complications at later time points.  
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Other investigators have illustrated the relationship between post-stroke complications 
and poor outcome (366), with particular emphasis on a poorer survival rate as time 
progresses. Bae et al. (2005) reported a 30- day mortality rate of 16.3%, contrasting 
with 29.4% at 90 days and 46.9% at one year in patients who had experienced at least 
one post-stroke medical complication (366). Their findings indicated a scope for 
shortening follow up periods to minimise mortality. This finding was not replicated in 
our investigation. However, further research is required. Prophylaxis for the post stroke 
complications identified in chapter 4 could attenuate both short and long term 
mortality rates.          
Documentation of post-stroke complications informs safety in future trials by providing 
an indication of the natural history of disease progression. Use of VISTA for this purpose 
was illustrated in chapter 5 in an investigation of complications after intracerebral 
haemorrhage (ICH). Extension of the haemorrhage was the most common post -ICH 
complication and significantly influenced the attainment of good functional outcome at 
90 days. We found that in placebo treated patients, the risk of thromboembolic 
complications (a common concern for trialists investigating haemostatic therapies for 
patients with ICH), were infrequent and did not significantly influence attainment of 
good functional outcome. The low risk of thromboembolic complications observed in our 
sample serves as a good standard to which occurrence in future clinical trials of 
haemostatic agents can be compared.  
Our results in chapter 5 are particularly informative for trialists as the patient 
population under examination was eligible for entry into a clinical trial. 
Characterisation of patient complications and indications of the types of events 
common for patients with differing stroke severities provides valuable information for 
prophylaxis. The sizable benefit from management of these complications should not be 
underestimated: Bae et al. (2005) identified a 48.3% difference in risk of mortality at 4 
years in patients with ischaemic stroke who had experienced a post-stroke complication 
compared with those who had not experienced a complication (366). Intraventricular 
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haemorrhage (IVH), a known predictor of functional outcome was not available for the 
purposes of our analyses for all patients with ICH within VISTA, however we are making 
efforts to include these data by acquiring CT and MRI scans from the clinical trials in 
question.  
Aside from the use of VISTA data to examine outcomes and natural history in a trial 
population, VISTA data could be used to inform the selection of interventions that are 
to make the leap from laboratory to clinical practice. Numerous clinical trials of stroke 
interventions have generated negative or neutral results and have consumed vast 
resources. We sought to pilot a use for VISTA as a resource for historical comparators in 
early phase trials. Due to the nature and depth of variables available within VISTA many 
parameters could be included in analyses. We developed recommendations to minimise 
bias and increase validity of historical comparators from VISTA. These included selecting 
comparator patients using the same eligibility criteria as the active group, using 
validated stroke scales to measure index stroke severity and outcome, prospectively 
matching actively treated patients with historical comparators based on demographic 
variables at admission, utilising similar follow up periods for evaluation and employing 
independent groups to match patients and /or carry out analyses.  
We exemplified use of VISTA historical comparators in chapter 7 by priming the 
database for use in a pilot device trial. In practice, the lack of uniform data collection 
within VISTA hindered data compilation. We addressed this issue by successfully 
developing an algorithm to increase patient eligibility for this investigation. We piloted 
a matching simulation to provide valid historical comparators for evaluation with 
patients who were implanted with the NeuroPath™ Device.     
We successfully implemented recommendations outlined by Bennett et al. (2003) such 
as the need for clear and detailed eligibility criteria, well defined variables and analysis 
of outcomes using both a cohort design and a matched case-control design (324). These 
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were facilitated by the presence of documentation that accompanied trial contribution 
to VISTA.  
We also utilised VISTA historical comparators to investigate stroke outcomes in 
situations where randomisation to a placebo group is unethical or infeasible. We 
compared functional outcome and survival in surgically treated patients with malignant 
middle cerebral artery occlusion from the DESTINY trial with historical comparators 
from VISTA in chapter 8. Although we managed to show that more patients in the 
DESTINY group attained a good functional outcome by mRS at 90 days, we were unable 
to replicate the beneficial survival seen in the original DESTINY trial. Our results could 
be interpreted in the light of the differing follow up periods employed in the two 
groups. We were unable to adhere to previous recommendations for uniform follow up 
periods in this investigation (302), as there were insufficient follow up data at 6 months 
within VISTA. However our functional outcome results were congruent with the previous 
findings of a beneficial survival rate in the decompressive surgery group. 
Re-analysis of patient data using surgically treated patients from the pooled analysis of 
the DESTINY, HAMLET and DECIMAL trials (142) would increase the sample size of 
patients in the treatment group and could allow patients to be prospectively matched 
with VISTA historical comparators. However in order to do this, VISTA would have to 
recruit more clinical trials that use a later follow up period to increase availability in 
the comparator group pool. Perhaps a condition for the use of historical comparators 
should be that the resource from which data are to be derived should be similar in 
baseline demographic variables to those in the treated group: this was not the case in 
the VISTA /DESTINY collaboration.        
The analyses in this thesis demonstrate the depth of data available from clinical trials 
and illustrate how these data can be put to greater use as opposed to remaining 
dormant in industry and academic archives. The establishment of VISTA has the 
potential to answer many questions about clinical trial design. VISTA has the benefit of 
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collating data on only trial -eligible patients, thereby providing trialists with the ideal 
patient database in which to query parameters.  
Analyses of data using this resource have some limitations. Lack of standardised case 
report forms (CRF) for data collection in clinical trials mean that trials invariably collect 
different secondary or tertiary data. This creates problems when attempting to 
aggregate data, and requires manipulation of variables to derive common measures 
amongst trials. However aggregation is aided by the presence of trial data dictionaries, 
protocols and annotated CRFs and these ensure the validity of derived fields.    
Additionally, trials contained within VISTA may focus on one particular area of stroke, 
for example, the acute stroke phase. However, VISTA is a continually evolving stroke 
resource. Initial trial recruitment focussed on acute stroke intervention trials, and was 
confined to participating trial centres typically in the UK, USA, Canada, Australia and 
Western European countries. Data were lacking from patients who were enrolled in 
clinical trials in many parts of Asia and South America. We sought to rectify this by 
continued recruitment of trials from different regions. This was exemplified by the 
contribution of the SAINT I and SAINT II trials which included patients who were enrolled 
in Brazil, Argentina, Chile, China and Singapore. We expect that continued contribution 
of trials will create a more representative sample of patients from these regions within 
VISTA.   
Data within VISTA were collected for the purposes of a clinical trial, and were therefore 
not tailored for an epidemiological investigation. Some principal investigators or data 
managers permitted the transfer of only demographic and outcome data to VISTA. 
Therefore, some trials within the resource, for example the NINDS trial do not contain 
adverse event data, or have insufficient documentation for tertiary outcome variables 
such as discharge setting. Additionally the limited transfer of data in some cases has led 
to the omission of variables such as socioeconomic status and rehabilitation resources. 
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These deficiencies are being addressed by continued documentation and elucidation of 
variable codes through communication with data managers and principal investigators.  
Adverse event data were recorded for most trials. However many observations are 
derived from physicians’ case notes, thereby increasing the possibility of bias or 
inaccuracies when recording these events. This bias is minimised through the use of the 
Medical Dictionary for Regulatory Activities (MedDRA) or World Health Organisation 
(WHO) classification schemes within many of the trials, allowing integration of these 
datasets from multiple trials.  
VISTA was developed primarily to inform clinical trial design and as such, data were 
principally collated on patients who are eligible for entry into clinical trials. This 
therefore limits the implications of novel research using VISTA to those patients who are 
trial –eligible. For a greater understanding of the natural history of stroke progression in 
all patient subgroups, analysis of data from stroke registries may be apt. We aim to 
continue recruitment of new trials and registries into VISTA to create a broader appeal 
for use of the resource in novel investigations.  
Having initiated development of VISTA and demonstrated its utility for novel analyses, 
we aim to build on our experiences by expanding the resource for future use. Over the 
past 3 years it has become increasingly apparent that CT or MRI data are necessary for 
many investigations. A high standard of imaging data is available only for a small subset 
of stroke patients within VISTA and this may be a reflection of the time consuming 
nature of conversion and anonymisation of CT/ MRI scans into a compatible format for 
use in adjunct with a database. Many trial sponsors retain these images after conclusion 
of the trial, and only certain variables that pertain to the original trial’s analysis plan 
are included within the trial dataset that is transferred to VISTA. There is a vast 
quantity of additional information contained within the brain scans that can be used by 
external investigators for novel analyses. We aim to collate CT and MRI scans from the 
GAIN International, GAIN Americas, CHANT and IMAGES trials for use in adjunct with the 
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existing datasets from each of these trials. This will broaden the resource further and 
allow us to meet the needs of many more investigators.  
Comparisons of disease burden amongst countries encourage investigators to examine 
both common and unique features amongst regions to elucidate the possible reasons for 
variation (367). It seems logical that we expand our investigation of regional differences 
in stroke outcomes to examine the rehabilitation resources available within different 
regions. This would be facilitated through expansion of the VISTA resource by recruiting 
more trials that deal with wider aspects of stroke care such as rehabilitation.    
Previous investigators have described the institutional control over patient data 
exhibited by academic medical centres, health management organisations and health 
networks as parochial, and have stated that these controls have created inefficiencies 
in fostering scientific discovery (368). The development of VISTA has facilitated 
collaboration whilst retaining the element of informed consent through the need for IRB 
approval before trial contribution to VISTA, and control of data dissemination through 
the establishment of the VISTA Steering Committee. This resource has the potential to 
maximise health gain for many patients, whilst providing a valuable and economic 
research platform for investigators.    
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10 Appendices 
10.1 Appendix 1: VISTA Constitution 
10.1.1 VISTA Steering Committee:   
Lees KR (chair), Bath PMW, Bluhmki E, Claesson L, Curram J, Davis SM, Diener HC, 
Donnan GA, Fisher M, Gregson BA, Grotta J, Hacke W, Hennerici MG, Hommel M, Kaste 
M, Lyden P, Marler J, Muir K, Sacco RL, Shuaib A, Teal P, Wahlgren NG, Warach S and 
Weimar C.   
10.1.2 Aims 
VISTA has been established to promote excellence in stroke care and stroke trial design. 
It will do so without favour to individual groups or sponsors. As such, membership is 
open to all groups who fulfil published criteria and the results of VISTA analyses should 
be used for the benefit of the wider clinical and academic community. Thus, whilst 
individual groups may propose and even sponsor certain analyses, the results of these 
analyses should normally be submitted for publication or at least recorded in the public 
domain. 
10.1.3 Membership Rules 
VISTA membership will be granted to trials or organisations rather than to individuals, 
but each organisation will be represented by a named individual who may nominate an 
alternate representative. VISTA is open to any stroke trial or register fulfilling criteria 
listed below.  These criteria may be modified from time to time by majority vote of the 
VISTA steering committee.
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10.1.4 Administrative Structure 
Steering committee 
 Executive committee 
 Publication committees 
Academic committee 
Sponsor Committee 
Data management committee 
 
The VISTA group will be run by a Steering Committee on which every contributing trial 
or organisation may be represented. The Steering Committee will have ultimate 
responsibility for all decisions regarding strategy, financial matters, confidentiality, 
scientific matters and for determining publication policy. For day to day running of 
VISTA, the Steering Committee may delegate authority to an executive committee 
elected from its members. Where matters of a potentially sensitive commercial nature 
are involved, the Steering Committee will delegate scientific decisions to an academic 
committee. Only independent academic individuals, excluding employees of 
pharmaceutical industry, may attend as academic committee members or have access 
to detailed minutes of such meetings; however, a summary of decisions will be 
distributed to the Steering Committee after exclusion of any commercially confidential 
information and approval of the relevant industrial contact. A sponsor committee will 
provide liaison between the steering committee and commercial interests.  
10.1.5 Representatives 
10.1.5.1 Academic committee 
The primary representative of an organisation should be the principal clinical 
investigator or steering committee chairman, rather than a representative of the 
sponsor. Where a trial was conducted by a sponsor without an external principal 
investigator, the VISTA executive may consider a nomination by the sponsor of any 
external expert to represent the interest of the sponsor. 
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10.1.5.2 Sponsor Committee 
Any commercial organisation or other sponsoring group (such as NIH, MRC, etc) that has 
contributed trial data, or has funded a VISTA analysis and formally committed to 
contribute future trial data, may send a representative to the sponsor committee. Only 
one representative of each sponsor may attend each meeting, but the sponsor may 
choose to vary its representative (eg. clinical scientist, statistician, data manager).  
One of the reasons for representation is to maximise use of the data in line with the 
ethical and clinical principles involved at the outset of the project, and to permit 
continuity over a number of years. There may also be requirements to consider 
confidential data in relation to commercial interests in order to adjudicate on analysis 
proposals from external companies or bodies. Staffing and responsibility changes within 
pharmaceutical companies conflict with these requirements of continuity and conflicts 
of interest could too easily arise. Conversely, pharmaceutical industry employees may 
have considerable expertise in issues such as data management & protection, regulatory 
affairs, financial and logistical planning etc, and as a group have generated much of the 
data that will be held by VISTA. Industry representatives must be able to contribute 
actively to the success of VISTA and to protect the interests of their constituency. 
10.1.5.3 Data Management Committee (DMC) 
A data management committee will be appointed by the executive committee to 
supervise the practical aspects of VISTA data management, confidentiality issues etc. As 
a minimum, this will include a statistician, programmer, data manager, academic and 
sponsor members. All DMC members will have equal voting rights on this committee. 
Members of the data management committee may attend Steering Committee meetings 
and, by invitation, executive committee meetings but will not have an independent 
vote on either committee. 
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All committee members and representatives will be covered by confidentiality 
agreements concerning both the data content and the background to any analysis 
proposals. This will be a condition of involvement. Where necessary, an employing 
organisation may sign the confidentiality undertaking on behalf of its employees; 
however, individual members must countersign such an agreement to limit transmission 
of confidential information within their organisation. 
10.1.6 Sponsors 
 
Direct employees of industrial sponsor organisations may not hold office as voting 
members on the VISTA steering committee or have direct access to data, but may 
normally attend meetings and may participate in discussions and offer proposals for 
analyses. In certain situations, where a proposed analysis from an external group can 
only be justified by submission of confidential and commercially sensitive information, 
VISTA committees may consider such material ‘in camera.’ 
10.1.7 Analyses 
Analyses may not be undertaken and published or reported to an outside group without 
the knowledge and approval of the VISTA executive, who will decide whether the 
analysis is academic or commercial in nature. 
10.1.8 Funding 
Analyses may be carried out on either an academic or commercial basis. Academic 
analyses may be proposed by any member of the VISTA group (who may also ‘sponsor’ 
an externally requested analysis). Provided that funding can be identified to cover the 
costs of the analysis, this may be approved by the executive. A fixed fee of £2000 or 
4000 USD will be charged for all academic analyses, with an additional cost of £150 per 
day or part of a day spent on data extraction. Funding will go towards VISTA costs, data 
extraction and day –to –day maintenance of the archive. All academic analyses should 
be considered for submission for publication. Commercial analyses may be proposed 
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that have limited academic interest, but which may facilitate a drug development 
programme. Such analyses must be supported by the full marginal cost plus a 
contribution to the generation and maintenance of VISTA (fixed cost contribution). A list 
of commercial analyses will be circulated to all VISTA members at least annually, and 
may be made available to other groups that have contributed to the fixed costs of VISTA 
within the preceding 2 years. 
It is understood that trial representatives or their institutions may hold consultancy 
contracts or similar arrangements with trial sponsors whom they represent, but these 
should be declared and must not specify exclusive arrangements or be incompatible 
with the aims of VISTA. 
10.1.9 Annual Reports 
The VISTA executive will issue a report annually to VISTA members. This will list the 
identity of the datasets, the number of patients on whom data are held within each 
major category, the committee membership, the analyses that have been commenced 
or completed, the names of organisations that have contributed to fixed costs, and a 
publication list. 
10.1.10 Confidentiality 
VISTA participants will hold as confidential any group data provided to the VISTA group, 
except as authorised for publication or reporting by the relevant VISTA committee(s). 
Personally identifiable information will not normally be held by VISTA, but where this is 
necessary or desirable, no such information will be transmitted or released to any 
external organisation except in accordance with data protection laws of the country and 
institution in which data are held and with any stipulations of the relevant ethics review 
committee and/or original consent of the patient. 
VISTA participants will hold as confidential any background material provided as 
justification for proposed analyses that is provided by commercial or academic groups, 
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except as required to facilitate such analyses (eg submission to ethics review 
committees, etc) and as agreed by the provider.  
10.1.11 Indemnity 
Academic representatives and VISTA data management teams will be covered with 
regard to approved VISTA activity by limited public liability and professional indemnity 
insurance held by the University of Glasgow; industry representatives will not be 
covered (but are expected to be covered by their employer).  
10.1.12 Publication Policy 
Publications arising from VISTA will acknowledge the trial groups that have contributed 
data to VISTA and will include the by-line ‘on behalf of the VISTA Investigators.’ The 
influence of individual trials or datasets on the overall result will not be revealed 
except by prior approval of all contributing organisations, and in such an event, 
authorship should be granted to the principal investigator of the named trials in any 
subsequent manuscript. VISTA analyses should not identify individual studies unless the 
study groups themselves have specifically agreed that this is both necessary and 
acceptable.  
VISTA publications will be prepared and submitted for publication by a writing 
committee that will normally include at least 3 members of the VISTA steering 
committee (2 clinical, one statistician) plus other relevant authors. Near final draft 
manuscripts will be circulated to all members of the VISTA executive for comment at 
least 3 weeks before submission and will be circulated to all VISTA representatives upon 
acceptance by a journal. This policy covers all articles, abstracts and presentations 
prepared based on VISTA data.  
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10.1.13 VISTA Eligibility 
10.1.13.1 Acute Stroke Trials or Registers 
• Minimum dataset of 100 patients 
• Documented entry criteria 
• Documented consent or waiver of consent following local IRB-approved procedure 
• Baseline assessment within 24 hours of stroke onset 
• Baseline assessment includes recording of neurological deficit by Oxford, NIHSS, SSS or 
similar 
• Confirmation of stroke diagnosis by cerebral imaging within 7 days 
• Outcome assessed between 1 and 6 months after stroke onset 
• Outcome assessment includes recording of at least one of NIHSS, SSS, Rankin, Barthel or GOS 
• Monitoring procedures existed to validate data 
 
10.1.13.2 Secondary Prevention Trials or Registers  
• Minimum dataset of 100 patients 
• Documented entry criteria 
• Documented consent following local IRB-approved procedure 
• Baseline assessment includes recording of persisting disability by at least one of NIHSS, SSS, 
Rankin, Barthel or GOS and of basic risk factors including diabetes, atrial fibrillation 
• Confirmation of stroke diagnosis by cerebral imaging within 7 days 
• Outcome assessment includes non-fatal stroke, non-fatal MI and mortality 
• Monitoring procedures existed to validate data 
 
10.1.14 Data 
Data will be converted to a common format. Only anonymised data will be stored. Most 
informed consent and IRB approvals have permitted storage and transmission of 
anonymised data. Within analyses, data will also be anonymised for trial source. A 
separate file may be kept that permits identification of trials and a description of entry 
criteria etc, in case analyses require selected datasets. Placebo data will be accepted 
on their own for VISTA, but in cases where active treatment data are also provided (for 
example, if no treatment effect existed or for drugs no longer under development) then 
data may be coded for treatment group but the key to the code will be stored 
separately from the dataset to prevent unauthorised analyses. Meta-analysis or re-
analysis to assess treatment effects is not an objective of VISTA. 
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10.1.14.1 Data Storage  
Secure storage of data will be offered initially by the Robertson Centre for Biostatistics 
at the University of Glasgow, but trial representatives may elect to retain their own 
converted data store and to provide the data only at the time of agreed analyses. The 
steering committee may appoint an alternative central data store. During analyses, the 
location of the analysis data store will be determined by the designated 
statistician/data manager, and will be subject to the agreement of the steering 
committee. Data security will be managed according to a standard operating procedure 
developed for this purpose by the Data management committee. 
10.1.14.2  Data Management 
During the development phase of VISTA, data management will be offered by Prof. K.R. 
Lees and colleagues in the Department of Medicine & Therapeutics and in the Robertson 
Centre for Biostatistics at the University of Glasgow. It would be undesirable and 
impractical to have sponsors check every VISTA analysis; however, the committee(s) will 
still need to assure themselves that any statistical approaches are valid and thus a 
statistics/data management group is needed.  
10.1.15 Finance 
VISTA will be a ‘not for profit’ organisation, but will seek to be self supporting through 
external grant support and industrial sponsorship of maintenance and analysis costs. 
Funds will initially be administered through the Finance Department of the University of 
Glasgow. The Steering Committee may appoint alternative financial administration. 
Annual accounts will be prepared by the executive committee and presented to the 
steering committee for approval. 
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10.1.16 Executive Committee 
The executive committee will include a chairman, honorary secretary, honorary 
treasurer and up to 5 additional academic members plus 2 non-voting sponsor members. 
At least one academic member should have statistical or data management expertise, 
and if necessary an additional member may be co-opted for this purpose. 
The executive committee will be empowered to take decisions on all administrative 
matters, to disburse funds of the VISTA group and to enter into agreements on behalf of 
the group but may not borrow funds beyond the resources of the VISTA group or 
otherwise enter into debt in the name of the VISTA group. 
Executive members will be elected by the Steering Committee following nomination by 
any two members of the steering committee. Where there are more nominations than 
positions available, the election will be determined by ballot amongst steering 
committee members. Sponsor members may participate in elections, but only academic 
members may be nominated to voting membership of the executive committee.   
Members of the sponsor committee may nominate or elect up to 2 representatives from 
their number to attend executive committee meetings or to represent them in 
executive committee discussions; these members may not be present during closed 
discussions on commercially sensitive proposals for analyses and will not have voting 
rights. 
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10.2 Appendix 2: Data Use Agreement 
10.2.1 Data request terms and conditions 
• Data can only be accessed with the correct password. 
• Data can only be accessed for the agreed duration stated in the project proposal submitted 
to the VISTA steering committee. 
• Should the need arise to extend this period the VISTA group should be notified; extensions by 
more than 25% of the planned duration will need committee approval. 
• Analyses may not be undertaken and/or published or reported to an outside group without 
the knowledge and approval of the VISTA steering group.   
• A fixed fee of £2000 or 4000 USD will be charged for all academic analyses, with an 
additional cost of £150 per day or part of a day spent on data extraction. Funding will go 
towards VISTA costs, data extraction and day –to –day maintenance of the archive. 
• Any abstracts or manuscripts should be reviewed by the steering group prior to submission 
for publication. This applies to both national and international publications.  
• Inadvertent un-blinding of any individual study in an internal report may not be perpetuated 
in any subsequent publication. 
• Any publication arising through VISTA analyses should be accompanied by acknowledgement 
that the study is a part of the VISTA investigations.    
• VISTA may contact collaborators following the analysis period to enquire as to the success 
and feedback of publication, and to gauge any improvements which can be made to the 
resource which VISTA provides.  
 
I hereby acknowledge that I have read, understood and will adhere to the terms and 
conditions of VISTA and that all publications will be reported as part of the VISTA 
investigations.   
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10.3 Appendix 3: Analyses Conducted by External 
Investigators  
Over the past 3 years VISTA has developed into a valuable stroke resource in which to 
pose queries regarding the natural history of disease and optimal selection of patients 
and outcome measures. There have been numerous applications for use of VISTA data. 
Details of the analyses carried out by external investigators are presented in this 
appendix.  
10.3.1 Completed investigations 
10.3.1.1 Predictors of early cardiac morbidity and mortality after ischemic stroke. 
Authors: Jane Prosser MBBS, FRACP; Lachlan MacGregor MBBS, MMedSc; Kennedy R. 
Lees MD, FRCP; Hans-Christoph Diener MD; Werner Hacke MD, PhD; Stephen M. Davis 
MD, FRACP; on behalf of the VISTA investigators. 
Publication: Stroke 2007;38;2295-2302 
10.3.1.1.1 Abstract 
Introduction: In the first three months after acute ischemic stroke, 2-6% of patients die 
from cardiac causes. This may reflect pre-existing cardiac disease, cardiac dysfunction 
related to the acute neurohumoral and autonomic stress response to stroke, or both. 
Delineation of a high-risk group could facilitate prevention strategies. We aimed to 
describe the temporal profile of cardiac risk after stroke and develop a predictive 
model of serious cardiac adverse events (SCAEs) using baseline demographic and clinical 
variables. 
Methods: We used individual patient data from the Virtual International Stroke Trials 
Archive. Survival analysis was used to describe the temporal profile of cardiac events 
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after stroke. Prognostic determinants were assessed with multivariable logistic 
regression, and a risk score was derived from the key predictor variables. 
Results: Of 846 ischemic stroke patients, 35 (4.1%) died from cardiac causes and 
161(19.0%) suffered at least one SCAE. The hazard of cardiac death was highest 
(0.001/day) in the second week, then declined. Hazard of a first SCAE peaked at 
0.02/day between day 2 and 3. The 5 factors most predictive of SCAEs were a history of 
heart failure (OR 1.93 [1.31, 2.85], p<0.001), diabetes (OR 2.11 [1.39, 3.21], p<0.001), 
baseline creatinine>115μmol/L (OR 1.77 [1.16, 2.70], p=0.008), severe stroke (OR 1.98 
[1.34,2.91], p=0.001) and a long QTc or ventricular extra systoles on ECG (OR 1.93 
[1.31, 2.85], p=0.001). Risk of SCAEs ranged from 6.3% (no predictors) to 62.2% (≥4 
predictors). 
Discussion: Serious cardiac events are common in the acute period after stroke. 
Patients at highest risk are identifiable and may benefit from more aggressive strategies 
to improve survival.   
 
10.3.1.2 Interconversion of National Institutes of Health Stroke Scale (NIHSS) and 
Scandinavian Stroke Scale (SSS) impairment/severity measures in stroke 
trials 
Authors: Laura J Gray, PhD; Myzoon Ali, M. Res; Philip M.W. Bath, MD, FRCP; for the 
VISTA Collaboration 
Publication: Presented at the European Stroke Conference 2007 (Glasgow, UK), 
Submitted to Stroke in April 2008 
10.3.1.2.1 Abstract 
Introduction: The National Institutes of Health Stroke Scale (NIHSS) and Scandinavian 
Stroke Scale (SSS) are both validated measures of impairment, share common domains 
and have been used in many acute stroke trials. However, they differ in their direction 
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of measurement, the weighting given to individual items, and inclusion of specific 
measures. Here, we describe methods for their interconversion. 
Methods: We included 5 acute stroke trials from the Virtual International Stroke Trials 
Archive (VISTA) where both NIHSS and SSS had been recorded at baseline; data were 
also available at 90 days post randomisation for each trial. Median scores were used to 
populate a conversion table. Equations were then developed using linear regression 
(both unadjusted and adjusted for age and sex) using 50% of the data. The remaining 
50% of data were used to test the accuracy of the models produced. The trials all 
excluded patients with mild impairment (e.g. NIHSS<3, SSS>50) and had exclusion 
criteria that will have confounded impairment, e.g. time to treatment and maximum 
age. We excluded data from the extremes of the scales where data were sparse. 
Results: Fitted models at baseline were NIHSS=25.90733–0.43909xSSS (n=977, R2=0.61, 
prediction error (PE) -0.1, p=0.38), and SSS=50.62325 –1.64148xNIHSS (n=879, R2=0.62, 
PE 0.1, p=0.67). 90 day models were NIHSS=22.71944-0.38365xSSS (n=792, R2=0.81, PE -
0.3, p=0.003), and SSS=56.76262–2.23975xNIHSS (n=770, R2=0.79, PE -0.2, p=0.49). 
Adjustment for age and gender did not materially improve R2 values. 
Discussion: The NIHSS and the SSS may be inter-converted; derived conversion 
equations may prove useful for both current clinical trials and meta-analyses of 
completed trials where different measures of impairment may have been used. 
10.3.1.3 Association between disability measures and healthcare costs after initial 
treatment for acute stroke. 
Authors: Jesse Dawson MRCP; Jennifer S. Lees BA; Tou-Pin Chang; Matthew R. Walters 
MD, FRCP; Myzoon Ali M. Res; Stephen M. Davis MD, FRACP; Hans-Christoph Diener MD; 
Kennedy R. Lees MD, FRCP; on behalf of the VISTA Investigators 
Publication: Stroke. 2007;38:1893-1898 
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10.3.1.3.1 Abstract 
Introduction: The distribution of 3-month modified Rankin scale scores (mRS) has been 
used as an outcome measure in acute stroke trials. We hypothesised that hospitalisation 
and institutional care home stays within the first 90 days after stroke should be closely 
related to 90-day mRS, that each higher mRS category will reflect incremental cost; and 
that resource use may be less clearly linked to NIHSS or Barthel index.  
Methods: We examined resource use data from the GAIN International trial, comparing 
90-day mRS with total length of stay (LoS) in hospital or other institutions during the 
first 90 days. We repeated analyses using NIHSS and Barthel index scores. Relationships 
were examined by ANOVA with Bonferroni contrasts of adjacent score categories. 
Estimated costs were based on published Scottish figures. 
Results: We had full data from 1717 patients. LoS was strongly associated with final 
mRS (P<0.0001). Each mRS increment from 0-1-2-3-4 was significant (mean LoS: 17, 25, 
44, 58, 79 days, P<0.0005). 95% confidence limits for estimated costs (£) rose 
incrementally: 2493-3412, 3369-4479, 5784-7008, 7300-8512, 10095-11141, 11772-13560 
and 2623-3321 for mRS 0-5 and dead respectively. Weaker relationships existed with 
Barthel and NIHSS. 
Discussion: Each mRS category reflects different average length of hospital and 
institutional stay. Associated costs are meaningfully different across the full range of 
mRS outcomes. Analysis of the full distribution of mRS scores is appropriate for 
interpretation of treatment effects after acute stroke and more informative than 
Barthel or NIHSS endpoints. 
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10.3.1.4 Hyperglycaemia in acute stroke trials: prevalence, predictors and 
prognostic value- An analysis of the Virtual International Stroke Trials 
Archive (VISTA).   
Authors: Keith W. Muir MD, FRCP; Michael T. McCormick MRCP; on behalf of the VISTA 
investigators 
Publication: Presented at the International Stroke Conference 2007, San Francisco, 
USA. 
10.3.1.4.1 Abstract 
Introduction: Post-stroke hyperglycemia (PSH) is associated with higher mortality and 
poorer functional outcome after stroke, but most prior studies have been single-centre, 
measured glucose up to 72h after stroke, and have used different definitions of 
hyperglycemia. We conducted an individual patient data analysis of a large database of 
acute stroke trials. 
Methods: Individual patient data were obtained for trials in the VISTA database where 
blood glucose had been recorded on admission. Associations of PSH were sought by 
binary logistic regression. Outcome was assessed by modified Rankin Scale (mRS) at 90 
days. PSH was defined as glucose>7.0mmol/l.  
Results: For 2645 subjects treated at a median 5.5h, admission PSH was present in 1126 
(42.6%, 95% CI 40.7-44.5%) and PSH within the first 48h in 1421 (53.7%, 95% CI 51.8-
55.6). 19.4% (95% CI 17.5-21.4%) of initially normoglycaemic subjects developed PSH 
between 24 and 48h. Blood glucose increase was documented in 908 / 1913 (47.5%, 95% 
CI 45.2-49.7%). Predictors of death at day 90 were PSH within 48h, age, and higher 
NIHSS score; rt-PA treatment and female sex were associated with reduced likelihood of 
death. Favourable outcome (mRS 0-1) at day 90 was less likely with PSH<48h, age, and 
higher NIHSS score, and more likely with rt-PA. Admission PSH was predicted by history 
of diabetes (hazard ratio 7.40, 95% CI 5.60-9.79) and higher NIHSS score, and was less 
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likely with later time windows. Diabetes, higher NIHSS, hypertension, and older age 
were associated with PSH within 48h. 
Discussion: Post-stroke hyperglycemia is common. Over 40% exhibit PSH on admission 
and 20% of those normoglycaemic on admission develop hyperglycaemia within 48h. 
Hyperglycaemia within the first 48h is independently associated with higher mortality 
and poorer functional outcome, with 44% increased odds of poor outcome, an absolute 
increase of 12.9%. 
10.3.1.5 Predicting long-term outcome after acute ischemic stroke – a simple index 
works in patients from controlled clinical trials 
Authors: Inke R. König PhD; Andreas Ziegler PhD; Erich Bluhmki PhD; Werner Hacke MD; 
Philip M. W. Bath MD; Hans-Christoph Diener MD; Christian Weimar MD; on behalf of the 
VISTA investigators 
Publication: Stroke 2008; 39 (In Press) 
10.3.1.5.1 Abstract 
Introduction: An early and reliable prognosis for recovery in stroke patients is 
important for initiation of individual treatment and for informing patients and relatives. 
We recently developed and validated models for predicting survival and functional 
independence within three months after acute stroke based on age and the National 
Institutes of Health Stroke Scale (NIHSS), assessed within six hours after stroke. Here, 
we demonstrate the applicability of our models in an independent sample of patients 
from controlled clinical trials. 
Methods: The prognostic models were used to predict survival and functional recovery 
in 5419 patients from the Virtual International Stroke Trials Archive (VISTA). 
Furthermore, we tried to improve the accuracy by adapting intercepts and estimating 
new model parameters. 
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Results: The original models were able to correctly classify 70·4% (survival) and 72·9% 
(functional recovery) of patients. Because the prediction was slightly pessimistic for 
patients in the controlled trials, adapting the intercept improved the accuracy to 74·8% 
(survival) and 74·0% (functional recovery). Novel estimation of parameters, however, 
yielded no relevant further improvement. 
Discussion: For acute ischemic stroke patients included in controlled trials, our easy-to-
apply prognostic models based on age and NIHSS correctly predict survival and 
functional recovery after three months. Furthermore, a simple adaptation helps to 
adjust for a different prognosis and is indeed recommended. 
10.3.1.6 Early and delayed calcium levels vs ischemic stroke outcomes  
Authors: Bruce Ovbiagele MD; Sidney Starkman MD; David S. Liebeskind MD; Judith Guzy 
RN; Philip Teal MD; Patrick Lyden MD; Markku Kaste MD; Stephen M. Davis 
MD; Werner Hacke MD; Monica Fierus; Jeffrey L. Saver MD; on behalf of the VISTA 
Investigators. 
Publication: Stroke 2008; (in press).  
10.3.1.6.1 Abstract 
Introduction: Calcium (Ca2+) plays a role in the cellular and molecular pathways of 
ischemic neuronal death. We evaluated the impact of early and delayed Ca2+ levels on 
clinical outcomes from acute ischemic stroke. 
Methods:  The relation between blood calcium level obtained early (< 4.5 hours), and 
delayed (72-96 hours) after ischemic stroke onset vs. clinical outcomes were analyzed in 
826 subjects enrolled in the modified Repinotan - Randomized Exposure Controlled Trial 
(mRECT) trial. Subjects were categorized into Ca2+ quartiles. Outcome measures 
analyzed included baseline and 72-96 hour stroke severity, as well as 3-month 
functional and global disability scales. The independent effect of calcium on outcome 
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was evaluated by median and logistic regression analysis, adjusting for other variables 
known to predict outcome after ischemic stroke.  
Results: 659 (80%) of mRECT subjects had complete baseline data including Ca2+ levels. 
Bivariately, the highest delayed Ca2+ quartile (vs. lowest) was associated with lesser 
stroke severity and better 3-month functional and independence scale outcomes 
(P<0.001), but no significant outcome differences were noted among early Ca2+ levels. 
In multivariate analysis, delayed Ca2+ in the highest quartile (vs. lowest quartile) was 
associated with greater 3-month independence score on the Barthel Index scale (76.9 
vs. 55.4, p=0.006). No other significant outcome differences were noted between 
highest and lowest quartiles for both early and delayed Ca2+ quartiles.  
Discussion: Elevated 72-96 hour serum calcium levels are associated with greater 
independence 3 months after ischemic stroke. Very early serum calcium levels do not 
appear to have any prognostic significance after ischemic stroke.  
10.3.1.7 Congestive heart failure after ischemic stroke: relevance to the 
development of albumin as a therapy for acute ischemic stroke 
Authors: Michael D. Hill MD, MSc; Myzoon Ali M. Res; Karla J. Ryckborst RN; Diego 
Tamariz MD; Myron D. Ginsberg MD; Yuko Y. Palesch PhD; Patrick Lyden MD; for the 
VISTA Collaborators. 
10.3.1.7.1 Abstract 
Introduction: High dose albumin is a potential new therapy for acute ischemic stroke. 
The major predicted toxicity of this therapy is volume-overload leading to congestive 
heart failure/pulmonary oedema. The natural history of congestive heart 
failure/pulmonary oedema after ischemic stroke is unknown. 
Methods:  We queried the Virtual International Stroke Trials Archive (VISTA), a resource 
that was established to facilitate exploratory analyses of this nature. We examined 
pooled clinical trial data of patients who received placebo/control and divided them 
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into those that received a saline vs. a non-saline control therapy. The risk of congestive 
heart failure/pulmonary oedema in the first week after stroke and the outcome are 
described. Risk factors for the development of congestive heart failure/pulmonary 
oedema were evaluated using logistic regression. 
Results: Among 4484 patients, the risk of congestive heart failure/pulmonary oedema 
was 1.1% (1.1%, 95% CI 0.1-1.4). Saline vs. a non-saline control was associated with an 
increased risk of congestive heart failure/pulmonary oedema (OR 5.2, 95% CI 2.0-13.2). 
Age, a history of hypertension and more severe stroke were also predictors of 
congestive heart failure/pulmonary oedema. The occurrence of congestive heart 
failure/pulmonary oedema was associated with a reduced of odds of independent 
outcome (OR 0.40 CI95 0.16-0.99, p=0.046), although this result is of borderline 
significance. 
Discussion: Congestive heart failure/pulmonary oedema are uncommon occurrences 
after stroke but it may be associated with a worse outcome at 90 days. Saline is not 
necessarily an inactive control therapy for stroke and should not be considered a true 
placebo. 
10.3.1.8  Anticoagulation after Cardioembolic Stroke 
Authors: Hen Hallevi MD; Karen C. Albright MD; Sheryl Martin-Schild MD PhD; Andrew D 
Barreto MD; James C Grotta MD; Sean I Savitz MD; on behalf of the VISTA investigators 
Publication: Cerebrovascular Diseases 2008;26:38-40 
10.3.1.8.1 Abstract 
Introduction: Cardioembolic Stroke (CES) comprises 20% of all ischemic strokes. While 
guidelines do not support acute anticoagulation of CES patients, uncertainty exists 
regarding the best timing and mode of starting chronic anticoagulation. 
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 Methods: We conducted a retrospective review of all patients admitted to our stroke 
centre with CES not treated with rt-PA. Patients were grouped by treatment: No 
treatment, aspirin only (ASA), aspirin followed by warfarin (WAR), IV heparin in the 
acute phase followed by warfarin (heparin bridging- HB), and high-dose enoxaparin 
combined with warfarin (enoxaparin bridging- EB). We also analyzed pooled data from 
the Virtual International Stroke Trials Archive (VISTA) project of CES patients.  
Results: 606 patients were analyzed. Recurrent stroke occurred in 1% of the Houston 
cohort and 4% of VISTA regardless of anticoagulation. Progressive stroke was the most 
frequent serious adverse event (5.4% in Houston and 8.2% in VISTA) and was significantly 
reduced with anticoagulation. Haemorrhagic transformation occurred in a bimodal 
distribution- an early benign HT and a late symptomatic HT (PH2). In Houston all PH2 
cases were in the EB group (10%, p=0.003). Systemic bleeding occurred in 1% of cases 
and was associated with HB (p=0.043). HB, EB and WAR were independently predictive 
of a favourable outcome (p=0.004) while ASA treatment predicated a poor outcome 
(p=0.003).  
Discussion: Anticoagulation of CES patients is associated with substantial reduction in 
progressive stroke and increased favourable outcome compared to aspirin or no 
treatment.  Heparin bridging increases the risk of systemic bleeding and enoxaparin 
bridging may confer increased risk of late, symptomatic HT.   
10.3.1.9 Delayed diagnoses of atrial fibrillation after ischemic stroke: Potential 
indication for prolonged cardiac monitoring 
Authors: Hooman Kamel, MD; Kennedy R. Lees, MD, FRCP; Patrick Lyden, MD; S. 
Claiborne Johnston, MD, PhD for the VISTA Investigators. 
Publication: Presented at the ISC 2007, Feb 7-9, San Francisco, Ca, USA. 
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10.3.1.9.1 Abstract 
Introduction: Detecting atrial fibrillation after ischemic stroke is important because 
anticoagulation reduces the risk of recurrent stroke. The standard stroke workup 
involves 24 or 48 hours of cardiac monitoring, but the optimum duration of monitoring is 
unknown. The aim of this study was to characterize the incidence, timing, and 
predictors of delayed diagnoses of atrial fibrillation after ischemic stroke. 
Methods: To take advantage of the close monitoring required in randomized trials, 3499 
patients were drawn from the placebo arm of acute ischemic stroke trials in the VISTA 
database. Patients were followed for 3 months. For our analysis, patients with known 
atrial fibrillation were excluded. Our primary outcome was an occurrence of atrial 
fibrillation, which was recorded as an adverse event or as an indication for therapy 
specific to atrial fibrillation. Time to diagnosis of atrial fibrillation was evaluated using 
Kaplan-Meier survival statistics. The association of a delayed diagnosis of atrial 
fibrillation with age, sex, congestive heart failure, coronary artery disease, 
hypertension, and diabetes was evaluated using multiple logistic regression, with 
stepwise backward elimination of all variables that were not significant (p < 0.10). 
Results: Of 2539 patients without atrial fibrillation at presentation, 174 (6.85% [95% CI, 
5.87 to 7.84%]) had a subsequent diagnosis of atrial fibrillation. The time of diagnosis 
was recorded in 93% of these patients. 85% of delayed diagnoses of atrial fibrillation 
were made after 24 hours, 70% after 48 hours, and 16% after 7 days. Delayed diagnosis 
of atrial fibrillation was associated with increasing age (OR 1.65 per decade; 95% CI, 
1.41 to 1.94; p < 0.0005), female sex (OR 1.73; 95% CI, 1.21 to 2.47; p = 0.002), and 
congestive heart failure (OR 2.06; 95% CI, 1.11 to 3.81; p = 0.022), and negatively 
associated with hypertension (OR 0.59; 95% CI, 0.40 to 0.86; p = 0.006). 
Conclusions: Many new diagnoses of atrial fibrillation in ischemic stroke patients are 
made more than 48 hours after presentation. This study probably underestimates the 
true rate of atrial fibrillation because patients underwent a limited period of cardiac 
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monitoring. Thus, 24 to 48 hours of cardiac monitoring may fail to detect atrial 
fibrillation in a substantial number of stroke patients. 
10.3.1.10 Does hemispheric lateralization influence functional and cardiovascular 
outcomes after stroke? An analysis of placebo-treated patients from 
prospective acute stroke trials. 
 
Authors: John N. Fink FRACP; Christopher M. Frampton PhD; Patrick Lyden MD; Kennedy 
R. Lees MD, FRCP; on behalf of the VISTA Investigators 
Publication: Stroke 2008; (In press).   
10.3.1.10.1 Abstract 
Background and purpose: The influence of stroke lateralization on functional and 
cardiovascular outcome after stroke is not well established. We evaluated the influence 
of hemispheric lateralization among patients enrolled in prospective acute stroke trials. 
Methods: We obtained data from the VISTA database for acute stroke trials which 
reported lateralization. Baseline demographic and clinical data, cardiac adverse events 
and 90-day outcomes were compared between right and left hemisphere stroke 
patients. A ‘hemisphere unbiased’ sub score of the NIHSS which omitted items strongly 
associated with lateralized cognitive deficits was also compared. A multivariate analysis 
of outcome predictors was performed.  
Results: Three acute stroke trials met the pre-specified inclusion criteria. 1644 
placebo-treated patients with documented hemispheric lateralization were included in 
the analysis. Baseline NIHSS was higher for left hemisphere patients (mean 16.2, vs 12.8 
right, p<0.001); there was no difference in the ‘hemisphere unbiased’ NIHSS sub score 
(10.88 left, 11.08 right, p=0.49). There was no difference between hemispheres in 90-
day mRS (3.43 left, 3.29 right, p=0.13), mortality (22.1% left, 19.5% right, p=0.20), or 
cardiac adverse events (p=0.71). Hemispheric lateralisation appeared as an independent 
Myzoon Ali, 2008  Appendix, 206 
 
  
predictor of outcome in the multivariate analysis, but this was dependent on an 
interaction with baseline NIHSS score.  
Conclusions: There is no difference in functional outcome between patients with right 
or left hemisphere stroke. Use of the baseline NIHSS score to predict stroke outcome 
must take hemispheric lateralisation into account. Stroke lateralisation is not an 
important predictor of cardiac adverse events or 90-day mortality. 
10.3.1.11 Using historical lesion volume data in the design of a new phase II clinical 
trial in acute stroke 
Authors: John Whitehead PhD; Kim Bolland PhD; Elsa Valdes-Marquez PhD; Anela Lihic 
MD; Myzoon Ali M. Res; Kennedy Lees MD FRCP; for the VISTA Collaborators. 
Publication: Stroke 2009;40 (in Press) 
10.3.1.11.1 Abstract 
Background and Purpose: Clinical research into the treatment acute stroke is 
complicated, costly and has often been unsuccessful. Developments in imaging 
technology based on CT and MRI scans offer opportunities for screening experimental 
therapies during phase II testing so as to deliver only the most promising interventions 
to phase III. We discuss the design and the appropriate sample size, for phase II studies 
in stroke based on lesion volume.   
Methods: The relationship between lesion volume and neurological outcome for placebo 
trial patients was examined using data from the Virtual International Stroke Trials 
Archive. We imposed a treatment effect on lesion volume, consistent with the 
assumption of proportional odds and determined the effect passed on to modified 
Rankin scores (mRS). We then computed sample sizes to detect effects on lesion volume 
of the magnitude consistent with clinical benefit on the mRS scale. We used simulation 
to evaluate different criteria for proceeding from phase II to phase III. 
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Results:  We found that the odds ratios for mRS correspond roughly to the square root 
of odds ratios for lesion volume, implying that for equivalent power specifications, 
sample sizes based on lesion volumes should be about one quarter of those based on 
mRS. Relaxation of power requirements, appropriate for phase II lead to further sample 
size reductions. For example, a phase III trial comparing a novel treatment with placebo 
with a total sample size of 1518 patients might be motivated from a phase II trial of 126 
patients comparing the same two treatment arms. 
Discussion: Definitive phase III trials in stroke should aim to demonstrate significant 
effects of treatment on clinical outcomes. However, more direct outcomes such as 
lesion volume can be useful in phase II for determining whether such phase III trials 
should be undertaken in the first place.   
10.3.1.12 Recovery potential after ischemic stroke: Criteria for good outcome by 
level of disability at day 7  
Authors: James Grotta MD; Hen Hallevi MD; Karen Albright MD; Sean Savitz MD; Miriam 
Moralles MS; on behalf of the VISTA Investigators 
Publication: Submitted to Neurology in June 2008.   
10.3.1.12.1 Abstract 
Background: Ischemic stroke is a leading cause of morbidity. Assessing the chances of 
recovery is critical to optimize post-stroke care.  
Methods:  We used a cohort of patients from the Virtual International Stroke Trial 
Archive (VISTA) that participated in acute stroke trials (control arm) and were followed 
for 90 days. The cohort was grouped by day 7 (D7) modified Rankin scale (mRS) scores 
and individual independent criteria of good outcome (mRS 0-2 at 90 days) were 
determined.  
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Results: We analyzed 1798 patients. The good outcome criteria identified were: D7 mRS 
of 3: age≤70, Barthel index (BI)>60, 0-2 risk factors, D7 NIHSS arm strength ≤ 1, D7 
NIHSS language score=0; for D7 mRS of 4: age≤70, BI ≥ 35, male gender, D7 NIHSS facial 
palsy ≤1, D7 NIHSS visual=0, D7 NIHSS leg strength ≤1; D7 mRS=5: age≤70, IV rt-PA 
treatment, D7 NIHSS facial palsy ≤ 1, D7 NIHSS leg strength ≤2, D7 NIHSS sensory score = 
0. After applying the predictors, the percentage of good outcome at 90 days in each D7 
mRS tier was plotted as-well-as the percentages of excellent outcome (mRS 0-1) and 
decrease of 1 or 2 levels of mRS at 90 days.   
Conclusion: We identified good outcome criteria that are specific to each day 7 mRS 
tier, and enable easy and informative assessment of the patient’s likelihood of 
achieving varying degrees of recovery at day 90. These results may be useful in both 
clinical practice and research. 
10.3.2 Ongoing investigations 
10.3.2.1 Natural history of non-intervention in spontaneous intracerebral 
haemorrhage 
Investigators: Barbara A. Gregson PhD; A David Mendelow PhD; Joseph P. Broderick MD; 
Daniel F. Hanley MD. 
The identification of priority areas of research and production of guidelines for the 
management of ICH is of vital importance in current stroke research. Since the 
International STICH trial was not conclusive (122) the group has felt it is highly 
important to bring together all the knowledge available from all the modern clinical 
trials in order to gain more insight into the most appropriate methods to use to treat 
ICH for the different subgroups of patient. As part of this work it is important to ensure 
that the natural history of patients with untreated ICH is understood. This task will be 
undertaken by Barbara Gregson under the auspices of the UK Stroke Association (and 
the NIH group known as SPOTRIAS).   
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We propose to set up an analysis of prospectively collected data on patients with 
spontaneous supratentorial ICH in collaboration with investigators who agree to share 
the information to allow two detailed statistical studies to progress rapidly over the 
next year. These will address: 1) The role of intervention and outcome in ICH and 2) the 
natural history of brain injury from ICH.  
Hypotheses: We want to do a patient specific pooling of data that allows us to better 
test some sub-populations of ICH patients and their response to surgery. Possible 
hypotheses include ‘Is very early surgery better?’, ‘Is surgery in a Western nation good?’ 
‘Is surgery in haematomas that reach the cortical surface good?’ 
Certain factors are suggestive of disease severity such as haematoma size, IVH extension 
and presenting location. Possible hypotheses include: Do these factors still influence 
outcome? What is the relative influence of each factor? What is the interdependence of 
each factor? 
10.3.2.2 Influence of hyperglycaemia on haemorrhagic transformation in patients 
treated with IV rt-PA in the SAINT 1 and SAINT 2 trials 
Investigators: Keith W. Muir MD, FRCP; Ashfaq Shuaib MD, FRCPC, FAHA. 
Background 
Hyperglycaemia during the first 48h after stroke is associated with a significantly higher 
mortality and reduced chance of good functional outcome (369;370). The mechanisms 
for this association remain unclear, but include the possibility that hyperglycaemia has 
a detrimental effect on neuronal survival after ischaemia (371). Hyperglycaemia has 
been associated with higher lactate concentrations and greater likelihood of infarct 
expansion in observational MRI-based studies (372-374) although interventional studies 
to date have been unable to find either a general beneficial effect on clinical outcomes 
(375), or on infarct expansion on MRI (376).  
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In a retrospective analysis of the NINDS trial, hyperglycaemia was associated with 
adverse outcomes independently of IV rt-PA treatment within 3 hours of onset, and in 
this study was also associated with a higher risk of symptomatic intracerebral 
haemorrhage (SICH) (377). A possible mechanism for this effect is the impairment of 
recanalisation by hyperglycaemia (378). However, other studies have not consistently 
reported an independent effect of hyperglycaemia on SICH with thrombolytic drugs 
(379-381) or with heparin (382), and further data on this relationship would be helpful. 
Differing definitions of SICH in different studies further confound the question. 
It is unclear to what extent the harmful effects of hyperglycaemia in rt-PA-treated 
patients are related to the occurrence of haemorrhage independent of infarct volume, 
and if CT scans are available, then analysis that takes into account volume of infarct at 
follow-up may allow distinction between alternative mechanisms. 
Hypotheses 
• That hyperglycaemia is associated with a higher risk of all types of haemorrhagic 
transformation in patients receiving IV rt-PA, specifically any haemorrhagic 
transformation; PH2 bleeds; symptomatic bleeds (defined as any bleed + deterioration by 
NIHSS>3, or by PH2 + NIHSS deterioration >3 points). 
• That hyperglycaemia is an independent predictor of poor outcome in patients treated 
with IV rt-PA. 
• That there is an interaction of hyperglycaemia and PH2 bleeds with poor outcome. 
 
Methods 
To undertake an exploratory analysis of the combined SAINT 1 and SAINT 2 data (and 
any additional datasets where treatment with IV rt-PA within 3h of stroke onset was 
undertaken, with pre-treatment documentation of blood glucose concentration, follow-
up CT result at day 3-4 with coding of haemorrhagic outcomes, and day 90 mRS) to 
explore the relationship between hyperglycaemia and risk of haemorrhagic 
transformation in patients who received rt-PA. 
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Data Required 
In those subjects who received IV rt-PA: 
 
• Baseline demographics (including all relevant medical history items, particularly diabetes 
mellitus), stroke characteristics (NIHSS score, time of onset etc), CT findings 
• Time of initial blood sample (especially in relation to time of rt-PA) 
• Blood glucose measurements at all time points 
• NIHSS at 24h, d3 and d7 (to define symptomatic v asymptomatic HTI) 
• CT findings at 72h 
• Medication prior to trial enrolment (particularly use of hypoglycaemic agents) 
• Medication during initial 72h (insulin or hypoglycaemic agents) 
• 3 month outcome data (mRS) 
 
If CT scans are available to review then this would also be very helpful. 
 
Analyses 
If CT scans are available for review, independent review of all CTs for baseline Alberta 
Stroke Programme Early Computed Tomography Score (ASPECT) score, presence of 
haemorrhage (and grading as HT1, HT2, PH1, PH2, PHr1, PHr2) at follow-up, as well as 
extent of final infarction (repeat ASPECT score). 
Comparison of proportions of different radiological grades of haemorrhagic 
transformation with presence of initial hyperglycaemia (main definition blood glucose 
>7mmol/l [126mg/dl], other thresholds to be tested if sufficient data), or later 
hyperglycaemia. Mean blood glucose concentration in each category of haemorrhagic 
transformation. Same analyses repeated for symptomatic ICH defined as per different 
definitions reported in SITS-MOST. 
If there are enough data, outcome at 3 months by mRS (favourable 0-1) and mortality 
using logistic regression analysis including NIHSS, age, onset to treatment time, 
haemorrhagic transformation, and hyperglycaemia. 
Prediction of haemorrhagic transformation (SICH and also alternative definitions) by 
baseline blood glucose, including NIHSS baseline ASPECT score, and outcome ASPECT 
score in a regression model (data permitting). 
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Resources for Analysis 
Analyses to be undertaken by the principal investigator assisted by a clinical research 
fellow (if appointed) who has independent funding. No additional resources are 
required. 
10.3.2.3 Validation of trial design for intravenous thrombolysis with rt-PA within 3 
hrs of stroke onset in patients aged more than 80 years using VISTA. 
Investigators: Danilo Toni MD 
VISTA data will be exploited in the context of a trial with IV t-PA in patients aged more 
than 80 years to inform this trial’s design. VISTA data can be used to address three key 
points.  
1. Our original trial design set the upper NIHSS score at 17, above which patients cannot 
be randomised, because by reviewing the data on the over 80 patients on the SITS-ISTR, 
it was found that over this score mortality and SICH steeply increased and, obviously, 
mRS 0-2- at three months steeply decreased. We are interested in investigating whether 
the placebo treated patients in VISTA have similar outcomes, which might strengthen 
our choice. 
2. We calculated the sample size based on the few data available in literature from 
patients aged over 80 treated with rt-PA compared to non treatment studies on clinical 
evolution of elderly stroke patients. We aim to use VISTA to estimate the 
independence/mortality rates in the over 80 placebo patient population. 
3. In order to inform possible stopping rules we wish to examine the rates of 
spontaneous intracerebral haemorrhage in VISTA. We have access to the SITS-ISTR data 
on fatal SICH in patients aged over 80 years and the comparison between the two 
datasets could be useful to define an upper limit of incidence of fatal SICH which should 
determine a warning procedure. 
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10.3.2.4 Relationship between high blood pressure, intermediate outcomes, and 
functional outcome in acute stroke 
Investigators: Philip M.W. Bath MD; Gill Sare, Chamila Geeganage, Laura Gray PhD. 
High blood pressure (BP) during the first 48h after stroke is associated with higher 
mortality and worse functional outcome (383-385). The mechanisms for these 
associations remain unclear but include the possibility that high BP promotes the 
development of intermediate outcomes including early recurrence, cerebral oedema 
and haemorrhagic transformation (HT) in patients with ischaemic stroke (383;385) and 
haematoma expansion in primary intracerebral haemorrhage (PICH) (386;387).  
Several large trials (n>1000 patients) of BP management are ongoing [COSSACS, ENOS, 
INTERACT, SCAST (388;389)] but they will take several more years to complete and 
report. VISTA offers the opportunity to further investigate the relationship between BP 
and subsequent events and outcome after acute ischaemic stroke and PICH. VISTA has 
facilitated a similar project assessing the relationship between physiological 
disequilibrium (hyperglycaemia) and functional outcome. 
Hypotheses 
• High BP is associated independently in ischaemic stroke with the development of 
intermediate outcomes including HT (any, PH2, symptomatic), recurrence, and cerebral 
oedema. 
• High BP is associated independently in PICH with the development of intermediate 
events including haematoma expansion. 
• High BP is associated independently with a poor outcome.  
• The development of intermediate events explains part of the poor outcome. 
 
Methods 
Analysis of VISTA trial data will include stroke type, enrolment BP, clinical intermediate 
events, radiological intermediate events, and functional outcome. Data will be obtained 
from the control groups of trials in patients given aspirin but not other haemostatically 
active drugs (thrombolysis, anticoagulation). 
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Data Required 
• Baseline demographics (including all relevant medical history items, particularly 
hypertension), stroke characteristics (impairment score, time of onset etc), CT findings 
• BP and heart rate measurements at all time points, and the times of these 
• Impairment (NIHSS, SSS) at 24 hours, day 3 and/or day 7 (to define symptomatic v 
asymptomatic HT) 
• CT findings at 24 hr to 10 days post stroke 
• Medication prior to trial enrolment (particularly use of BP lowering agents) 
• BP medications during initial week 
• 3 month outcome data (mRS, BI) 
 
Analyses 
• Derivation of haemodynamic measures from BP and heart rate: mean BP, rate-pressure 
product. 
• Assessment of digit preference in haemodynamic measures. 
• Relationship between blood pressure and stroke subtype/severity. 
• Relationships between baseline haemodynamic measures and HT, recurrence and 
cerebral oedema in acute ischaemic stroke. 
• Relationships between baseline haemodynamic measures and haematoma expansion in 
PICH. 
• Relationships between baseline haemodynamic measures and functional outcome. 
• Relationships between intermediate outcomes and functional outcome. 
• Analyses will separate ischaemic stroke and PICH. 
• HT (fatal, non-fatal symptomatic, asymptomatic, none) and functional outcome will be 
analysed as ordinal scales (using ordinal regression). 
 
Publication 
The management of high blood pressure in acute stroke is highly topical and information 
based on analysis of data from VISTA is expected to be highly publishable. The large 
amount of data (numbers of subjects and variables) available in VISTA means that the 
analyses will build on earlier ones involving either very large trials with few variables 
(IST) (383) and smaller trials with many variables (e.g. GAIN, TAIST (385;390)). 
Resources for Analysis 
Analyses will be undertaken by clinical research and statistical staff working with the 
chief investigator. No additional resources are required. 
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10.3.2.5 Is rt-PA as effective in stroke patients over 100 kg? 
Investigators: Aitziber Aleu MD; Lin Liu; Rema Raman; Patrick Lyden MD. 
Currently, rt-PA dosing is weight-adjusted with a maximum dose of 90 mg based on the 
NINDS rt-PA trial protocol. Therefore, patients who weigh over 100kg all receive the 
same dose, regardless of their weight. Our hypothesis is that such patients might be 
relatively underdosed and would consequently have a worse outcome.  
Maximum dose of rt-PA in the NINDS trial was established in dose escalation trials that 
included very few patients over 100kg. Higher doses of rt-PA have been safely used in 
other stroke trials or for other purposes e.g. myocardial infarction or pulmonary 
embolism.  
To that purpose, we compared the month 3 mRS and symptomatic ICH rate for patients 
under and over 100kg from a prospective database at the UCSD stroke centre. Baseline 
characteristics including age, gender, diabetes, hypertension, hyperlipidemia, time 
from onset to treatment, baseline glucose and NIHSS were also assessed between 
groups. Fisher’s exact test and Wilcoxon rank-sum test, as appropriate were used for 
the comparisons.  
Of 373 patients evaluated during this period, 120 (32%) were treated with rt-PA. 
Outcome data at 3 months (mRS) were available in 102/120 patients treated with rt-PA. 
Among the rt-PA treated patients, 84/102 (82.3%) weighed <100kg and 18/102 (17.6%) 
weighed> 100kg. Favourable outcome (mRS 0-1) was similar between the patients 
weighing <100kg (30%) compared to the patients over 100kg (22%). No events of SICH 
were reported in patients <100kg and 1 event of SICH occurred in patients over 100kg. 
Patients in the >100 kg group were older (p<0.001), male (p=0.067), had a greater 
history of diabetes (p=0.003), and had a higher baseline glucose (p=0.012).  
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Based on these preliminary results, patients over 100kg tended to be younger, male and 
diabetic. Glucose at presentation was higher than patients under 100kg. There was no 
evidence of harm in these patients and we could not find data to suggest that heavier 
patients were under-dosed with rt-PA because the 3-month Rankin scores were similar. 
Given the nominally lower frequency of good outcome in the >100kg patients, however, 
there remains the possibility of an effect not detected in this small sample. Greater 
sample size is needed to study confirm this however as well as for analysis and exclusion 
of confounders. Therefore, we submit this request to VISTA.  
If available, we would like to compare 3-month outcome in rt-PA treated patients less 
than versus greater than 100kg. Also, if we could confirm with a higher sample size that 
patients over 100kg have a worse outcome based on their lower dose of rt-PA, and 
exclude the hyperglycaemia and diabetes mellitus as confounders, our next step would 
be a safety pilot trial randomizing patients over 100kg to weight adjusted dose of rt-PA 
versus fixed maximum dose of rt-PA. Eventually, if this was safe, a further multi-centre 
randomized trial would be planned.  
To date, no study has been done regarding this subject. Little is known about the effect 
of rt-PA in these groups of patients. We believe it is important to address this question, 
because we might be exposing patients to rt-PA risk with lesser benefit or maybe to 
higher SICH risk. Furthermore, it is foreseen that the percentage of patients over 100kg 
may increase due to rising incidence of obesity.  
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10.3.2.6 The effect of pre-treatment with Angiotensin Converting Enzyme Inhibitors 
(ACEI) and/or Angiotensin Receptor Blockers (ARB) on stroke severity at 
presentation. 
Investigators: Jane Morris MD; Marc Fisher MD. 
Background  
Given the limitations in the application of effective therapies in acute stroke 
treatment, neuroprotection prior to ischemia is an attractive alternative approach. With 
recent data suggesting that statins may have neuroprotective effects in patients who 
are on them at the time of stroke (391) other commonly used medications should be 
investigated for similar benefits. The Angiotensin Converting Enzyme Inhibitors (ACEI) 
and the Angiotensin Receptor Blockers (ARBs) are widely used antihypertensive 
medications that may have protective effects beyond their blood pressure lowering 
capabilities. 
The central nervous system is known to have its own independently regulated renin-
angiotensin-aldosterone system (RAAS) (392). Angiotensin II (AngII) has myriad effects 
beyond its ability to modulate vascular tone. AngII regulates sympathetic nervous 
system activity, modulates endothelial function, and stimulates inflammatory, 
proliferative and fibrotic processes (393). There are several putative mechanisms by 
which Ang II may be detrimental during an acute stoke. As a potent cerebral smooth 
muscle vasoconstrictor it could impair cerebral blood flow during ischemia, therefore 
compromising the potential recovery of the penumbra. Due to its pro-inflammation 
properties and the production of free radical oxygen species it may contribute to 
apoptosis of neurons (393;394). It also may impair CNS autoregulation by opposing the 
actions of nitric oxide on vascular smooth muscle that can impair endothelial function 
(394). All of these properties make the modulation of the RAAS a potential target in 
acute ischemic stroke. 
Myzoon Ali, 2008  Appendix, 218 
 
  
Many experiments in animals support a beneficial effect of modulating the RAAS in 
ischemic stroke. When ACE inhibitors were given prior to MCA occlusion in 
spontaneously hypertensive rats they were able to prevent the ischemia-induced 
increases in tissue lactate concentration and maintain ATP concentrations (395). The 
ACEIs enalapril and moexipril were shown to reduce free radical-induced neuronal 
damage and ischemic brain injury in normotensive rats when administered 1 hour before 
permanent MCA occlusion (396). Captopril has also been shown to improve functional 
neurologic outcome when infused during incomplete cerebral ischemia in rats (397). 
Chronic pre-treatment with the ARB candesartan was shown to normalize 
cerebrovascular autoregulation and to protect against cerebral ischemia in 
spontaneously hypertensive rats after MCA occlusion (398). Those same investigators 
went on to perform a comparative study of the ACEI captopril, the ARB candesartan and 
the calcium channel blocker nicardine in the same model of complete MCA occlusion in 
rats. They showed a greater reduction in infarct size in the angiotensin modulating arm 
when compared with nicardipine, despite similar reductions in blood pressure (399). 
In humans, the renal and cardiac advantages of ACEIs and ARBs are well recognized and 
accepted as having benefits beyond their ability to lower blood pressure. The role of 
these hormones in stroke has yet to be elucidated fully. In the ACCESS Study, patients 
with ischemic stroke and systolic blood pressure ≥ 200 mm Hg or diastolic blood 
pressure ≥ 110 mm Hg were randomized to the ARB candesartan or placebo. The trial 
was stopped early due to a significant decrease in mortality and number of vascular 
events in the candesartan arm (400). Several trials on secondary vascular events suggest 
a potential for ACEI and ARBs to be superior to other BP lowering agents in preventing 
recurrent events. The PROGRESS trial showed superior secondary stroke prevention of 
the ACEI perindopril when combined with the thiazide diuretic indapamide over placebo 
(401). The MOSES trial showed that despite similar reduction in BP, the ARB eprosartan 
was more effective than the dihydropyridine calcium channel blocker (DHP-CCB) 
nitrendipine in reducing secondary stroke and cardiovascular events (402). The VALUE 
trial showed improved cardiovascular outcomes in patients treated with valsartan-based 
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vs. amlodipine-based treatment, and the LIFE trial showed superiority of losartan-based 
versus atenolol-based BP management (403;404).  
Hypothesis:  That patients who were on either an ACEI or an ARB at the time of their 
stroke have better initial stroke scores than age and sex matched patients who were not 
taking either of these medications. 
Methods: A retrospective analysis of Virtual International Stroke Trials Archive (VISTA) 
database.  The VISTA database has been described in detail previously (155). In our 
study, patients with ischemic stroke in which baseline stroke scores were measured by 
the NIHSS will be investigated for use of an ACEI or ARB prior to onset of stroke. 
Baseline stroke scales of patients on ACEI/ARB treatment will be compared to age and 
sex matched patients with the same stroke subtype not on either class of medication. 
One ACEI/ARB patient will be compared to 2 matched control patients. Patients 
receiving rt-PA will be excluded from the analysis and patients will be matched by time 
to first neurological assessment. Data on potential confounding baseline characteristics, 
such as vascular risk factors and other medication use, will be analyzed as well. A 
separate analysis of each class of medication will also be examined to establish whether 
or not there is a difference between treatments with an ACEI versus treatment with an 
ARB. 
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10.3.2.7 Baseline serum uric acid and 90-day functional outcomes following acute 
ischaemic stroke 
Investigators: Kennedy R. Lees MD, FRCP; Jesse Dawson MRCP; Matthew Walters FRCP; 
Christopher J. Weir PhD. 
Background 
Uric acid (UA) is a breakdown product of ingested and endogenously synthesized 
purines. It is increasingly recognized that there is an association between elevated 
serum UA and cardiovascular morbidity and mortality (405).  
In patients with essential hypertension, an association with elevated serum UA 
concentration and increased cardiovascular event rate, mortality and all cause mortality 
has been demonstrated in several studies (406-409). In patients with diabetes, 
increasing serum UA has been associated with an increased risk of stroke (410), 
increased prevalence of peripheral arterial disease (411;412) and an increased risk of 
recurrent vascular events following stroke. Elevated serum UA has been shown to be 
predictive of all cause mortality in patients with angiographically defined coronary 
artery disease (412;413), and to predict mortality and need for cardiac transplantation 
in those with cardiac failure (414;415). Furthermore, there is evidence that UA 
contributes to the atherosclerotic process. Perhaps most convincingly, UA stimulates 
vascular smooth muscle cell proliferation (416-418) via effects on several intracellular 
pathways and its generation via xanthine oxidase creates oxidative stress. 
The situation is less clear in the acute period after stroke. In a large study of 2498 
patients with acute stroke, increasing serum UA levels have been associated with a 
reduced likelihood of a favourable outcome, increased risk of early clinical 
deterioration (419) and an increased risk of recurrent vascular events (420), an 
association which was more prominent in those with diabetes (421). However, in a study 
of 800 patients with acute ischaemic stroke, increasing UA levels were associated with a 
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good outcome (OR 1.12, 95% CI 1-1.25 per additional mg/dl UA) at seven days (422). 
Furthermore, in a small study of 23 patients with ischaemic stroke, a UA infusion was 
found to reduce markers of oxidative stress and was associated with no adverse events 
(423). This is plausible - UA has antioxidant activity (424), which may be beneficial 
during an acute ischaemic event and infusion of UA was found to reduce infarct volume 
and improve behavioural outcome in a rat transient ischaemia model (425). 
The available evidence does not allow us to draw firm conclusions regarding whether 
serum uric acid is harmful or beneficial after acute ischaemic stroke, although it is 
clearly a risk factor for cardiovascular events and mortality in those with risk factors or 
stable established cardiovascular disease. No study in the acute phase after stroke has 
used robust outcome measures that we expect in randomised clinical controlled trials. 
Furthermore, the trials that suggest elevated uric acid is beneficial in the acute phase 
after stroke (422) did not adjusted for baseline variables such as NIHSS and it is possible 
that spurious associations have been generated. This conflict must be resolved – trials of 
UA infusion in acute ischaemic stroke are underway but should be based upon more 
consistent evidence base. Equally, the increasing body of evidence that suggests UA 
reduction will yield improvements in cardiovascular health in a variety of settings 
cannot be ignored. 
We propose to evaluate the association between baseline serum uric acid and 90-day 
outcomes after acute ischaemic stroke using robust data gathered during acute stroke 
clinical trials. 
Hypothesis 
We hypothesise that increasing serum UA will be associated with increasing mortality 
rate and worse 90-day functional outcomes after acute ischaemic stroke after 
adjustment for variables known to influence UA level and outcomes such as baseline 
stroke severity. 
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Methods 
The study will involve collaboration with the VISTA investigators and will be performed 
at the Division of Cardiovascular and Medical Sciences at the Western Infirmary, 
Glasgow, UK with support from the Robertson Centre for Biostatistics. 
Our primary outcome measure will be poor outcome defined as either death or mRS ≥ 4 
on day 90 assessment. Secondary outcomes include a good outcome, defined as mRS ≤ 2 
at day 90, and similar 7 day outcomes. For each outcome we will evaluate the 
relationship with baseline serum uric acid with full adjustment for potential 
confounding variables. 
Statistical Analysis 
Descriptive statistics will be used to describe the population with mean (±SD) and 
median (± IQR) values calculated. Next we will explore univariate differences in clinical 
features between outcome groups using the Fisher’s exact test (binary variables), the 2 
test (categorical variables), the Mann-Whitney test (continuous variables), and 2 test 
for linear trend (ordered categorical variables). We will then use multiple logistic 
regression to assess the effect of UA concentration and control for potential 
confounding factors. All variables that differ significantly between outcome groups in 
the univariate analysis or that are already established as predictors of stroke outcome 
will be added to the model.  
10.3.2.8 VISTA Proposal – Effect of sulfonylurea use on ischemic stroke outcomes  
Authors: Tony Chou MD; Bruce Stouch PhD; Kennedy R. Lees MD, FRCP.    
The NCCa-ATP channel is a non-selective cation channel that is expressed in the CNS only 
under conditions of injury or ischemia (426;427). Channel opening, which is triggered by 
ATP depletion, results in cytotoxic oedema, oncotic cell death and cerebral oedema 
(428). Like the KATP channel in pancreatic β cells, it is regulated by sulfonylurea 
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receptor 1 (SUR1) and is blocked by sulfonylureas such as glyburide. Simard et al. (429) 
reported that this channel is up-regulated in rodent models of ischemic stroke, and that 
post-event block of the channel with glyburide reduces mortality, cerebral oedema, and 
infarct volume by half.  
Kunte et al. (430) explored the translation of these results into the treatment of human 
stroke, and reported that the use of sulfonylureas prior to and during the acute phase of 
stroke may have a significant, clinically meaningful effect on stroke outcome in patients 
with type 2 diabetes mellitus (NIDDM). In this study medical records of NIDDM patients 
hospitalized within 24 hours of onset of acute ischemic stroke in the Neurology Clinic, 
Charité Hospital, Berlin, Germany, during 1994-2000 were reviewed. After exclusions, 
the cohort comprised 33 patients taking a sulfonylurea at admission through discharge 
(treatment group) and 28 patients not on a sulfonylurea during either the pre-stroke or 
treatment period (control group). All sulfonylureas were second generation 
sulfonylureas, which are known to have a more lipophilic side chain, increased 
hypoglycemic potency, and be more compatible with concurrent administration of other 
pharmacologic agents than the first generation sulfonylureas (431).  
The primary outcome measure was defined as a decrease in National Institutes of Health 
Stroke Scale (NIHSS) of 4 points or more from admission to discharge or a discharge 
NIHSS score = 0. The secondary outcome measure was defined as a discharge modified 
Rankin Scale (mRS) score ≤ 2. The primary outcome was reached by 36.4% of patients in 
the treatment group and 7.1% in the control group (p=0.007). The secondary outcome 
was reached by 81.8% vs. 57.1% (p=0.035). Subgroup analyses showed that 
improvements occurred only in patients with non-lacunar strokes, and were 
independent of all baseline variables recorded, including gender, previous TIA, and 
blood glucose levels.  
Apart from a desire to replicate these results in the VISTA database, Kunte’s study 
identified two limitations of the analysis that we believe can be addressed by the VISTA 
Myzoon Ali, 2008  Appendix, 224 
 
  
database: (1) the sample size was small; (2) outcomes were assessed at the time of 
discharge, not 30 and 90 days.  
Primary and Secondary Analyses  
Prior to performing the analyses, the specification of the derived datasets will be 
prepared to support the Statistical Analysis Plan. The primary and secondary endpoints 
and a synopsis of the proposed analysis models are presented below.  
Analysis of the Primary Endpoint  
The primary endpoint for analysis will be disability at 90 days, as measured by the 
modified Rankin Scale (mRS), a 6-point scale ranging from 0 (no residual symptoms) to 5 
(bed-bound, requiring constant care). Two datasets will be generated to examine the 
results: Observed cases and Observed with Imputed Cases. For patients who do not have 
a 90-day mRS score, the Observed with Imputed Cases dataset will use the last rating 
for survivors; a mRS score of 5 will be imputed for deaths within 90 days for any cause. 
Results will be analyzed using the Cochran-Mantel-Haenszel test (CMH), comparing the 
response of patients with and without sulfonylurea exposure, adjusted for a variety of 
stratification factors. The CMH test is a nonparametric rank-based test across 
categorized data.  
Secondary analyses of the primary endpoint will be a comparison of the proportion of 
patients with a mRS ≤ 2 at 90 days by sulfonylurea exposure using a Cox proportional 
hazards regression model. This model will permit inclusion of factors to evaluate 
possible interactions and effect of a variety of covariates.  
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Analysis of the Secondary Endpoints  
mRS Recorded at 30 days  
Two analysis datasets will be prepared to investigate the effect of sulfonylurea 
exposure on disability at 30 days: Observed Cases and Observed with Imputed Cases. For 
patients who do not have a 30-day mRS score, the Observed with Imputed Cases dataset 
will use the last rating prior to 30-days for survivors; a mRS score of 5 will be imputed 
for deaths within 30 days for any cause. Results will be analyzed using the CMH test, 
comparing the response of patients with and without sulfonylurea exposure, adjusted 
for a variety of stratification factors. Secondary analyses will include a comparison of 
the proportion of patients with a mRS ≤ 2 at 30 days by sulfonylurea exposure using a 
Cox proportional hazards regression model.  
 NIHSS  
The proportion of patients with an NIHSS of either a 0 or 1 at 90 days will be analyzed 
using the CMH test, comparing the response of patients with and without sulfonylurea 
exposure, adjusted for a variety of stratification factors. This analysis will be repeated 
for NIHSS recorded at 30 days. Similar to the construct of the analysis datasets for mRS, 
an Observed Cases and Observed with Imputed Cases dataset will be prepared.  
Additional Analyses, Tests of Assumption, and Evaluation of Covariates  
A subgroup analysis of the Glyburide patients should be performed. If daily dose is 
available for Glyburide, response rates for subjects by dose should be reported.  
Analyses should be performed to determine effects of baseline variables on outcomes 
and adjustments or stratifications made accordingly. In particular, as many of the 
following should be considered: baseline HbA1c, duration of diabetes, statin use, 
baseline NIHSS (dichotomized or trichotomized), rt-PA vs. no rt-PA, age (dichotomized 
at 75 years), gender, glucose at admission (dichotomized at 140 mg/dL), and time from 
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stroke to admission should be studied. Subgroup analysis should be performed on stroke 
type (lacunar vs. others).  
10.3.2.9 Study of effect of inflammation and fever on stroke thrombolysis 
Investigators: Ashfaq Shuaib MD, FRCPC, FAHA; Monica Saini MD.  
Stroke is not only a major cause of mortality, it is also an important factor leading to 
significant disability and dependence. It is thus, important to determine factors that 
determine good functional recovery in patients of stroke. The Copenhagen stroke study 
showed that body temperature is a strong predictor of functional outcome following 
stroke (432). Body temperature is a modifiable factor and several studies have 
evaluated body temperature in relation to type, location, severity and mechanism of 
stroke as also the effect of hyperthermia on post stroke morbidity and mortality. Reith 
et al showed that the relative risk of poor outcome increased by 2.2 for each 1 degree 
Celsius increase in body temperature (433). There is however conflicting evidence for 
the prognostic implication of hyperthermia in stroke. According to Boysen et al, though 
there is a significant increase in body temperature within 6 hours of onset of stroke, it 
has no prognostic value on the outcome at 3 months (434).  
In-vitro data indicates that thrombolysis with rt-PA is temperature dependent, and is 
more effective with hyperthermia (435). In-vivo and clinical studies have however 
shown contrary results. Ernon et al evaluated the effect of body temperature on 
response to rt-PA in 100 patients with ischemic stroke. The results showed that 
hyperthermia relative to baseline temperature in the first 24 hours after thrombolysis is 
associated with unfavourable outcomes (436). Interestingly, Audebert et al have shown 
that successful thrombolysis is related to a significant attenuation of inflammatory 
response, which includes increase in body temperature (437). 
Inflammatory response, following stroke, is associated with increase in levels of 
inflammatory markers including white blood cells, CRP, IL-6, ICAM-1, VCAM, fibrinogen , 
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in addition to increase in body temperature. A recent study evaluated the correlation 
between hyperthermia, inflammatory markers and infarct volume. The results showed 
that after adjustment for pro-inflammatory response, hyperthermia was not 
independently associated with either volume of infarct or the outcome at 3 months 
(438). Another group has shown that low levels of IL-10, an anti-inflammatory marker, 
in the early period following stroke correlates with early clinical deterioration 
irrespective of the size, location or mechanism of infarct (439). This data indicates that 
the balance between pro and anti-inflammatory response is an important determinant 
of outcome following stroke. The pro-inflammatory response includes increase in pro-
coagulant activity; whether this has a bearing on the response to thrombolysis is yet 
unclear. The inflammatory response following myocardial infarction has been shown to 
be modified by use of statins (pravastatin); whether such a benefit can be seen in 
patients of stroke has not yet been investigated.  
Hypotheses: 
Hyperthermia is secondary to an inflammatory response following Stroke onset. The 
degree of inflammation determines the effectiveness of Stroke thrombolysis. Degree of 
inflammation may be modified by factors including preceding infection or use of statins. 
Methods: 
This will be a retrospective analysis of data from the Virtual International Stroke Trials 
Archive. Data will be obtained for patients of acute ischemic stroke. In addition, a 
separate analysis will be done for patients who received thrombolytic therapy (rt-PA). 
Baseline characteristics of patients will include age and gender, previous medical 
history, history of fever or infections preceding stroke onset, history of smoking and use 
of medications including statins, ACE inhibitors and NSAIDs. The type and location of 
stroke will be noted, and wherever possible, CT will be used to determine volume of 
infarct. Baseline deficits will be determined using the NIHSS and modified Rankin scale. 
Details regarding dose and time of rt-PA administration will be noted.  
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Baseline temperature and daily body temperature (7 days) will be studied in relation to 
infarct topography and volume, and also in relation to baseline and serial measurements 
of WBC, ESR, CRP and fibrinogen. Wherever possible, in patients with hyperthermia at 
baseline, lab investigations including urine microscopy and X ray chest will be analyzed. 
Stroke outcome will be analyzed in relation to body temperature in all patients of acute 
ischemic stroke. Following thrombolysis, outcome (as determined by 30 day and 90 day 
NIHSS and MRS) will be studied in relation to body temperature and inflammatory 
markers, as specified.  
10.3.3 Abandoned /Postponed Projects 
10.3.3.1 Preliminary studies for acute lacunar stroke trial design 
Investigators: Stella Aslanyan MD, Kennedy R. Lees MD, FRCP, Christopher J. Weir PhD, 
Keith W. Muir MD, FRCP 
Introduction  
Lacunar strokes (small sub-cortical infarcts) constitute about 25% of all ischaemic 
strokes and are particularly associated with hypertension. No acute treatment has yet 
been developed specifically for lacunar stroke; indeed, most current clinical trials have 
targeted cortical stroke. 
The final results of the MRC-funded Intravenous Magnesium Efficacy in Stroke (IMAGES) 
randomised controlled trial (RCT) showed an unexpected but plausible beneficial effect 
of MgSO4 in patients with non-cortical stroke in a planned subgroup analysis (108). One 
of the intriguing features of the initial examination of the data is that the strength of 
the effect appears to increase as the definition of lacunar stroke becomes tighter (from 
unselected non-cortical stroke through to ischaemic lacunar stroke). IMAGES also 
reported a significant interaction between treatment effect and baseline mean arterial 
blood pressure (BP) (p=0.019), patients with higher pressures benefiting more. Thus, the 
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effect of magnesium on lacunar stroke may be mediated by an acute blood pressure 
influence. An optimal trial design is essential if the evidence from further exploration of 
IMAGES data confirms the feasibility of a RCT of Magnesium in acute lacunar stroke. 
The aim of the proposed study is to explore the natural history of lacunar stroke in 
regard to the optimal acute lacunar stroke trial design utilising VISTA. More specifically 
we intend to (1) examine the prognostic value of BP, (2) develop prognostic models and 
(3) select the optimal RCT inclusion and exclusion criteria and outcome measures for 
lacunar stroke. 
Methods 
1. We have previously investigated relationships between BP during acute ischaemic 
stroke and stroke outcome in patients from the GAIN International trial (390;440). The 
limited sample precluded detailed subgroup analyses. The prognostic value of BP during 
acute stroke is controversial and was not specifically investigated for lacunar stroke. 
VISTA will allow similar analyses on a larger scale for the subgroup of lacunar stroke. 
Individual patient data with available outcome measures at 1-3 months and recording of 
at least baseline BP, age and baseline National Institutes of Health Stroke Scale (NIHSS) 
score will be selected from the archive. The prognostic value of BP will be examined 
using logistic regression modelling. The analysis will adjust for trial, treatment group, 
age and baseline NIHSS score. Stroke risk factors will be considered as well if available.  
2. The best prognostic model, judged according to predictive accuracy and 
generalisability, will be selected. This model will be used in prognosis-related 
stratification and patient specific outcome assessment. 
3. Using simulation studies, the best outcome measure (together with the optimal cut-
point) will be selected (350;441). Similarly, the optimal inclusion criteria will be 
identified (442). Optimising the outcome measure and inclusion criteria will be 
considered simultaneously. Our simulations will employ the treatment effect pattern 
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observed in the IMAGES trial. Other plausible treatment effects will be investigated in 
sensitivity analysis.    
Implications 
Recognising the heterogeneity of ischaemic stroke and considering trials with inclusion 
criteria based on stroke pathophysiological or clinical subtype are important. The 
proposed study will contribute to the optimising the design of such trials in lacunar 
stroke. 
10.3.3.2 Robust associations between clinical factors and 90-day changes in the 
NIH stroke scale. 
Investigators: Robert A. Lew PhD, Michael Krams, MD, Jerry Weaver, PhD, Marc Fisher 
MD, Sean Savitz, MD, Thomas Bowman and Elizabeth Lawler, PhD  
Simple binary endpoints based on detailed scoring systems, such as the NIH stroke scale, 
coarsen the endpoint by discarding potentially useful details. This is one among many 
elements that has have made it more difficult to establish better stroke treatments in 
randomized clinical trials.  We propose to find robust associations between clinical 
factors and changes in stroke scale scores that sharpen inclusion and exclusion criteria 
so that patients in a study are more likely to respond to the experimental treatment. 
Endpoints now include changes in the NIH stroke scale. Michael Krams, MD, and Jerry 
Weaver, PhD, recently evaluated data from a Pfizer stroke trial using a 90-day success 
endpoint that could be attained either by having a final score of 0 or 1 or by decreasing 
(improving) 9 or more points. Also, Young et al. (443) found in their simulation study 
based on the GAIN trial that for prognosis-adjusted outcome, we found greatest power 
if we defined success as achieving a score ≤1 or improvement by at least 11 points from 
baseline. 
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Ideally, robust associations hold over a variety of institutions and research settings. To 
begin to assess our findings we need to combine clinical trials data with cohort 
administrative data. We propose to use specialized statistical techniques to deal with 
the irregularities in such heterogeneous data. 
Non-treatment factors such as the type of stroke, time until treatment, type of stroke-
associated deficit, chronic comorbid conditions, baseline NIHSS score, baseline Glasgow, 
Barthel, and modified Rankin score, physiologic and laboratory measurements including 
scans, age, and sex are associated with improvements of 9 or more points. Some of 
these associations hold up in both clinical trial and administrative (cohort) datasets. 
Two approaches will be taken to generating and confirming associations: 
First we will start with charts. The most detailed data is likely to come from the 
abstracted electronic charts. These data will generate potential hypotheses. We will try 
to identify surrogate variables for variables in the charts but not in the other datasets. 
This will enhance our exploration of which associations hold more generally. To account 
for error introduced by surrogate measures we will use error-in-measurement 
methodology (Carroll, Ruppert, and Stefanski).   
Second we will use cross-validation.  In particular, we will partition the large databases 
in k parts, generate associations, and the validate them (Hastie and Tibshirani). 
This dual approach will indicate which associations arise in both and which ones arise in 
only one approach.  
Finally, we will validate the most promising associations on a small set of new cases, 
most likely gathered from anonymised electronic charts gathered from the VA record 
system. 
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10.3.3.3 Definition of a target stroke patient sub-population for a potential “proof of 
concept” study to investigate the anti-Nogo-A antibody ATI355. 
Investigators: Klaus Kucher, M.D and Roland Fisch, Ph.D.  
Regeneration and plastic “hardware” changes in the adult central nervous system (CNS) 
of mammals and humans are extremely restricted, a phenomenon which represents the 
main reason for the low degree of recovery following CNS tissue injury. The molecular 
impediments that form the basis of this phenomenon are proteins expressed in CNS 
myelin which inhibit neurite growth after CNS injury. One of the most potent neurite 
growth inhibitory molecules in myelin is Nogo-A, a membrane protein comprising 
multiple inhibitory domains that activate independent receptors (444). 
Monoclonal antibodies against Nogo-A have been shown to neutralize the inhibitory 
activity of purified or recombinant Nogo-A, oligodendrocytes and CNS myelin in vitro 
(445;446) and, more importantly, mediate significant improvements in functional 
recovery in rodent models of non-traumatic brain injury (447). Furthermore, anti-Nogo-
A antibody treatment facilitates neuroregeneration at the anatomical level in a non-
human primate model of spinal cord injury (448).  
The mechanism of action of anti-Nogo-A antibodies involves steric hindrance of the 
inhibitory domains of Nogo-A and internalization of the Nogo-A-antibody complex. Based 
on this mode of action of anti-Nogo-A antibodies, an approach was taken to develop a 
neutralizing antibody. The antibody selected for early development (ATI355) is a fully 
human monoclonal antibody generated from Medarex mice which are genetically 
reconstituted with human immunoglobulin genes, and is directed against human Nogo-A 
protein. The antibody is of the IgG4/k class and is designed to treat acute injuries to 
the CNS with markedly reduced potential for antigenicity and immune cell and 
complement interactions. 
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Hypothesis: 
The investigational compound ATI355, a monoclonal anti-Nogo-A antibody, improves 
recovery from ischemic stroke when administered intrathecally two to four weeks 
following the event. By definition of a well-characterized sub-group from the overall 
ischemic stroke population treatment effects of the anti-Nogo-A antibody ATI355 can be 
demonstrated in a proof of concept study using a sample size of about 80 – 100 stroke 
patients. 
Methods: 
ATI355 will be investigated in a randomized, rater-blinded, patient-blinded, sham-
placebo controlled, group sequential study to assess safety, tolerability and efficacy of 
a 4 week continuous intrathecal ATI355 infusion in patients suffering from ischemic 
stroke. 
Depending on the sub-population selected approximately 80 – 100 patients will be 
randomized to receive either a 4 week treatment of ATI355 (xx mg/day) or sham-
placebo, with a 1:1 treatment allocation ratio. The study will be designed to provide 
“proof of concept” information on ATI355, on which internal decision making can be 
based on. Using the VISTA database an optimal sub-population for this “proof of 
concept” study will be identified. 
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